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Abstract 
Background: Autosomal dominant Hyper IgE Syndrome (AD-HIES) is a rare 
primary immunodeficiency characterized by high serum IgE levels, 
eosinophilia, and skin and lung infections. Additional features of AD-HIES 
include characteristic facial appearance, scoliosis, retained primary teeth, and 
joint hyperextensibility. Recently, AD-HIES has been associated with 
heterozygous dominant negative mutations in the signal transducer and 
activator of transcription 3 (STAT3) which plays a key role in the signal 
transduction of a broad range of cytokines, and is crucial for IL-6-mediated 
regulation of Th17 cells.   
Objective: We aimed to characterize patients with the clinical diagnosis of AD-
HIES, to identify STAT3 mutations, and to assess the frequency and functional 
consequences of these mutations. Furthermore, we studied STAT3-dependent 
signalling pathways in patients with an AD-HIES phenotype but no STAT3 
mutation.  
Methods: We sequenced STAT3 in 153 patients with a strong clinical suspicion 
of AD-HIES and further components of the IL-6 signalling pathway in patients 
found to be STAT3 wild type. The impact of the mutations on immune cell 
function was assessed by measurement of cytokine release by immune cells, 
T cell phenotyping and STAT1 phosphorylation assays.   
Results: About 60% of the AD-HIES patients revealed mutations in STAT3. All 
mutations found were heterozygous, clustered mainly in the DNA-binding or 
the SH2 domain and exerted dominant-negative effects. Functional analysis of 
mutations affecting different domains of STAT3 revealed that some mutations 
might have a less severe impact on functionality of STAT3, About 40% of our 
cohort of patients presenting with AD-HIES phenotype harboured wild type 
STAT3 and may carry mutations in other genes of either the same or closely 
related signalling pathways. Nevertheless, we ruled out mutations affecting the 
IL-6 pathway iIn five Sardinian patients with wild type STAT3.  
Impact of findings: The results lead to a better characterization of 
heterozygous STAT3 mutations and of the pathogenesis of AD-HIES.  
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1.1 The JAK-STAT signalling pathway 
Cytokines are small signalling molecules secreted by numerous cells for 
intercellular communication and as such they control a variety of biological 
responses. Each cytokine has a matching cell-surface receptor and the binding 
of a cytokine to its receptor induces the activation of intracellular signalling 
cascades leading to specific responses by the target cells. Depending on the 
signal, tissue, or cellular context these responses include proliferation, 
differentiation, migration, apoptosis, and cell survival (Alberts et al., 2002). 
Members of the type I and type II cytokine receptor families have no own 
catalytic kinase activity and rely on the Janus kinase/signal transducers and 
activators of transcription (JAK-STAT) signalling pathway (Alberts et al., 2002). 
Therefore, JAK-STAT signalling is essential for several developmental and 
homeostatic processes, such as haematopoiesis, immune cell development, 
stem cell maintenance, organismal growth, and mammary gland development  
and provides one of the most direct routes from the cell surface to the nucleus 
(Ghoreschi et al., 2009; Harrison, 2012).  
The cytokine receptors consist of two or more transmembrane polypeptide 
chains. Some cytokine receptor chains are specific to a particular cytokine 
receptor, while others are shared among several such receptors. All cytokine 
receptors, however, are associated with one or more JAKs (Alberts et al., 
2002).  
The binding of a cytokine to its receptor induces the oligomerization of the 
receptor chains bringing two or more intracellular, receptor-associated JAKs 
into close proximity and allowing them to cross-phosphorylate each other.  
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Once activated, JAKs phosphorylate tyrosine residues on the cytoplasmic tail 
of the receptors, creating docking sites for members of the STAT family and 
other signalling proteins (Darnell et al., 1994; Kiu and Nicholson, 2012). 
Upon binding to the receptor through their Src homology 2 (SH2) domains, the 
STATs become themselves phosphorylated by the JAKs. Phosphorylation of a 
conserved tyrosine residue located between the SH2 domain and the C-
terminal transcriptional activation domain (TAD) results in the dissociation of 
the STAT molecules from the receptor and in the formation of phosphorylated 
STAT dimers (Meyer and Vinkemeier, 2004; Shuai et al., 1994). 
These STAT dimers enter the nucleus where they bind to specific regulatory 
sequences within the promoter regions of target genes to activate or repress 
their transcription (Ihle, 1996; Schindler and Darnell, 1995) (Figure 1.1).  
The signal transduction is terminated by dephosphorylation of STAT dimers 
but,contrary to the previous assumption that the dephosphorylation of the 
leads to the release of the STATs from the DNA, it  has recently been shown 
that the DNA binding protects STATs from dephosphorylation (Meyer and 
Vinkemeier, 2004). 
 Once released from the DNA, STAT dimers undergo conformational changes 
and exit the nucleus (Mertens et al., 2006; Zhong et al., 2005).This canonical 
model of JAK-STAT signalling has recently been challenged by the 
observation that some STAT family members undergo constitutive shuttling 
between the nuclear and cytosolic compartments even in the absence of 
cytokine stimulation. Research indicated that STATs use two different import 
pathways: unphosphorylated STATs migrate via a carrier-free mechanism that 
involves direct interactions with nucleoporins, whereas the nuclear import of 
tyrosine-phosphorylated STAT dimers is dependent on importins (Meyer and 
Vinkemeier, 2004).  
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Both pathways operate simultaneously and make the nucleocytoplasmic 
cycling of STAT proteins much more dynamic than initially thought. 
Based on their tissue specificity and the receptors engaged, different JAKs and 
STATs are recruited in the signalling event (Schindler and Plumlee, 2008). 
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Figure 1.1: The JAK-STAT signalling pathway 
Upon binding of an extracellular ligand, changes of the receptor permit the intracellular 
JAKs associated with the receptor chains to phosphorylate one another. Trans-
phosphorylated JAKs then phosphorylate the receptor chains. STAT proteins are 
recruited to the resulting binding sites. Subsequently STATs get phosphorylated by the 
JAKs, dissociate from the receptor chains, dimerize and translocate to the nucleus 
where they regulate the transcription of target genes. 
GAS: Interferon-gamma activated sequence; ISRE: Interferon stimulated response 
element 
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1.1.1 Janus kinases (JAKs) 
Janus kinases (JAKs) are a family of intracellular, receptor associated, tyrosine 
kinases. 
Initially JAKs were named "just another kinase".  But when their importance 
became apparent, the acronym JAK was changed to "Janus kinase" after the 
'two-faced', roman god 'Janus' in reflection of their characteristic structure (Kiu 
and Nicholson, 2012). 
There are four known members of the mammalian JAK family, JAK1-3 and the 
tyrosine kinase2 (TYK2). 
JAKs are large kinases with molecular weights ranging from 120-140 kDa and 
seven conserved regions of homology called Janus homology domains 1 to 7 
(JH1-7). (JH1) at the C-terminus of the kinase is followed by a pseudokinase 
domain (JH2), an SH2-like domain (JH3-JH4) and finally a divergent four-
point-one, ezrin, radixin, moesin (FERM) domain (JH4-JH7) at the N-terminus 
(Imada and Leonard, 2000; Leonard and O’Shea, 1998) (Figure 1.2). 
The tyrosine kinase domain (JH1) is essential for the enzymatic activity of the 
JAK and contains conserved tyrosines necessary for JAK activation. The 
phosphorylation of the tyrosines leads to a conformational change of the 
protein enabling the binding of substrate. The "pseudokinase domain" (JH2), is 
structurally similar to a tyrosine kinase domain and negatively regulates the 
kinase activity of the tyrosine kinase domain JH1. The JH3-JH4 domains of 
JAKs share homology with SH2 domains yet lacking some of the key residues 
usually present within SH2 domains (Yamaoka et al., 2004). 
The N-terminal FERM domain of the JAKs are involved in the binding of JAKs 
to the cytokine receptors (Haan et al., 2001). These domains usually form a 
three-lobed structure; encompassing a ubiquitin-like fold (F1), an acyl-
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coenzyme A binding-like fold (F2) and a pleckstrin homology domain fold (F3) 
(Pearson et al., 2000). 
Although once thought to reside strictly in the cytoplasm, recent evidence 
shows that JAK1 and JAK2 are present in the nucleus of certain cells often 
under conditions associated with high rates of cell growth. Therefore, besides 
their canonical role as activators of the STAT transcription factors, these JAKs 
are now known to affect gene expression by activating other transcription 
factors and exerting epigenetic actions by phosphorylating histone H3 (Zouein 
et al., 2011) 
 
 
1.1.2 Signal transducers and activators of transcription 
(STATs) 
The signal transducers and activators of transcription (STATs) are the 
substrates of the JAK kinases and act as transcription factors, directly linking 
the cytokine receptor to the regulation of gene expression. To date there are 
seven known members of the mammalian STAT family (STAT1, 2, 3, 4, 5a, 5b 
and 6 (Leonard and O’Shea, 1998). All STATs range in size from 750 to 900 
amino acids and each STAT consists of seven conserved functional domains: 
the N-terminal (NT) domain, a coiled-coil (CC) domain, a central DNA-binding 
domain (DBD), a linker region, a Src-homology2 (SH2) domain followed by a 
single conserved tyrosine residue and a C-terminal  transcriptional activation 
domain (TAD) (Figure 1.2) (Kiu and Nicholson, 2012; Schindler et al., 2007). 
The selectivity of different STATs in binding various cytokine receptors is 
mainly determined by differences in the SH2 domains (Murray, 2007). 
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In resting cells non-phosphorylated STATs form homodimers through 
interactions between the NT domains, and reside in the cytoplasm  (Braunstein 
et al., 2003; Ndubuisi et al., 1999). However, upon cytokine stimulation, the 
STATs are recruited to the receptor where the conserved tyrosine is 
phosphorylated by activated JAKs. The activation of the STAT proteins in turn 
leads to the dissociation from the receptor chain and to the spatial 
reorganisation of the dimer complex, stabilized by reciprocal SH2- 
phosphotyrosine interactions (Kiu and Nicholson, 2012). 
Phosphorylated STAT dimers translocate to the nucleus through the nuclear 
pore complex with a mechanism dependent on importin α-5 (Fagerlund et al., 
2002; Meyer and Vinkemeier, 2004). 
In the nucleus, STAT dimers oligomerize to form tetramers or higher order 
complexes through interactions of the NT domain. These oligomers bind to 
tandem sequence elements within promoter regions (often referred to as 
Gamma activated sequence (GAS) elements) to activate or repress the 
transcription of specific gene subsets (Vinkemeier et al., 1996).  
Nevertheless, it has been observed that some unphosphorylated STAT family 
members additionally undergo constitutive shuttling between the nuclear and 
cytosolic compartments even in the absence of cytokine stimulation, 
suggesting that the nucleocytoplasmic cycling of STAT proteins is a dynamic 
process (Meyer and Vinkemeier, 2004)  
All STATs except STAT2 can get phosphorylated on at least one serine 
residue in their TAD by various serine kinases (e.g. MAPK, p38, JNK, PKCδ, 
mTOR and PI3K) (Decker and Kovarik, 2000; Kovarik et al., 1998).  This 
serine phosphorylation enhances the STAT-mediated gene transcription (Goh 
et al., 1999; Visconti et al., 2000). 
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Figure 1.2: Schematic structure of JAKs and STATs  
The JAK family comprises four structurally related kinases: JAK1, JAK2, JAK3, and 
TYK2. JAKs consist of seven JH domains. The JH1 domain is a kinase domain and 
the JH2 domain is a pseudokinase domain. JH3 and JH4 form the SH2-like domain, 
JH4-JH7 the FERM domain. The FERM domain mediates JAK binding to the 
transmembrane cytokine receptor.  
There are seven members of the mammalian STAT family (STAT1, 2, 3, 4, 5a, 5b and 
6). Each STAT consists of seven domains: the N-terminal domain, a coiled-coil 
domain, a central DNA-binding domain, a linker region, a SH2- domain followed by a 
single conserved tyrosine residue and a C-terminal  transcriptional activation domain. 
JH, JAK homology; FERM, four-point-one, ezrin, radixin, moesin domain; SH2, Src-
homology2; TAD, transcriptional activation domain.  
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1.1.3 Role of the JAK-STAT signalling pathway 
1.1.3.1 JAKs 
As most cytokine receptors do not have an own kinase activity they depend on 
the signal transmission by cytoplasmic, receptor-associated tyrosine kinases 
like JAKs (Ghoreschi et al., 2009).  
JAK1, JAK2 and TYK2 are ubiquitously expressed in mammals, whereas the 
expression of JAK3 is restricted to cells of the hematopoietic lineage and 
vascular smooth muscle cells (Musso et al., 1995; Schindler et al., 2007). 
Cytokines signalling via type II cytokine receptors (Type I Interferons (IFN-α/β), 
type II Interferon (IFN-γ), Interleukin (IL)-10, IL-20, IL-22 and IL-28), those 
which signal through the common γ chain (γc) (IL-2, IL-4, IL-7, IL-9, IL13, IL15 
and IL-21) as well as the ones using the gp130 subunit, mainly signal through 
JAK1. The signal is transmitted either by JAK1 alone or in association with 
other JAKs (Ghoreschi et al., 2009). JAK1 knock-out mice have a severely 
impaired lymphopoiesis and die shortly after birth showing that JAK1 signalling 
is essential for the signalling of a broad range of cytokines (Rodig et al., 1998).  
JAK2 is implicated in the response to hormone-like cytokines like the Growth 
hormone (GH), Prolactin (Prl), Erythropoetin (Epo), Thrombopoietin (Tpo), and 
cytokines involved in the hematopoietic cell development, such as IL-3 and 
Granulocyte macrophage colony-stimulating factor (GM-CSF) as well as IFN-γ 
(O’Shea et al., 2002; Schindler et al., 2007). Consistent with its role in 
erythropoiesis JAK2-deficient mice die at embryonic stages (Neubauer et al., 
1998).  
 JAK3 exclusively mediates signals through cytokines using the common γ 
chain (γc) (Leonard and O’Shea, 1998; Hofmann et al., 2004). This family of 
cytokines comprises IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. Both the γc and 
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JAK3 are essential for the function of all cytokine receptors of this family and 
are required for the development and the maintenance of the lymphoid cell 
system. Genetic defects of γc or JAK3 results in a severe combined immune 
deficiency (SCID) characterized by the lack of T, B, and NK cells in both mice 
and humans (Kovanen and Leonard, 2004) (see chapter 1.1.5). 
TYK2, the first described member of the JAK family, associates with cytokine 
receptors that signal through various combinations with JAK1 and JAK2 but 
not with JAK3 and has major effects on the transduction of the type I IFNs, IL-
6, IL-10 and IL-12/IL-23 cytokine families (Kisseleva et al., 2002) (Figure 1.3). 
In addition to the cytoplasm, JAK1 and JAK2 have been found to be present as 
well in the nucleus where they directly affect gene expression by activating 
other transcription factors and exerting epigenetic actions by phosphorylating 
histone H3 (Zouein et al., 2011).  
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Figure 1.3: JAK signalling 
Schematic representation showing the preferential cytokine/growth factor usage of 
different JAKs. Cytokines of the IL-6 family of cytokines as well as the Leukemia 
inhibitory factor (LIF) and the Granulocyte colony-stimulating factor (G-CSF) signal 
only via JAK1. The type I IFNs, IL-10, IL-13 and IFN-λ use a combination of JAK1 and 
TYK2, and IL-12 and IL-23 mediate their signals via the combination of JAK2 and 
TYK2. IFN-γ, IL-20 and IL-22 activate JAK1 and JAK2, whereas γc chain containing 
receptors, including the receptors for IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21, use a 
combination of JAK1 and JAK3. Other cytokines like IL-3, IL-5, the Granulocyte 
macrophage colony-stimulating factor (GM-CSF), the Growth hormone (GH), 
Erythropoetin (Epo), Leptin and Prolactin (Prl) signal through JAK2. 
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1.1.3.2 STATs 
STAT1, 3, 4, 5 and 6 form homodimeric complexes, whereas STAT1 and 
STAT3 can, at least in vitro, form a heterodimeric complex (Ho and Ivashkiv, 
2006). STAT2 primarily forms heterotrimers with STAT1 and the interferon 
regulatory factor 9 (IRF9), but can also act independently of STAT1 (Hahm et 
al., 2005). 
STAT1 is widely expressed, with high levels in heart, thymus and spleen and 
has a pivotal role in the biological response to both type I and type II IFNs. 
Type I IFNs induces the formation of IFN-stimulated gene factor 3 (ISGF3) 
complexes consisting of phosphorylated STAT1, phosphorylated STAT2 and 
the IRF9.  The complexes are assembled in the cell cytoplasm and 
translocated to the nucleus where they bind the interferon stimulated response 
element (ISRE). Stimulation with type II IFN leads to the formation of STAT1 
homodimers (Durbin et al., 1996; Schindler et al., 1992; Shuai et al., 1992). In 
the nucleus STAT1 homodimers bind to the GAS promoter to induce 
expression of Interferon stimulated genes (ISG). 
Like STAT3 and STAT6, STAT2 is expressed in the majority of tissues (Hou et 
al., 1994; Zhong et al., 1994).  
STAT3  is known to transduce signals of the entire IL-6-family cytokines (IL-6, 
IL-11, IL-27, IL-31, the Leukemia inhibitory factor (LIF), Oncostatin M (OSM), 
the Ciliary neurotrophic factor (CNTF) and cardiotrophin-1), the IFN-family 
cytokines (IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IFN-α/β and IFN-γ), the IL-2-
family cytokines (IL-2, IL-7, IL-9, IL-15 and IL-21), IL-5, IL-23, the Granulocyte 
colony-stimulating factor (G-CSF), the Epidermal growth factor (EGF), the 
Macrophage colony-stimulating factor (M-CSF) and leptin (Darnell, 1997; Levy 
and Lee, 2002). Stat3-deficient mice die embryonically at day E6.5–7.5 
underscoring the vital role of Stat3 in development (Takeda et al., 1997). 
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Paradoxically, STAT3 mediates signals of both pro- and anti-inflammatory 
cytokines; how STAT3 precisely promotes inflammation in some 
circumstances and inhibits it in others is unknown (El Kasmi et al., 2006; 
O’Shea and Plenge, 2012). Is it however known that STAT3 mediates the 
signals of IL-6 and IL-23 and is therefore critical for the differentiation of Th17 
cells in mice and humans (Chen et al., 2006; Milner et al., 2008).   
An important factor determining STAT3 functional heterogeneity is probably 
the existence of two alternatively splice isoforms: the fulllength STAT3α and 
the truncated STAT3β, which lacks the C-terminal activation domain. STAT3β 
was generally thought to act as a dominant negative factor but it has been 
shown to be involved in inflammation exerting anti-inflammatory functions by 
modulating directly or indirectly IL-10 expression  (Maritano et al., 2004). 
Unlike other STATs, such as STAT1 and STAT2, STAT3 can accumulate in 
the nucleus independently of its phosphorylation. The mechanisms underlying 
these differences relate to the involvement of distinct importins used by STATs 
for their nuclear import. STAT3 binds constitutively to importin- 3 and 6, and 
the shuttling of STAT3 in and out of the nucleus seems independent of its 
phosphorylation (Yang and Stark, 2008). In addition, the rate of import and 
export does not change following phosphorylation (Cimica et al., 2011). 
It has been shown that unphosphorylated STAT3 can as well function as a 
transcription factor, in part by binding to unphosphorylated nuclear factor κB 
(NFκB) in competition with inhibitor of NFκB (IκB), driving expression of a small 
subset of genes that also respond to activated NFκB, (Yang and Stark, 2008; 
Yang et al., 2007).  
The expression of STAT4 is restricted to myeloid cells, thymus and testis 
(Zhong et al., 1994). STAT4 is mainly phosphorylated by IL-12 and is therefore 
critical for the Th1 cell differentiation. STAT4 plays an analogous role in the IL-
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12 dependent activation of NK cells (Kaplan et al., 1996; Thierfelder et al., 
1996).  
 STAT5 consists of two isoforms, STAT5a and STAT5b which are closely 
related (96% amino acid identity) and result from a gene duplication event 
Both STAT5a and STAT5b exhibit differential expression in muscle, brain, 
mammary gland and secretary organs (seminal vesicles and salivary gland)  
and are required to direct the biological response to the IL-3 (IL-3, IL-5, and 
GM-CSF) and γc (IL-2, IL-7, IL-9, IL-15, and possibly IL-21) receptor families 
as well as the growth hormone (GH), prolactin (Prl), erythropoetin (Epo) and 
thrombopoietin (Tpo) (Liu et al., 1995, 1997; Schindler et al., 2007). 
STAT6 transduces signals for both IL-4 and IL-13, which share receptor 
components and is therefore critical for the IL-4/IL-13-dependent polarization 
of naïve CD4+ lymphocytes into Th2 effectors, as well as proliferation and 
maturation of B cells (Shimoda et al., 1996; Takeda et al., 1996) (Figure 1.4). 
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Figure 1.4: STAT signalling 
Schematic representation showing the preferential cytokine/growth factor usage of 
different STATs. Type II IFNs signal through STAT1 whereas Type I IFNs lead to the 
formation of heterotrimers of STAT1, STAT2 and IRF9. STAT3 is known to transduce 
signals of a broad range of cytokines including the IL-6-family cytokines the IFN-family 
cytokines and the IL-2-family cytokines. STAT4 is mainly phosphorylated by IL-12 
whereas STAT6 transduces signals for both IL-4 and IL-13. STAT5 directs the 
biological response to the IL-3 and γc receptor families as well as the growth hormone 
(GH), Prolactin (Prl), Erythropoetin (Epo) and Thrombopoietin (Tpo).     
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1.1.4 Regulation of the JAK-STAT signalling pathway 
Regulation of the JAK-STAT pathway allows fine-tuning and prevents 
inappropriate cytokine responses. There are several negative feedback loops 
including dephosphorylation by protein tyrosine phosphatases (PTPs) and the 
direct inhibition by protein inhibitors of activated STATs (PIAS) and suppressor 
of cytokine signalling (SOCS) proteins (Kiu and Nicholson, 2012). 
Several phosphatases (SHP1, SHP2, PTP 1B, TC-PTP and CD45) as well as 
the dual-specificity phosphatase (DUSP) family proteins have been recognized 
to be involved in the attenuation of the signal. These phosphatases target 
either the receptor complex at the membrane or the phosphorylated STAT 
molecules in the nucleus (Kiu and Nicholson, 2012). 
The PIAS protein family members (PIAS1, PIAS3, PIASx and PIASy) inhibit 
STAT signalling in different ways. PIAS1 and PIAS3 bind STAT1 and STAT3 
respectively and prevent them from binding DNA whereas PIASx and PIASy 
were shown to inhibit STAT1- and STAT4-mediated signalling without affecting 
the DNA-binding (Wormald and Hilton, 2004). 
The family of suppressor of cytokine signalling (SOCS) proteins has eight 
members (SOCS1-7 and cytokine inducible SH2-containing protein CIS) and 
represent the best studied inhibitors of the JAK-STAT pathway. All SOCS 
family members have a central SH2 domain flanked by an N-terminal domain 
of variable length and a C-terminal domain called SOCS box (Kile et al., 2002; 
Starr and Hilton, 1998).  
The transcription of SOCS genes is induced by activated STAT proteins 
creating a negative feedback loop.  
Activated SOCS proteins regulate signal transduction in different ways. 
SOCS1 and SOCS3 can be recruited to the receptor through the SH2 domain 
binding either to the receptor or to the receptor associated JAKs. This way the 
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SOCS proteins physically obstruct the recruitment of STATs and block JAK 
kinase activity. In addition, SOCS proteins facilitate the ubiquitinylation of JAKs 
targeting them for proteosomal degradation (Wormald and Hilton, 2004). 
As revealed by gene-targeting experiments, loss of SOCS1, SOCS2 or 
SOCS3 results in excessive STAT activity in response to IFN-γ, IL-4 (SOCS1), 
growth hormone (SOCS2), G-CSF and those cytokines which signal through 
gp130 (SOCS3) (Kimura et al., 2004; Kiu and Nicholson, 2012) (Figure 1.5). 
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Figure 1.5: Negative regulation of the JAK-STAT signalling pathway 
The JAK-STAT signal transduction is repressed by three distinct mechanisms. SHP1 is 
constitutively expressed and can dephosphorylate activated JAKs or receptors. PIAS 
proteins are also constitutively expressed and inhibit transcriptional activation of 
STATs. SOCS proteins are induced in response to cytokine signalling and can inhibit 
JAK activity or target signalling components for ubiquitination and subsequent 
proteolysis. GAS: Interferon-gamma activated sequence; ISRE: Interferon stimulated 
response element. Figure modified after Wormald and Hilton, 2003. 
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1.1.5 Congenital errors of human JAK-STAT signalling 
To date germline mutations in the genes encoding two human JAKs (JAK3 and 
TYK2) and three human STATs (STAT1, STAT3 and STAT5b) have been 
described. Mutations of the two JAKs and STAT1 mainly manifest as 
immunological and infectious phenotypes, whereas STAT3 and STAT5b-
deficiency comprise extrahaematological features (Casanova et al., 2012; 
Kralovics et al., 2005; Mead et al., 2012). In addition somatic and germline 
gain-of-function mutations of JAK2 have been associated with 
myeloproliferative disorders (Kralovics et al., 2005; Mead et al., 2012) whereas 
genetic variations in components of the IL-4R axis, including STAT6, have all 
been associated with atopy and asthma (Chatila, 2004) (Table 1.1).   
The first mutations in the human JAK-STAT pathway were characterized in the 
IFN-γ system; heterozygous mutations in STAT1 were found in children highly 
susceptible to mycobacterial infections (Dupuis et al., 2001; Levy and Loomis, 
2007). The complete deficiency of human STAT1 was described in 2003; 
these patients suffered from life-threatening intramacrophagic bacterial and 
viral diseases (Dupuis et al., 2003) but unlike patients with heterozygous 
STAT1 mutations, whose outcome is favourable, these patients died in the 
absence of haematopoietic stem cell transplantation (HSCT) (Casanova et al., 
2012). In contrast, gain-of-function mutations in human STAT1 were found to 
impair IL-17 immunity and to be one cause of chronic mucocutaneous 
candidiasis (CMC) (Liu et al., 2011b).  
JAK3 has an essential role in the signalling events of T lymphocyte cytokines; 
inactivating JAK3 mutations have been documented in humans with severe 
combined immunodeficiency (SCID), characterised by the absence of T and 
NK cells, abnormal B cell function and hypoplasia of lymphoid tissues (Macchi 
et al., 1995; Notarangelo et al., 2000; Russell et al., 1995). The immunological 
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and clinical phenotype of JAK3 deficiency is indistinguishable from that of X-
linked SCID. The latter syndrome is due to mutations in the interleukin-2 
receptor gamma (IL-2RG) gene encoding the common gamma chain (γc), 
which is shared by cytokine receptors for interleukin IL-2, IL-4, IL-7, IL-9, IL-15, 
and IL-21. In all these receptors the γc is coupled with JAK3, thus explaining 
phenotypic similarity of defects in these genes. JAK3-deficient patients present 
with the classical clinical features of SCID during the first few months of life, 
i.e. chronic diarrhoea, failure to thrive, recurrent respiratory infection and/or 
generalized infections from opportunistic pathogens, or signs of graft-versus-
host reaction from transplacental acquired maternal T cells. The treatment of 
choice for JAK3 deficiency is allogeneic HSCT that has been demonstrated to 
be life-saving (Notarangelo et al., 2001; O’Shea et al., 2004). 
As expected from the interactions of TYK2 with numerous cytokine receptors, 
homozygous TYK2 mutations cause multiple defects of innate and acquired 
immunity (Levy and Loomis, 2007). To date two patients with TYK2 deficiency 
have been described.  Both were highly susceptible to infections, suffered from 
disseminated Bacille Calmette–Guérin (BCG) and herpes zoster infections 
(Kilic et al., 2012; Minegishi et al., 2006).  
The patient’s cells showed defective responses to IL-12, type I IFNs, IL-6, IL-
23 and IL-10, demonstrating the importance of TYK2 for both innate and 
acquired immunity in humans (Minegishi et al., 2006).  
STAT5b deficiency is an autosomal recessive disorder presenting with short 
stature and growth hormone (GH) insensitivity syndrome (GHIS), facial 
dysmorphism, severe infections, and lymphoid interstitial pneumonitis 
(Casanova et al., 2012; Kofoed et al., 2003). STAT5b is a critical transducer of 
IL-2-mediated signals and is therefore essential for the development of 
regulatory T cells (Tregs), a subset of T cells important for the maintenance of 
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tolerance to self-antigens. The reduced number of Tregs associated with 
homozygous STAT5b mutations appears likely to contribute to the 
immunodeficiency observed in these patients (Torgerson and Ochs, 2007). 
In 2007 heterozygous dominant-negative mutations in STAT3 were shown to 
be causative for the autosomal dominant Hyper IgE Syndrome (AD-HIES) 
(Holland et al., 2007; Minegishi et al., 2007).  
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Gene  Type of 
mutation 
Trait Human Phenotype 
JAK1 Not reported 
JAK2 GOF  Polycythemia vera, 
Hereditary Thrombocytosis, 
Primary myelofibrosis 
JAK3 homozygous 
LOF 
recessive Severe combined 
immunodeficiency (SCID) 
TYK2 homozygous 
LOF 
recessive Susceptibility to mycobacterial 
and viral infections. Elevated IgE 
levels in one patient 
STAT1 heterozygous 
LOF 
dominant-negative Susceptibility to mycobacterial 
infections 
homozygous 
LOF 
recessive Susceptibility to mycobacterial 
and viral infections 
heterozygous 
GOF 
dominant Chronic mucocutaneous 
candidiasis (CMC)  
STAT2 Not reported 
STAT3 heterozygous 
LOF 
dominant-negative Autosomal dominant Hyper IgE 
Syndrome (AD-HIES) 
STAT4 Not reported 
STAT5a Not reported 
STAT5b homozygous 
LOF 
recessive Insensitivity to growth hormone 
Immunedysregulation due to Treg 
deficiency 
STAT6   genetic predisposition for atopic 
diseases 
 
Table 1.1: JAK-STAT mutant phenotypes in human. 
LOF: loss of function, GOF: gain of function 
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1.2 CD4 T cell differentiation 
T helper (Th) cells are an important part of the immune system, in particular of 
the adaptive immunity. Mature Th cells express the surface protein CD4 and 
are therefore usually referred to as CD4+ T cells. When activated by pathogens 
in a specific cytokine environment naïve T helper cells differentiate into distinct 
lineages and acquire specialized properties and effector functions.  
Initially the existence of two different effector Th cell subsets was proposed 
based on the cytokine profiles: Th1 and Th2 cells (Mosmann et al., 1997). Th1 
cells are activated by IL-12; they produce IFN-γ and protect against 
intracellular pathogens. The differentiation process from naïve T cells to Th1 
cells is regulated by STAT4 and the Th1 cell- lineage-restricted transcription 
factor T-bet. By contrast, Th2 cells differentiate in response to IL-4, which 
activates STAT6, resulting in the induction of GATA3. Th2 cells produce IL-4 
and IL-13 and coordinate the clearance of extracellular pathogens (Bettelli et 
al., 2008). Recently two additional subsets of Th cells have been identified: 
The regulatory T cells (Tregs) which modulate the immune system, maintain 
tolerance to self-antigens and prevent autoimmune disease; and the Th17 
cells. Th17 cells are positioned at the intersection between innate and adaptive 
immune response and play a significant role in defence against extracellular 
pathogens, as well as facultative and obligate intracellular pathogens, 
including intracellular bacteria and fungi (Peck and Mellins, 2010) (Figure 1.6).  
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1.2.1 Differentiation of Th17 cells 
The differentiation of Th17 cells is orchestrated by an intricate network of 
signalling pathways and transcriptional regulators in T cells. Antigen-
presenting cells (APCs) drive T cell differentiation by providing the antigenic, 
co-stimulatory and cytokine signals. Dendritic cells (DCs) are the most 
important APCs to bridge the crosstalk between innate and adaptive immunity 
(Joffre et al., 2009). Like other APCs, DCs express a repertoire of pattern 
recognition receptors (PRRs), that sense microbial products which are 
generally referred to as pathogen-associated molecular patterns (PAMPs). The 
binding of PAMPs to the PPRs initiates a signalling cascade culminating in the 
activation of DCs and the induction of adaptive immunity (Huang et al., 2012). 
Among the most important factors to polarize human Th17 cell differentiation is 
the STAT3-activating cytokine IL-6 (Laurence and O’Shea, 2007). Although the 
transforming growth factor β (TGF-β) plays a critical function in the 
differentiation of murine Th17 cells, studies indicate that this cytokine is not 
needed for IL-17 production in human T cells; in fact, TGF-β inhibits IL-17 
production in human cells (Acosta-Rodriguez et al., 2007; Wilson et al., 2007). 
Additionally, these groups showed that IL-1 is a very effective inducer of IL-17 
protein expression in activated human CD4+ T cells (Laurence and O’Shea, 
2007).   
IL-21, a cytokine produced by Th17 cells themselves, regulates the 
differentiation of CD4+ T cells to Th17 cells in an autocrine manner, thereby 
amplifying the Th17 responses and inducing its own expression in an autocrine 
loop (Korn et al., 2007; Nurieva et al., 2007). 
Finally, the heterodimeric cytokine IL-23 is important for the expansion and IL-
17 production of the already Th17-committed CD4+ T cells although it is 
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dispensable for their commitment (Stockinger and Veldhoen, 2007). Both IL-21 
and IL-23 signal via STAT3 (Figure 1.6). 
Essential for Th17 cell differentiation is the expression of the lineage-restricted 
transcription factor RORγt (Huang et al., 2012). Similar to T-bet in Th1 cells 
and GATA3 in Th2 cells, RORγt is highly induced in Th17 cells and plays a 
central role in specifying the lineage differentiation. Importantly, STAT3 
deficiency greatly decreased the expression of RORγt indicating the essential 
function of STAT3 in the global regulation of Th17 cell gene expression and 
Th17 cell differentiation (Dong, 2011; Nurieva et al., 2007) (Figure 1.7). 
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Figure 1.6: Differentiation of T helper cells 
Once activated naïve CD4+ T cells differentiate to become Th1 cells in the presence of 
IL-12. This process is regulated by STAT4 and T-bet. In response to IL-4, naïve T cells 
differentiate to Th2 cells through the activation of STAT6 and GATA3. In the presence 
of TGF-β naïve T cells become CD4+CD25+Foxp3+ cells with suppressive effects. In 
the presence of IL-6, mouse naïve T cells develop to become IL-17-producing Th17 
cells. In human T cells, IL-1 synergizes with IL-6 and IL-23 inducing Th17 
differentiation. STAT3 and RORγt are the key transcription factors controlling this 
process. Figure modified after Deenick and Tangye, 2007. 
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Figure 1.7: Induction of Th17 cells 
The development of human Th17 cells is induced by IL-6 and IL-1 secreted by 
activated dendridic cells.  IL-23 is not critical for Th17 commitment, but appears to be 
required to amplify and/or stabilize the Th17 phenotype. IL-21, a cytokine produced by 
Th17 cells themselves, provides an additional autocrine amplificatory signal. Figure 
modified after Matsuzaki and Umemura, 2007. 
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1.2.2 Cytokine profile and function of Th17 cells 
Th17 cells are generally thought to be pro-inflammatory and play an important 
role in host defense against infection, by recruiting neutrophils and 
macrophages to infected tissues. 
Th17 responses are likely to emerge as an early response to a number of 
pathogens not handled well by Th1- or Th2-type immunity and which require 
robust tissue inflammation to be cleared. Indeed, Th17 cells rapidly appear at 
sites of inflammation and attract other T cell subsets and neutrophils to the 
infection sites at later stages of the inflammatory process (Bettelli et al., 2008). 
Mature Th17 cells mainly secrete IL-17A, IL-17F and IL-22 but also IL-9, IL-21, 
IL-26 and the chemokine CCL20. It has become clear that Th17 cells exhibit a 
high degree of plasticity in terms of cytokine production, which is mainly 
dependent on the surrounding cytokine milieu (Zhu and Paul, 2010).  
IL-17A is the prototypic cytokine of the IL-17 family, which includes six 
members: IL-17A, B, C, D, E and F (Kolls and Lindén, 2004). IL-17A and IL-
17F are both secreted by Th17 cells but also by other cell types, such as γδ T 
cells, NKT cells, NK cells, neutrophils, and eosinophils (Korn et al., 2009; Park 
et al., 2005). Both IL-17A and IL-17F induce the production of proinflammatory 
cytokines, chemokines and metalloproteinases from a broad range of tissues 
and cell types (Bettelli et al., 2008). In particular IL-17A, is involved in the 
recruitment, activation and migration of neutrophil granulocytes by inducing the 
production of colony stimulatory factors and  the chemokine ligand CXCL8 by 
both macrophages and tissue resident cells (Annunziato and Romagnani, 
2009). Thus, IL-17 is important to control and clear various pathogens 
including Candida albicans (Ouyang et al., 2008; Puel et al., 2010).   
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IL-22 is a cytokine of the IL-10 family of cytokines. In addition to IL-10 and IL-
22 this family comprises IL-19, IL-20, IL-24, IL-26, IL-28, and IL-29. IL-22 is 
produced by terminally differentiated Th17 cells (Wolk et al., 2010). 
Like the IL-17 receptor (IL-17R), the receptor for IL-22 (IL-22R) is widely 
expressed, including epithelial and endothelial cells. In contrast to IL-17R, IL-
22R is not expressed on immune cells, and thus IL-22 is used by Th17 cells to 
communicate with tissues but not with other immune cells (Wolk et al., 2010). 
IL-22 induces the expression of β-defensins in epithelial cells and promotes 
epidermal hyperplasia suggesting an essential role for the immune barrier 
function of epithelial cells (Liang et al., 2006; Wolk et al., 2004; Zheng et al., 
2007). 
IL-21 belongs to the IL- 2 family of cytokines and uses the γc as part of its 
receptor.  In addition to the differentiation of Th17 cells, IL-21 stimulates the 
proliferation and differentiation of CD8+ T cells, B cell differentiation and 
antibody class switching and differentiation of NK cells (Korn et al., 2009). 
Moreover, human Th17 cells produce the chemokine CCL20 (Wilson et al., 
2007). CCL20 is a ligand for CCR6 and has antimicrobial as well as 
chemoattractive activity. Notably, human Th17 cells express CCR6; through 
CCL20 secretion, Th17 cells regulate their own recruitment to inflamed tissues 
(Korn et al., 2009) (Figure 1.8). 
It has been shown that some T cells can produce both the hallmark Th1 
cytokine IFN-γ and IL-17 in vitro and in vivo; IL-17/IFN-γ double-positive T cells 
are found in elevated numbers in both human- and mouse-inflamed tissues, 
and similar populations are observed in human Th17 cells differentiated in vitro 
from naїve CD4+ T cells. Exactly where these cells fit in the spectrum of Th17 
and Th1 cells is unclear as it has not been shown conclusively, whether the 
production of IFN-γ by Th17 cells is a protective or pathogenic mechanism 
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(Boniface et al., 2010; O’Shea et al., 2009). Considering the amount of tissue 
damage that can be induced by Th17 cells and the fact that IFN-γ-deficient 
animals develop exacerbated disease in several autoimmune disease animal 
models, it is possible that IFN-γ produced by Th17 cells ultimately serves to 
limit Th17-induced inflammation (Peters et al., 2011). 
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Figure 1.8: Cytokines and chemokines produced by human Th17 cells 
and their target 
 
IL-17A induces epithelial cells, endothelial cells, and fibroblasts to produce the 
chemokine ligand CXCL8, which is crucial for the recruitment of neutrophil 
granulocytes. IL-22 induces the expression of β-defensins in epithelial cells. IL-21 
activates NK cells and CD8+ T cells and is a powerful B cell stimulatory factor. IL-21 
also provides an autocrine amplification loop for Th17 cells themselves. Figure 
modified after Annunziato et al., 2012. 
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1.3 The Hyper IgE Syndrome 
1.3.1 Primary immunodeficiencies –definition and 
classification 
Primary immunodeficiencies are a heterogeneous group of disorders, which 
affect cellular and humoral immunity or non-specific host defense mechanisms 
mediated by complement proteins, and cells such as phagocytes and natural 
killer (NK) cells (Lim and Elenitoba-Johnson, 2004).  
These disorders of the immune system cause increased susceptibility to 
infection, autoimmune disease, and malignancy. There are over 80 primary 
immunodeficiencies, many of which are very rare, and in most cases 
associated with inherited genetic defects (Geha et al., 2007). In the majority of 
cases, the primary immunodeficiencies manifest in the first year of life. They 
can, however, present at any age, including adulthood (Sicherer and 
Winkelstein, 1998). The advent of molecular genetic analyses now allows the 
detection and confirmation of immunodeficiencies that were otherwise not 
severe enough to have led to a specific diagnosis. In addition, effective 
treatment for many disorders has led to increased survival of many children 
with primary immunodeficiency into adult life (Korpi et al., 2000; Puck, 1997). 
The identification of many genes responsible for primary immunodeficiencies 
has provided insights regarding the spectrum of clinical severity seen in a 
particular disorder and the phenotypic overlap resulting from mutations of 
different genes.  
Over 200 distinct genes have been identified to date, whose abnormalities 
account for more than 150 different forms of primary immunodeficiencies 
(Geha et al., 2007; Al-Herz et al., 2011; Notarangelo et al., 2009). 
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There are eight different classes of primary immune disorder. 
1) Combined T and B cell deficiencies 
2) Predominantly antibody deficiencies 
3) Other well-defined immunodeficiency disorders 
4) Diseases of immune dysregulation  
5) Congenital defects of phagocyte number, function or both 
6) Defects in innate immunity 
7) Autoinflammatory disorders 
8) Complement deficiencies 
 
1.3.1.1 Epidemiology 
Many immunodeficiencies are rare, however, the incidence of primary 
immunodeficiencies has increased by 10-fold since 1969 to 1 in 10,000. This is 
partly due to increased identification of affected patients, reduced morbidity 
and mortality from the introduction of antibiotics, enhanced methods of 
detection of immunological abnormalities, and the identification of gene 
mutations responsible for the disorders (Lim and Elenitoba-Johnson, 2004). 
This figure does not take into account people with mild immune system defects 
who have not received a formal diagnosis. 
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1.3.2 The Hyper IgE Syndrome (HIES) 
The Hyper IgE syndrome (HIES) is a rare congenital immunodeficiency 
(incidence <1:1 000 000), characterized by the classic clinical triad of: 
 
- Eczema with massively elevated serum IgE (>2000 IU/mL), and eosinophilia, 
- Recurrent skin abscesses, usually caused by Staphylococcus aureus and 
- Recurrent pneumonia leading to the formation of lung cysts  
 
The HIES usually presents within the first few years of life and has no gender 
predilection (Grimbacher et al., 2005).  
 
“So went Satan forth from the presence of the Lord, and smote Job with sore 
boils from the sole of his foot unto his crown."  
 
With this quote from the book of Job 2:7 Davis, Schaller and Wedgewood 
coined the term Job's syndrome. In 1966 they reported two girls with red hair, 
chronic dermatitis, and recurrent staphylococcal abscesses and pneumonias 
and named the disease after the biblical character Job (Davis et al., 1966). In 
1972, Buckley et al. described two boys with similar symptoms who also had 
distinctive facial appearances and extremely elevated IgE levels (Buckley et 
al., 1972). Following this publication, elevated IgE were found as well in the 
two girls from the initial report, showing that Job syndrome and Buckley 
syndrome represented the same condition. This syndrome is now referred to 
as Hyper IgE Syndrome (HIES). 
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Most cases of HIES are sporadic, but both autosomal dominant (AD-HIES) 
and autosomal recessive traits of inheritance (AR-HIES) have been described 
(Grimbacher et al., 1999a; Renner et al., 2004). 
 
1.3.3 The autosomal dominant Hyper IgE syndrome (AD-
HIES) 
1.3.3.1 Clinic 
The autosomal dominant Hyper IgE Syndrome (AD-HIES), also named type 1 
HIES has been recognized as multisystem disorder and is characterized by 
both immunologic and non-immunologic manifestations. High serum IgE 
levels, eosinophilia, eczema, skin and lung infections constitute the 
immunologic profile of AD-HIES, whereas characteristic facial appearance, 
scoliosis, retained primary teeth, joint hyperextensibility, recurrent bone 
fractures following minimal trauma, and craniosynostosis are the main non-
immunologic manifestations (Grimbacher et al., 1999a). Main clinical 
symptoms of AD-HIES patients and the respective frequencies are 
summarized in Table 1.2. 
Most sporadic patients present with AD-HIES phenotype.  
  
Chapter 1: General Introduction 
 
54 
 
Table 1.2: Clinical features and laboratory parameters of AD-HIES 
patients, and their frequency.  
(Grimbacher et al., 1999a). 
 
 
Clinical features and laboratory paramenters Frequency 
Immunologic features Eczema 100 % 
Skin Abscesses 87% 
Recurrent Pneumonia 
Pneumatoceles 
87 % 
77% 
Mucocutaneous Candidiasis 83 % 
Non immunologic 
features 
Characteristic Face 
Increased nose width (interalar distance) 
83 % 
65 % 
Retained Primary Teeth 72 % 
Hyperextensibility 68 % 
Recurrent Fractures  57 % 
Scoliosis (more than 10°) 63 % 
Laboratory 
Parameters 
Serum-IgE (>2000 IU/mL) 97 % 
Eosinophilia  93 % 
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Most of AD-HIES patients had a history of a newborn rash, which usually starts 
within the first weeks of life, typically presenting on the scalp and face 
(Eberting et al., 2004, 2004). Additionally, recurrent skin abscesses occur; 
these are preferably caused by Staphylococcus aureus and are typically 'cold' 
as they lack classic signs of inflammation such as redness, warmth, or pain 
(Chamlin et al., 2002; Minegishi and Saito, 2012). 
Very often AD-HIES patients suffer from recurrent infections of the upper 
respiratory tract, such as sinusitis, bronchitis, otitis media and mastoiditis 
predominantly caused by Staphylococcus aureus (Grimbacher et al., 2005).  
A clinical hallmark of AD-HIES is recurrent pneumonia. By early adulthood, 
more than 50% of patients have had three or more X-ray proven pneumonias 
(Grimbacher et al., 1999a). S. aureus is the most common pathogen, with 
Streptococcus pneumoniae and Haemophilus influenzae also occurring 
frequently (Freeman and Holland, 2010). For reasons not yet understood, 
tissue healing after pneumonias is abnormal and results in the destruction of 
lung tissue, leading to the formation of lung cavities (pneumatoceles) or 
scarring and thickening of the lower air ways (bronchiectasis). Once 
parenchymal lung damage has occurred, the colonization with opportunistic 
pathogens such as Pseudomonas aeruginosa or Aspergillus fumigatus is 
favored. These secondary infections are difficult to control and represent the 
major cause of morbidity and mortality for these patients (Eberting et al., 2004; 
Freeman et al., 2007). Additionally chronic candidiasis of the mucous 
membranes and/or the nail bed has been observed in more than 80% of the 
AD-HIES patients (Grimbacher et al., 1999a). 
In addition to the accumulation of respiratory infections, other symptoms can 
be found in these patients: More than half of the patients suffered fractures, 
which often occur without adequate trauma and mainly affect the long bones 
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and ribs rather than the spine. Furthermore, AD-HIES is associated with a 
hyperextensibility of the joints, and scoliosis of varying degree and severity 
(Eberting et al., 2004; Grimbacher et al., 1999a). A distinct facial appearance 
has been described (rough skin, facial asymmetry, a prominent forehead, 
deep-set eyes, broad nasal bridge and a fleshy nasal tip, prognathism), along 
with midline anomalies (Borges et al., 1998). 
Abnormalities in primary teeth exfoliation is a common finding in AD-HIES 
patients. Reduced resorption of the primary tooth root leads to their 
persistence preventing the normal eruption of permanent teeth. The absence 
of loss of primary teeth can cause a double row formation because the 
permanent teeth emerge behind the milk tooth in the dental lamina (O’Connell 
et al., 2000). 
The role of the highly elevated polyclonal serum IgE in the pathogenesis of 
HIES remains unclear. Values of more than 10,000 IU/mL (raising up to 
100,000 IU/mL) are characteristic for AD-HIES, however, the serum IgE levels 
vary widely over the time and do not correlate with the clinical presentation of 
the patients (Buckley and Becker, 1978). Occasionally IgE values reach 
normal values despite the persistence of symptoms. 
Most AD-HIES patients present eosinophilia (a significantly increase proportion 
of eosinophilic neutrophils). However, no correlation between eosinophilia, IgE 
levels and infectious complications has been observed (Grimbacher et al., 
1999a, 2005). 
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1.3.3.2 Genetics 
Despite many years of intense research AD-HIES remained one of the last of 
the major primary immunodeficiencies for which no genetic aetiology was 
known. 
 
Although Davis et al. first reported two unrelated, fair-skinned girls with red hair 
it soon became clear that AD-HIES can occur in all ethnic groups with 
approximately equal gender distribution (Erlewyn-Lajeunesse, 2000) and 
pedigrees of HIES families showed an autosomal inheritance (Blum et al., 
1977; Donabedian and Gallin, 1983; Grimbacher et al., 1999b; Van Scoy et al., 
1975). 
In 1997 Hershey et al. detected a polymorphism in the IL-4 receptor (Q576R) 
associated with the occurrence of atopic dermatitis and suggested a link to 
AD-HIES. However, the correlation of the AD-HIES phenotype with the Q576R 
allele, was soon ruled out (Grimbacher et al., 1998; Hershey et al., 1997). 
An AD-HIES patient with mental retardation who was found to have an 
interstitial deletion of 15–20 Mb on chromosome 4q drew attention to this 
region (Grimbacher et al., 1999c). Linkage analysis of 19 HIES families 
showed linkage to the proximal arm of chromosome 4q (Grimbacher et al., 
1999b). However, six of the 19 families were not linked to this region, 
suggesting genetic heterogeneity (Grimbacher et al., 2005). 
In early 2007 our group screened a cohort of 30 sporadic patients with the 
typical AD-HIES phenotype for submicroscopic insertions or deletions. Using 
50k and 250k SNP mapping arrays, we were able to rule out the presence of 
overlapping deletions in these patients, making it unlikely that a common 
microdeletion, accounts for the majority of cases with AD-HIES (Pfeifer et al., 
2007). 
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Finally in summer 2007, mutations in STAT3 were identified as a cause of AD- 
HIES (Holland et al., 2007; Minegishi et al., 2007). Mutations were shown to be 
dominant-negative and to inhibit the activity of the wild-type allele. 
 
1.3.3.3 Pathogenesis 
Since the identification of mutations in STAT3 as major cause of AD-HIES 
great efforts have been made to understand the pathogenesis of the disease 
that can now be explained to a certain extent.  
As previously described, the STAT3 molecule plays a central role in signal 
transduction induced by multiple cytokines, including IL-6, IL-10, IL-11, IL-17, 
IL-21 and IL-22. 
It has become clear that AD-HIES is a disease of both too much inflammation, 
as well as too little inflammation; patients lack classical inflammatory 
responses are often afebrile and feel well, despite serious inflammation 
(Freeman and Holland, 2010). This can partially be explained by the role of 
STAT3 in the regulation of various cytokines. In fact STAT3 is essential for the 
signal transduction of multiple cytokines, including the proinflammatory 
cytokine IL-6 as well as the anti-inflammatory cytokine IL-10 (Eberting et al., 
2004). However, the precise mechanisms that allow STAT3 to promote 
inflammation in some instances and to inhibit inflammation at other times have 
not been fully resolved (O’Shea and Plenge, 2012). 
Inherited deficiencies of IL-10 or IL-10 receptor (IL-10R) have been described 
in patients with life-threatening early-onset enterocolitis (Shah et al., 2012). 
The fact that the phenotype of IL-10 signalling deficiency does not overlap with 
to that of STAT3 deficiency may be due to the residual signalling activity of 
STAT3 in AD-HIES.  
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Mutations in STAT3 lead to failure of Th17 cell differentiation. It has been 
shown that significantly reduced numbers of Th17 cells are a common feature 
in patients with AD-HIES. Indeed, reduced numbers of Th17 cells are thought 
to attribute most to the clinical phenotype of AD-HIES in particular to the high 
susceptibility to bacterial and fungal infections (de Beaucoudrey et al., 2008; 
Ma et al., 2008; Milner et al., 2008). 
Defective Th17 responses play a central role in several immunodeficiencies 
with increased susceptibility to Candida infection (Puel et al., 2012). 
Furthermore, IL-17 signaling is involved in neutrophil proliferation and 
chemotaxis. Therefore, impaired neutrophil responses and recruitment to lung 
and skin may, at least partly, account for the recurrent staphylococcal 
infections observed at these particular sites (Laan et al., 1999)  
Specifically, respiratory epithelial cells and keratinocytes have been 
demonstrated to be tightly dependent on IL-17 for induction of antimicrobial 
molecules, including those responsible for antifungal responses (Minegishi et 
al., 2009).  
Th17 cells also secrete IL-22, which is responsible for upregulating secretion 
of antimicrobial peptides like human beta defensins and CCL20 which have 
been implicated in both staphylococcal-driven atopic dermatitis and CMC 
(Conti et al., 2011; Kolls et al., 2008). The production of these antimicrobial 
peptides from keratinocytes and lung epithelial cells (when stimulated by T 
cells) is reduced in AD-HIES patients (Minegishi et al., 2009; Yong et al., 
2012). 
STAT3 has important roles in the differentiation of both osteoblasts and 
osteoclasts in vitro, and mice with Stat3-deficient osteoblasts show an 
osteoporotic phenotype (Itoh et al., 2006; O’Brien et al., 1999; Zhang et al., 
2005). Osteoclasts from AD-HIES patients with STAT3 mutations were shown 
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to have a higher bone resorption activity compared to those from control 
subjects. This may reflect the liability to fractures due to minor trauma 
observed in AD-HIES patients (Minegishi et al., 2007).  
IL-11 is a member of the IL-6-type cytokine family and as such signals via 
STAT3. It has recently been shown that inactivation of IL-11 signalling caused 
by a homozygous missense mutation in the IL-11R alpha is associated with 
craniosynostosis and delayed tooth eruption (Nieminen et al., 2011). These 
missense mutations (specifically Arg296Trp) rendered IL-11R alpha unable to 
stimulate STAT3-mediated signal transduction, hence resulting in clinical 
features seen in STAT3 deficiency (Yong et al., 2012).  
 
1.3.3.4 Diagnostic criteria 
AD-HIES affects multiple organ systems and patients should be carefully 
evaluated. 
In 1999, the National Institutes of Health (NIH) clinical HIES scoring system 
based on 20 clinical and laboratory findings was introduced as a diagnostic 
tool. A point scale was developed: more specific and objective findings were 
assigned more points. Scores of at least 40 points suggested AD-HIES, 
whereas a score below 20 made the diagnosis unlikely. For intermediate 
values, no firm conclusion could be reached (Figure 1.9).  
This clinically validated scoring system has facilitated the clinical diagnosis of 
AD-HIES and should therefore preferably be used (Grimbacher et al., 1999a).  
Further to this, an alternative scoring system to distinguish patients with and 
without STAT3 mutations has been suggested by our group (Woellner et al., 
2010). 
This scoring system divided patients into three categories: 
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1) possibly mutant STAT3, with an IgE >1,000 IU/ml plus a weighted score of 
>30 of recurrent pneumonia, newborn rash, pathologic bone fractures, 
characteristic facies and high palate; 2) probably mutant, with these features 
and a lack of Th17 cells or a definite family history of HIES; and 3) definitely 
mutant, with these features and a dominant-negative heterozygous mutation in 
STAT3 (Woellner et al., 2010). 
Although the scoring system represents a useful tool for screening patients for 
genetic testing for STAT3 mutations, the scores should not be used to keep 
physicians from pursuing a molecular diagnosis in a particular patient. Patients 
with AD-HIES accrue findings over time. Aggressive treatment with antibiotics 
can forestall infectious complications that would be diagnostic if allowed to 
occur (Woellner et al., 2010; Yong et al., 2012). 
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Figure 1.9: Clinical HIES scoring system based on 20 clinical and 
laboratory findings.  
(Grimbacher et al., 1999b) 
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1.3.4 The autosomal recessive Hyper IgE syndrome (AR-
HIES) 
The autosomal recessive form of HIES (AR-HIES), or type 2 HIES is very rare. 
Like the more frequent AD-HIES the disorder is characterized by the triad of 
highly elevated levels of IgE in serum, recurring abscesses of the skin, and 
recurrent pneumonia (Grimbacher et al., 2005; Renner et al., 2004).  
In contrast to AD-HIES, the AR variant is further characterized by a high 
susceptibility to viral infections such as herpes simplex and herpes zoster, 
molluscum contagiosum and human papillomavirus. These infections are 
usually extensive, difficult to control and mutilating and often occur 
concurrently (Su et al., 2011).  
Other clinical features such as the involvement of the CNS (facial paralysis, 
hemiplegia, ischemic infarction, and subarachnoid hemorrhage), or 
autoimmune phenomena are variably associated with the disease whereas 
vascular disorders appear to be common. The AR-HIES has high mortality due 
to sepsis and early onset of malignancies. Unlike AD-HIES, 50–80% of 
patients develop severe allergies, including anaphylaxis, to food and 
environmental antigens, as well as asthma (Su, 2010). The dental, skeletal 
and connective tissue anomalies, as well as the characteristic facies and 
pneumatoceles present in AD-HIES are absent in AR-HIES (Renner et al., 
2004).  
In all patients with AR-HIES both highly elevated serum IgE levels and 
increased IgG levels could be detected. Although eosinophilia is a common 
finding in both AD- and AR-HIES it tends to be more severe in the AR variant 
and often reaches values of up to 17.500/µL (normal range <700/µL) (Renner 
et al., 2004). 
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1.3.4.1 Genetics and pathogenesis 
The genetic defect underlying AR-HIES has only recently been unveiled.  
In 2006 a single patient with AR-HIES-like phenotype was reported with a 
homozygous deletion of four base pairs in the TYK2 gene leading to absence 
of TYK2 protein (Minegishi et al., 2006).  
The patient described was a 22 year old male from a consanguineous 
marriage, suffering from eczema, recurrent sinopulmonary infections, 
candidiasis Molluscum contagiosum and herpes infections with high serum IgE 
levels.  
However, unlike the other AR-HIES patients, he had experienced an episode 
of Bacille Calmette-Guerin (BCG) infection and non-typhi salmonella 
gastroenteritis. Subsequently, our group showed that TYK2 deficiency is not a 
common cause for the AR-HIES. We concluded that TYK2 deficiency more 
likely represents a distinct, yet similar, immunodeficiency disorder (Woellner et 
al., 2007).  
In 2012, a second case of TYK2 deficiency was published. This patient 
suffered from disseminated BCG infection, neurobrucellosis, and cutaneous 
herpes zoster infection but did not have a hyper IgE phenotype (Kilic et al., 
2012). 
Homozygous mutations of the dedicator of cytokinesis 8 (DOCK8) gene have 
been shown to be responsible for many, although not all, cases of autosomal-
recessive Hyper IgE syndrome (Engelhardt et al., 2009; Zhang et al., 2009). 
Since the discovery in 2009 that loss-of-function mutations in DOCK8 underlie 
AR-HIES, an estimated more than 100 patients worldwide have been 
identified.  
DOCK8 is a member of the DOCK family of guanine nucleotide exchange 
factors (GEFs), which function as activators of small G proteins (such as RAC 
Chapter 1: General Introduction 
 
65 
and CDC42) and play roles in regulation of cell migration, morphology, 
adhesion, and growth (Ruusala and Aspenström, 2004). DOCK8 is highly 
expressed within the immune system, especially in lymphocytes, suggesting 
crucial functions in these cell types and DOCK8 deficiency appears to  impair 
the CD4+ and CD8+ T cell proliferative responses (Lambe et al., 2011).  
The mutations found appear unique to each family. They encompass large 
deletions, point mutations that alter splicing to cause nonsense mutations, in-
frame nonsense mutations, and small insertions and deletions that cause out-
of-frame nonsense mutations (Engelhardt et al., 2009).  
 
1.3.5 Management, treatment and prognosis of HIES 
The therapeutic approach involves prevention and management of infections. 
Long-term administration of systemic antibiotics, antifungal and antiviral drugs 
is recommended. Lung abscesses may require surgery but possible 
complications require close attention (Freeman and Holland, 2010). For both, 
STAT3 and DOCK8 deficiency haematopoietic stem cell transplantation 
(HSCT) has been shown to be curative (Barlogis et al., 2011; Goussetis et al., 
2010; McDonald et al., 2010). However, due to several side effects including 
massive immunosuppression, HSCT is a risky intervention and should be 
considered only in severe cases. 
Although AD-HIES is associated with significant morbidity and mortality, 
adequate care, close monitoring and patient compliance has improved the 
prognosis, with survival to 50 years of age or over. For DOCK8-deficient AR-
HIES the prognosis without HSCT is poor. 
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1.4 Aim of the thesis 
Despite many years of intense research, the genetic aetiology of AD-HIES 
remained elusive until 2007, when heterozygous mutations in STAT3 were 
identified as a cause of AD-HIES.  
The aims of this thesis were:  
• to characterize a cohort of 153 patients with the clinical phenotype of 
AD-HIES, to identify STAT3 mutations and to assess their frequency   
• to explore the functional consequences of various STAT3 mutations 
and to associate the kind of mutation with the patients’ phenotype   
• to assess whether the application of functional tests and the  
enumeration of IL-17 producing T-helper cells might be used to predict 
the presence of a STAT3 mutation, therefore avoiding to sequence the 
entire STAT3 gene. 
• to further characterize HIES patients without STAT3 mutations by  
sequencing genes of related signalling pathways and analyzing 
cytokine release profiles of immune cells after stimulation. 
Studies of patients with AD-HIES can be used to explain the role of Th17 cells 
in infection and in other forms of dysregulated immunity.  
In general, the proposed work aimed at generating basic knowledge of the 
molecular biology of STAT3 signalling in AD-HIES patients and thus may pave 
the way to develop alternative therapies for patients suffering from either AD-
HIES or other diseases presenting with imbalanced Th17 cells. 
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2.1 Patients and Controls  
In a worldwide collaboration we have collected genomic DNA or RNA of 153 
unrelated patients with the suspected diagnosis of autosomal dominant Hyper 
IgE Syndrome (AD-HIES); 125 patients were referred to us with a completed 
NIH-clinical scoring sheet, of the remaining 28 patients DNA or blood was sent 
without detailed clinical information (but according to the referring 
immunologist all with strong suspicion of AD-HIES). Nine patients had one or 
more affected family members (Figure 3.14).  
Of the 153 patients 80 were male and 73 female; the age of the patients at the 
time of clinical evaluation ranged between 1 and 59 years. One hundred and 
twenty-four patients came from Europe (44 from Great Britain, 25 from Italy, 18 
from Poland, 14 from Germany, 10 from Spain, 3 from Sweden, 2 from Ireland, 
2 from Greece, 2 from Finland, 2 from the Czech Republic, one form Norway 
and one from Austria), 21 from the Middle East (10 from Iran, 6 from Israel and 
5 from Turkey), 7 from South America (Colombia), and 1 from North America 
(Canada). 
Ninety-two of the 125 patients who were referred to us with clinical information, 
had HIES scores ≥40, suggesting that these patients probably had AD-HIES, 
whereas 33 of the 125 patients had scores below 40, suggesting a diagnostic 
uncertainty or a variant of AD-HIES. Detailed information on patients, including 
available clinical scores and detected STAT3 mutations, are summarized in 
Table 1 of the Appendix.  
Genomic DNA from 100 healthy Caucasian subjects were used as control. In 
addition, 24 controls were studied for their lymphocyte phenotype. All patients 
and controls or their parental or legal guardians provided written consent for 
the study in line with local ethics committee requirements.  
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2.2 Molecular Biology  
2.2.1 Isolation of leukocytes from whole blood  
Leukocytes from patients and healthy controls were extracted from 5-10mL 
whole blood. 30mL of RBC (Red Blood Cell Lysis Buffer; 10mM NH4HCO3 and 
0.14M NH4Cl) buffer were added to 10mL whole blood, mixed by inverting 
several times and incubated on ice for 10 minutes. After centrifugation (10 min 
at 3500rpm) the supernatant was carefully discarded, leaving some residual 
liquid and the white blood cell pellet. The pellet was re-suspended in the 
residual liquid and the tube vortex vigorously. To eliminate residual 
erythrocytes the procedure was repeated adding 20mL of RBC buffer to the re-
suspended cell pellet. Isolated leukocytes were then subjected to DNA or RNA 
extraction. 
 
2.2.2 DNA isolation  
DNA of the patients and the healthy controls was isolated either from purified 
Leukocytes obtained as described above or from Peripheral Blood 
Mononuclear Cells (PBMCs) isolated as described in section 2.4.1.  
For the isolation of the DNA the Gentra Puregene Blood Kit (Qiagen, UK) 
was used according to the instructions of the manufacturer.   
In brief: 5mL of cell lysis solution (Gentra® Puregene®, Qiagen, UK) were 
added to pelleted leukocytes or PBMCs and mixed thoroughly to lysate the 
cells. Subsequently 3mL of protein precipitation solution (Gentra® Puregene® 
Qiagen, UK) were added to the cell lysate. The sample was then centrifuged at 
3500rpm for 20 minutes at 4°C. After centrifugation 10mL isopropanol were 
added into a clean 50mL tube and the supernatant from the previous step was 
added carefully. The tube was then inverted gently 50 times until the DNA 
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became visible as threads or clumps. The precipitated DNA was centrifuged at 
3500rpm for 10 minutes at 4°C, the supernatant was discarded and the pellet 
washed with 70% ethanol and centrifuged as above. After discarding the 
supernatant, the pellet was dried at room temperature for approximately 1 hour 
and rehydrated in appropriate amount of DNA hydration solution (Gentra® 
Puregene®, Qiagen, UK) depending on pellet size. 
 
2.2.3 RNA isolation 
Total RNA was isolated either from purified leucocytes or from peripheral blood 
mononuclear cells (PBMCs) using an RNA Isolation kit (RNeasy Mini Kit, 
Qiagen, UK) according to manufacturer’s instructions.  
 
2.2.4 Determination of DNA and RNA concentration 
To determine the DNA or RNA concentration samples were diluted 1:50 or 
1:100 with ddH2O. The absorbance of the sample was then measured 
photometrically of 260nm. To assess the purity of the nucleic acid the 
absorption of proteins was measured in parallel at a wavelength of 280nm. 
Ratio of readings at 260nm and 280nm [A260/A280] provides an estimate of 
purity of the nucleic acid. Pure preparations of DNA and RNA have ratios of 
1.8 – 2.0. If there is significant contamination with protein the ratio will be lower 
and accurate quantitation is not possible. 
 
2.2.5 cDNA synthesis (Reverse Transcription) 
For the synthesis of complementary DNA (cDNA) from total RNA the 
QuantiTect® Reverse Transcription Kit (Qiagen, UK) was used according to the 
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instructions of the manufacturer. The amount of template RNA used for 
reactions ranged between 200-500ng. 
 
2.2.6 Polymerase chain reaction (PCR) 
Genomic DNA or cDNA was amplified by polymerase chain reaction (PCR) in 
20µl reactions. All PCR consumables were purchased from Qiagen (UK) or 
PeqLab (UK).  
 
Standard 20µl PCR reactions were pipetted as follows: 
- 2µL 10x PCR-reaction-buffer  
- 2µL 1mM dNTP-Mix  
- 0,5µL 25µM forward-Primer 
- 0,5µL 25µM reverse-Primer 
- 0,2µL Taq DNA Polymerase (1U) 
- 1µL Template-DNA (ca. 50ng)   
- 4µL 5x Q-Soultion or enhancer solution (if needed) 
- ddH2O 
Total volume 20µl  
 
The following PCR program was used: 
 
 Temperature in °C Time Number of Cycles 
Denaturation 95 5 min 1 
Denaturation 
Annealing 
Extension 
95 
50-60 
72 
15 sec 
30 sec 
50 sec - 3 min 
 
30 
Extension 72 10 min 1 
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The annealing temperature used was determined either by the 4GC/2AT-rule 
or by a gradient PCR. The extension times were chosen according to the 
expected PCR product lengths (approximately 60 sec extension time per 1 kb). 
Primers used for the amplification are listed in the Appendix. 
 
2.2.7 Analysis of PCR products 
All amplified PCR products were analyzed by horizontal gel electrophoresis in 
1.0% agarose gels. 0.5µg/mL ethidium bromide (Sigma-Aldrich, UK) were 
added to the gel to enable the detection of double stranded DNA fragments 
with ultraviolet light. Two µL PCR product were diluted with 6x loading buffer 
(Sigma-Aldrich, UK), loaded on the gel and separated for 30 minutes at 100V. 
Afterwards the DNA fragments were visualized with a gel documentation 
system with UV light (295 nm). The correct PCR product size was verified 
using the molecular weight marker Hyperladder I (200bp- 10.000bp) (Bioline, 
UK).  
 
2.2.8 Purification of PCR products 
For removal of unincorporated dNTP’s and excess primers interfering with the 
subsequent sequencing, PCR reactions were digested with 1µL Shrimp 
alkaline phosphatase (SAP; Promega, UK) and 0.5µL Exonuclease I (Thermo 
Scientific, UK) which were added to the residual 18µL PCR reaction. SAP 
catalyzes the dephosphorylation of 5’ phosphates from nucleic acids and is 
completely and irreversibly inactivated by heat treatment for 15 minutes at 
65°C whereas the Exonuclease catalyzes the removal of nucleotides from 
single-stranded DNA in the 3' to 5' direction. The enzyme digestion was 
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performed in a PCR machine, for 15 minutes at 37°C followed by an enzyme 
inactivation step of 15 minutes at 80°C. 
 
2.2.9 Sequencing reaction 
Purified PCR products were sequenced with ABI PRISM BigDye Terminator 
cycle ready reaction kit V3.1 (Applied Biosystems). 
 
Sequencing reactions were pipetted as follows: 
- 1 - 3µL PCR-product (~ 50 ng) 
- 1µL Big Dye Terminator 3.1 
- 1,3µL Primer (2,5 µM) 
- ddH2O 
Total volume 20µl  
 
For the sequencing-reaction the following PCR program was used: 
 
 Temperature in °C Time Number of Cycles 
Denaturation 96 1 min 1 
Denaturation 
Annealing 
Extension 
96 
50-60 
60 
10 sec 
5 sec 
4 min 
 
30 
 
Annealing temperatures and primer sequences used were the same as for the 
previous PCR reactions. 
To remove unincorporated dye terminators and excessive primers, the 
sequencing reaction products were precipitated.   
Ethanol precipitation is a commonly used technique for concentrating and de-
salting nucleic acid (DNA or RNA) preparations in aqueous solution. The basic 
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procedure is that salt and ethanol are added to the aqueous solution, which 
forces the nucleic acid to precipitate out of solution. The precipitated nucleic 
acid can then be separated from the rest by centrifugation. 
Two µL 125mM EDTA, 2µL 3M sodium acetate and 50µL 100% ethanol were 
added to the sequencing reactions. Samples were incubated at room 
temperature for 15 minutes in the dark and then centrifuged at 3500rpm for 30 
minutes at 4°C. The supernatant was discarded carefully without disrupting the 
pellet. The pellet was washed with 120µL 70% ethanol and again centrifuged 
(3500rpm, 10 min, 4°C). The supernatant was discarded and the pellet dried at 
96°C for 3 minutes to eliminate the residual ethanol. The pellet was then re-
dissolved in 50µL H2O before loading onto the sequencer. 
Sequencing was carried out with the 3130xl Applied Biosystems Genetic 
Analyzer. 
 
2.2.10 Analysis of sequences 
Data obtained were analyzed with Sequencing Analysis software, version 5.2 
(Applied Biosystems) and SequencherTM, version 4.8 (Gene Codes 
Corporation). Reference sequences were available from the genbank 
“Ensemble” (http://www.ensembl.org/index.html). 
 
2.2.11 Bioinformatic tools  
2.2.11.1 PolyPhen-2 
PolyPhen-2 (Polymorphism Phenotyping v2) is a web-based tool, which 
predicts the possible impact of an amino acid substitution on the structure and 
function of a human protein using physical and comparative considerations. 
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For each amino acid substitution both a qualitative prediction (one of 'probably 
damaging', 'possibly damaging', 'benign' or 'unknown') and a score is given. 
The PolyPhen score represents the probability that a substitution is damaging 
(http://genetics.bwh.harvard.edu/pph2), 
 
2.2.11.2 Mutation Taster 
MutationTaster is a free, web-based application for rapid evaluation of the 
disease-causing potential of DNA sequence alterations. MutationTaster 
integrates information from different biomedical databases and uses 
established analysis tools. Analyses comprise evolutionary conservation, 
splice-site changes, loss of protein features and changes that might affect the 
amount of mRNA. Test results are evaluated by a naive Bayes classifier, which 
predicts the disease potential (http://www.mutationtaster.org and Schwarz et 
al., 2010). 
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2.3 Protein Biochemistry 
2.3.1 Preparation of protein extracts 
Cell extracts of patients’ and healthy donors’ PBMCs were prepared by using 
cell lysis buffer (Cell Signaling, UK) supplemented with 1mM of the protease 
inhibitor Phenylmethylsulfonylfluorid (PMSF). 107 cells were first washed once 
with PBS and pelleted by centrifugation before 400µl of lysis buffer were 
added. Cells were incubated on ice for 15 minutes and sonicated briefly. 
Afterwards extracts were centrifuged at 14,000g for 10 minutes at 4°C. Protein 
concentration of the supernatants was measured and extracts were stored at -
80°C until further use.  
 
2.3.2 Determination of protein concentration  
The protein content of cell lysates was determined using the BCATM protein 
assay kit (Thermo Scientific, UK).  
With this kit the total protein concentration is exhibited by a colour change of 
the sample solution from green to purple in proportion to protein concentration. 
The colour change can then be measured using a photometer. 
In a first step the proteins and Cu2+ ions form a Cu2+-protein complex under 
alkaline conditions which is followed by the reduction of the Cu2+ to Cu1+. The 
amount of reduced Cu2+ is proportional to the amount of protein present in the 
solution. Next, bicinchoninic acid (BCA) forms purple-blue complexes with Cu1+ 
in alkaline environments, thus providing a basis to monitor the reduction of 
alkaline Cu2+. The purple-coloured reaction products strongly absorb light at a 
wavelength of 562 nm. The absorbance is directly proportional to protein 
concentration. 
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A calibration curve for the quantification of protein content was created using 
serial dilutions of Bovine serum albumin (BSA). 
 
2.3.3 SDS-Polyacrylamide-gelelectrophoresis (SDS-PAGE) 
Proteins of cell extracts were separated according to their molecular weight by 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). SDS 
is an anionic detergent which denatures proteins and confers negative charge 
to the polypeptide according to its length.  To reduce disulphide bridges in 
proteins 2- mercaptoethanol was added. In these denaturing SDS-PAGE 
separations therefore, migration through polyacrylamide gel is determined only 
by molecular weight.  
The most commonly used system of SDS-PAGE is the Laemmli method.  
The Laemmli system uses buffers of different pH and composition to generate 
a voltage gradient and a discontinuous pH between a stacking and a resolving 
gel. A lower concentrated stacking gel (pH 6.8) is poured on top of a more 
concentrated resolving gel (pH 8.8). The stacking gel concentrates the proteins 
on top of the resolving gel. After entering the resolving gel the proteins are 
separated according to relative molecular size.  
For our purpose a stacking gel with an acrylamide concentration of 6% (0.5 
Tris-HCl pH 6.8; 20%(w/v) SDS; Acrylamide/Bis-acrylamide (30%/0.8% w/v); 
10%(w/v) ammonium persulfate (APS); 0,02mL TEMED) and a resolving gel 
with a concentration of 10% was used (1.5M Tris-HCl pH 8.8; 20%(w/v) SDS; 
Acrylamide/Bis-acrylamide (30%/0.8% w/v); 10%(w/v) ammonium persulfate 
(APS); 0,02mL TEMED).  
The protein extracts to analyse (5-20µg total protein) were added to 5x sample 
buffer (10%(w/v) SDS; 10mM beta-mercapto-ethanol; 20%(w/v) Glycerol; 0.2M 
Tris-HCl pH6.8; 0.05%(w/v) Bromophenolblue), denatured for 5 minutes at 
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95°C, cooled on ice and applied to the gel. The electrophoresis was carried out 
for about 2 h at 120V in SDS-PAGE running buffer (25mM Tris-HCl; 200mM 
Glycine; 0.1%(w/v) SDS). The size of the proteins was assessed by adding a 
size standard. 
 
2.3.4 Transfer of proteins separated by gelelectrophoresis on 
membranes (Western Blot) 
In order to make them accessible to antibody detection, proteins separated by 
gel electrophoresis were moved from within the gel onto a polyvinylidene 
difluoride (PVDF) membrane by a second electrophoretic transfer by using a 
semi-dry transfer system. The gel and membrane were sandwiched between 
two stacks of filter paper wetted with transfer buffer (25mM Tris-HCl; 250mM 
Glycine; 20% methanol) and placed in a transfer chamber as shown below. 
 
 
  Cathode (-) 
  - Filter paper 
  - Gel 
  - Membrane 
  - Filter paper 
  Anode (+) 
 
 
Application of voltage across the electrodes makes the proteins migrate from 
the gel to the membrane. The transfer took an hour at a voltage of 12V. 
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2.3.5 Detection of electrophoretically separated proteins with 
specific antibodies 
After the transfer the membrane was incubated for one hour with 5% (w/v) milk 
powder in PBS  +0.1%Tween20 to block unoccupied binding sites on the 
membrane and thus to prevent nonspecific binding of antibodies. After this 
blocking step the membrane was incubated overnight at 4°C with the primary 
antibody (diluted according to manufacturer’s recommendations in PBS-Tween 
containing 5% milk powder). 
After three washing steps with PBS-Tween (15 min each), the membrane was 
incubated for 1 hour at RT with a horseradish peroxidase-linked secondary 
antibody. After another washing step the secondary antibodies were visualized 
using a chemiluminescence-based kit (LumiGLO®, Cell Signalling, UK).  
The chemiluminescent reaction is based on the emission of light during the 
horse radish peroxide-catalyzed oxidation of luminol. The kit was used 
according to the instructions of the manufacturer. After incubation the excess 
of LumiGLO® was drained, the membrane wrapped in plastic and exposed to 
an X-ray film. 
 
2.3.6 TNF-α Enzyme linked immunosorbent assay (ELISA) 
To assess the capability of IL-10 to inhibit the TNF-α release in 
patients'/healthy controls' PBMCs and/or monocytes/macrophages, these cells 
were pre-incubated with 25ng/mL IL-10 (R&D, UK) for 1 hour and then 
stimulated overnight with 50ng/mL Escherichia coli LPS (Sigma, UK). TNF-α 
release was measured by using an ELISA self-development kit (PeproTech, 
UK) in accordance with the manufacturer’s instructions. In brief, ELISA-
microplates (Nunc, Germany) were coated overnight with anti-TNF-capture 
antibodies. After three washing steps with washing buffer (0.05% Tween-20 in 
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PBS), 300µL blocking buffer (1% BSA in PBS) were added to each well and 
incubated for 1 hour to prevent unspecific bindings. After a further washing 
step, samples and serial dilutions of a TNF-α standard provided by the 
manufacturer were added to the wells in duplicates and incubated for 2 hours. 
The plate was then washed and 100µl biotinylated detection antibody were 
added to the wells containing standards/samples.  After another 2-hour 
incubation and a further washing step, Avidin-HRP conjugate were added for 
30 minutes. Finally, 100µl substrate 2,2′-Azino-bis(3-ethylbenzothiazoline-6-
sulfonic acid) (ABTS) Liquid Substrate (Sigma-Aldrich, UK) were added to 
each well. The development of a greenish color indicated the presence of 
TNF-α in the samples/standards. Quantitative analysis was carried out by 
using an ELISA reader; optical densities were read at 405nm with wavelength 
correction set at 650nm. Accurate TNF-α concentrations were worked out 
using the Magellan software (Tecan, Switzerland).  
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2.4 Cellular Biology 
2.4.1 Isolation of peripheral blood mononuclear cells 
(PBMCs) from whole blood or buffy coats. 
EDTA-blood of patients was sent by referring physicians, blood of healthy 
controls was obtained from volunteer donors from the National Blood Service. 
PBMCs were separated from whole blood by gradient separation using 
Lymphoprep® (Axis-Shield, UK). The blood was mixed 1:1 with PBS, gently 
layered onto 15mL of Lymphoprep® in 50mL tubes and centrifuged at 1600rpm 
for 20 minutes. Mononuclear cells formed a distinct band at the sample 
interface between plasma and Lymphoprep® while red cells were pelleted at 
the bottom of the tube (Figure 2.1). PBMCs were harvested with a Pasteur 
pipette, washed with PBS and pelleted by centrifugation for 5 minutes at 
1500rpm. Cells were then processed immediately or frozen for later use.  
 
 
 
Figure 2.1: Use of Lymphoprep® to separate mononuclear cells from 
whole blood.  
After centrifugation PBMCs are visible as thin layer in-between plasma and the 
Lymphoprep® solution. 
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2.4.2 Freezing and thawing of cells 
Cell pellets from above were re-suspended in freezing medium (50% FCS, 
40% RPMI, 10% Dimethyl Sulfoxide (DMSO)) and aliquots of 5-10x106/mL 
cells were frozen overnight at -80°C. After 24 hours cells were transferred to 
liquid nitrogen to store them until use. 
Frozen PBMCs were gently thawed in a water bath at 37°C, washed twice with 
warm RPMI Medium (supplemented with 10% FCS; 1% penicillin/streptomycin 
(all from Gibco, UK) and 1% L-Glutamine (Lonza, UK) and centrifuged at 
1500rpm for 5 minutes. Cells were then ready for further experiments. 
 
2.4.3 Generation of monocyte-derived macrophages 
Freshly isolated or thawed PBMCs were re-suspended at a concentration of 
106/mL in RPMI medium (prepared as described above) into 24-well plates 
(Nunc, UK). Monocytes were allowed to adhere to the bottom of the plate for 1 
hour at 37°C, non-adherent cells were then removed by vigorous washing with 
PBS. Monocyte-derived macrophages were generated as previously described 
(Buettner et al., 2005), kept in Opti-Mem I serum free medium (Life 
technologies, UK), and differentiated by adding 50ng/mL M-CSF (Peprotech, 
UK) per day. After 5 days of culture, the monocytes/macrophages were used 
for further experiments. 
 
2.4.4 Stimulation of cells 
Freshly isolated or thawed PBMC were re-suspended at a concentration of 
106/mL in RPMI medium (prepared as described above) in 24-well plates and 
exposed to either Staphylococcus enterotoxin B (SEB) 1µg/mL or to Phorbol 
12-myristate 13-acetate (PMA) 50ng/mL and Ionomycin (all from Sigma, UK) 
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1µg/mL for 5 or 16 hours at 37°C and 5% CO2. After one hour, brefeldin A 
(Sigma, UK) 5µg/mL was added. Both ways of stimulation assessed the 
physiological cytokine production of already committed T cells. These 
stimulations do not drive naїve T cells into the T cell differentiation, but merely 
make visible already committed T cells.  
 
2.4.5 Cell staining and Fluorescence activated cell sorting 
(FACS) 
To identify certain T cell subsets, PBMCs were stained using primary 
antibodies conjugated with the fluorochromes PE, PE-Cy7, PerCP, FITC and 
Alexa Fluor 647 and analysed by flow cytometry. 
For surface stainings ~106 cells were washed and re-suspended in 50µl of 
FACS buffer (PBS with 1% BSA) with fluorochrome-conjugated monoclonal 
antibodies specific for the respective cell surface protein and incubated for 30 
minutes at 4°C. The antibodies used to stain surface molecules included anti-
CD3PerCP, anti-CD3PE, anti-CD4PerCP, anti-CD4PE and anti-CD45ROPE-
Cy7 (all from BD Bioscience, UK). To carry out additional intracellular stainings 
cells were fixed and permeabilized by using the BD Cytofix/Cytoperm 
Fixation/Permeabilization Kit (BD Biosciences, UK). Intracellular stainings were 
accomplished by using anti-IL-17Alexa Fluor 647- (eBioscience, UK), anti-
IL21PE-, anti-IL22PE-, anti-IFN-γFITC- and anti RORγtPE-antibodies (all from 
BD Bioscience, UK). 
After carrying out the staining procedures cells were washed and re-
suspended in 500µl buffer for analysis.  
Flow cytometry analysis was performed using an LSR II flow cytometer; data 
were analysed using FACS Diva software (BD Biosciences, UK) and FlowJo 
8.7.3 (Treestar, US).  
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2.4.6 FlowCytomixTM Multiple Analyte Detection System 
The FlowCytomixTM Multiple Analyte Detection System (eBioscience, UK) is a 
kit designed to quantify up to 20 target proteins simultaneously. The 
FlowCytomix™ technology uses fluorescent beads coated with specific 
antibodies to quantify multiple proteins in a single tube. The combination of two 
different bead sizes (4 and 5µm) and different internal fluorescent dye 
intensities makes it possible to distinguish up to 20 bead sets in one 
fluorescent channel. Streptavidin-PE, which binds to the biotin conjugate, 
emits at 578nm allowing the quantification of the analyte. 
FlowCytomix™ bead-based assays follow the same principle as a sandwich 
immunoassay: In a first step antibody-coated beads are added to the sample 
to analyze. Then biotin-conjugated, antibodies specific for another epitope of 
the bound analytes are added. Streptavidin-PE is added for detection of biotin-
conjugated antibody. The bead populations are finally analysed according to 
bead size and fluorescent signature by flow cytometry (Figure 2.2). Flow 
cytometry analysis was performed using an LSR II flow cytometer (BD 
Biosciences, UK). FlowCytomix™ Pro Software was used to calculate analyte 
concentrations in the samples.  
For our experiments the Human Th1/Th2 11plex Ready-to-Use FlowCytomix 
Multiplex kit was used. This kit is designed for the measurement of human 
IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12 p70, TNF-α and TNF-β. 
Human IL-17A/F and human IL-22 FlowCytomix™ Simplex for the 
simultaneous measurement of IL-17 and IL-22 were added.   
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Figure 2.2: FlowCytomix™ bead-based assays 
The bead based FlowCytomixTM Multiplex Immunoassays assays enables the parallel 
analysis of multiple analytes in short time. (A) Staining of cytokines (B) Flow cytometry 
is used to differentiate bead populations according to bead size and fluorescent 
signature. Figure modified after eBioscience FlowCytomix™ Multiple Analyte Detection 
User Guide. 
B 
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3.1 Introduction 
In 2007, mutations in the signal transducer and activator of transcription 3 
(STAT3) were shown to cause autosomal dominant Hyper IgE Syndrome (AD-
HIES). Minegishi et al. described five different heterozygous STAT3 mutations 
in eight out of fifteen unrelated non-familial AD-HIES patients. All mutations 
affected the DNA-binding domain of STAT3 (Minegishi et al., 2007).   
In parallel, Holland et al. sequenced STAT3 in DNA samples from 50 AD-HIES 
patients and 48 unaffected relatives from 35 unrelated families. All 50 affected 
individuals carried heterozygous mutations in STAT3 (Holland et al., 2007). 
The STAT3 mutations were localized either to regions encoding the DNA-
binding domain or the SH2 domain. It became apparent that most mutations 
cluster together and form mutational “hot spots”. All variations found were 
heterozygous missense mutations or in-frame deletions or duplications, 
associated with normal protein expression. The observed heterozygous 
mutations were shown to exert dominant-negative effects (Minegishi et al., 
2007).  
It has previously been shown that homozygous loss of Stat3 leads to the death 
of deficient mouse embryos, whereas mice heterozygous for the Stat3 
mutations are phenotypically normal and fertile. Therefore, Stat3 is necessary 
for survival, but haploinsufficiency does not result in an apparent phenotype in 
mice (Takeda et al., 1997). This finding is consistent with the observation that 
dominant-negative STAT3 mutations decrease STAT3 homodimer activity to 
approximately 25% of the normal level (Minegishi and Karasuyama, 2009; 
Minegishi et al., 2007) (Figure 3.1).  
 
 
 
Chapter 3: Sequencing of STAT3 
88 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: The JAK-STAT signalling pathway with heterozygous STAT3 
mutations  
The observed heterozygous mutations have been shown to exert dominant-negative 
effects (Minegishi et al., 2007). Statistically, 75% of the STAT3 dimers are either 
heterozygous wild-type/mutated or homozygous mutated and thus not functional. The 
residual STAT3 activity (25%) might rescue the patients from early embryonic death, 
which is observed in Stat3-deficient mice (Takeda et al., 1997). (A) Pathway in normal 
condition. (B) Pathway with heterozygous mutated STAT3. 
  
A B 
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Since 2007, more than 200 patients carrying STAT3 mutations, including 64 
from this study, have been reported in literature either in individual case 
reports or national and international studies (Anolik et al., 2009; Avery et al., 
2008, 2010; de Beaucoudrey et al., 2008; Chandesris et al., 2012; Holland et 
al., 2007; Jiao et al., 2008; Kim et al., 2009; Kumánovics et al., 2010; Liu et al., 
2011b; Ma et al., 2008; Milner et al., 2008; Minegishi et al., 2007; Powers et 
al., 2009; Renner et al., 2007, 2008; Schimke et al., 2010; Vinh et al., 2010; 
Woellner et al., 2010; Xie et al., 2010) (Figure 3.2). Nevertheless not all 
patients with the clinical diagnosis of AD-HIES present mutations in STAT3 
(Minegishi et al., 2007; Renner et al., 2008; Woellner et al., 2010).  
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Figure 3.2: Schematic structure of STAT3 revealing mutational hotspots 
in the DNA-binding and SH2 domain 
Schematic representation of STAT3 showing the positions of the STAT3 mutations. 
Mutations affect the amino-terminal (NT), the DNA-binding (DNA-B), the linker, the Src 
homology 2 (SH2) and the transcriptional activation (TAD) domains. Mutations on the 
upper part of the cartoon were identified in patients of the current study (Woellner et 
al., 2010). Underscored mutations have not yet been published in literature. Figure 
modified after Chandesris et al., 2012.  
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3.2 Questions  
1) Do all Patients with the clinical diagnosis of AD-HIES carry mutations in 
STAT3? And how common is a diagnosis of AD-HIES without a STAT3 
mutation?  
2) Do all mutations affect the DNA-binding domain or the SH2-domain of 
STAT3 or are there other domains hit by mutations? 
3) Is there segregation of the mutations with the affection status of family 
members in AD-HIES families with more than one affcted patient? 
4) What is the bioinformatic assessment of STAT3 missense changes 
using the online prediction tool PolyPhen? 
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3.3 Results 
3.3.1 STAT3 mutations 
We amplified and sequenced all coding parts of STAT3 in 153 patients with 
suspected AD-HIES. All patients showed normal PCR amplification for all 
coding exons (exons 2-24; exon 1 is not coding) analysed, and all PCR 
products had the expected length. PCR products of a representative patient 
are shown in Figure 3.3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: STAT3 PCR products 
Agarose gel of amplified STAT3 PCR products for one patient with suspected AD-
HIES. Exons 9 and 10 as well as exons 12 to 14 and exon 16 and 17 are located in 
close proximity on the genomic DNA and were amplified in one PCR product. All 
amplified products showed the expected length. Although the band of exon 16 and 17 
is fainter than the others it was good enough for sequencing.  M, marker; bp, base 
pairs.  
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Out of the 153 patients sequenced, 82 carried heterozygous mutations in 
STAT3. Seventy-one patients did not show any mutation in the coding regions 
of STAT3 or their flanking intronic sequences. Overall, we found 39 different 
mutations: Fifty-five patients carried mutations described previously, (de 
Beaucoudrey et al., 2008; Holland et al., 2007; Jiao et al., 2008; Ma et al., 
2008; Milner et al., 2008; Minegishi et al., 2007; Renner et al., 2008) 27 
patients harboured yet undescribed, novel mutations. 
The mutations affected the DNA-binding domain, the SH2 domain, the 
transcriptional activation domain, and the N-terminal domain. Seventy-two 
mutations were missense mutations in which a single nucleotide was replaced, 
resulting in an amino acid exchange, one patient harboured an in-frame 
duplication of three amino acids and one patient carried an in-frame deletion of 
one amino acid.  
Six mutations, seen in eight patients, were heterozygous mutations at the 
intron-exon boundaries of exons 12 or 22, affecting the DNA-binding and 
transcriptional activation domain, respectively. Each of these intronic mutations 
led to an incorrect splicing of its adjacent exon (Table 3.1).  
None of the mutations identified in our patients was observed in 100 healthy 
controls or reported in any of the SNP databases. 
A substantial portion (71 patients) of our cohort did not have mutations in the 
coding or splice regions of STAT3. To exclude undetected splice site variants 
not yet described in healthy individuals, we sequenced the cDNA from 25 of 
these patients, none of whom revealed any mutation or exon skipping. 
Because of the limited availability of samples, the cDNA of the other patients 
was not examined. 
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Number 
of 
patients 
Protein domain Site of 
mutation 
DNA sequence change Predicted 
amino acid 
change 
1 N-terminal  Exon 3 c.172C>T H58Y 
1 DNA-binding Exon 10 c.982_990dupTGCATGCCC C328_P330dup 
1 DNA-binding Exon 10 c.1025G>A G342D 
3 DNA-binding Intron 11 c.1110–2A>G D371_G380del 
1 DNA-binding Intron 11 c.1110–1G>A D371_G380del 
1 DNA-binding Intron 12 c.1139+1G>T D371_G380del 
1 DNA-binding Intron 12 c.1139+1G>A D371_G380del 
1 DNA-binding Intron 12 c.1139+2insT D371_G380del 
16 DNA-binding Exon 13 c.1144C>T R382W 
1 DNA-binding Exon 13 c.1145G>T R382L 
11 DNA-binding Exon 13 c.1145G>A R382Q 
1 DNA-binding Exon 13 c.1150T>A 
F384L 
2 DNA-binding Exon 13 c.1150T>C 
1 DNA-binding Exon 13 c.1166C>T T389I 
1 DNA-binding Exon 14 c.1234A>G T412A 
1 DNA-binding Exon 14 c.1268G>A R423Q 
1 DNA-binding Exon 16 c.1387_1389delGTG V463del 
1 DNA-binding Exon 16 c. 1396 A>G N466D 
1 DNA-binding Exon 16 c.1397A>G N466S 
1 DNA-binding Exon 16 c.1397A>C N466T 
1 DNA-binding Exon 16 c.1398C>G N466K 
1 DNA-binding Exon 16 c.1407G>T Q469H 
1 SH2 Exon 20 c.1771A>G K591E 
2 SH2 Exon 20 c.1843A>G K615E 
1 SH2 Exon 20 c.1865C>T T622I 
1 SH2 Exon 21 c.1907C>A S636Y 
12 SH2 Exon 21 c.1909G>A V637M 
1 SH2 Exon 21 c.1909G>T V637L 
1 SH2 Exon 21 c.1910T>C V637A 
1 SH2 Exon 21 c.1915C>T P639S 
1 SH2 Exon 21 c.1916C>G P639R 
1 SH2 Exon 21 c.1918T>A Y640N 
2 SH2 Exon 21 c.1970A>G Y657C 
1 SH2 Exon 21 c.2003C>T S668F 
1 TAD Exon 22 c.2113T>C Y705H 
1 TAD Exon 22 c.2117T>C L706P 
2 TAD Exon 22 c.2124C>G T708S 
1 TAD Exon 22 c.2129T>C F710C 
1 TAD Exon 22 c.2141C>G T714A 
1 TAD  Intron 22 c.2144+1G>A p.? 
Table 3.1:  STAT3 mutations of the 153 AD-HIES patients studied  
Of the 153 patients studied, 82 patients had 39 distinct mutations. Fourteen of these mutations 
were reported previously (Minegishi et al, 2007; Holland et al, 2007; Renner et al, 2008; Milner 
et al, 2008; Ma et al, 2008; de Beaucoudrey et al 2008 and Jiao et al, 2008) The other 25 
mutations, which are shaded in this table, were not reported at the time of discovery. TAD, 
transcriptional activation domain; p.?, unknown effect on protein level. 
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3.3.2 Mutation in the N-terminal domain  
The N-terminal domain, comprising approximately 130 amino acids, is 
conserved among the STATs and represents an independently folded and 
stable moiety (Kisseleva et al., 2002). It has been shown that the N-terminal 
domain is needed for the formation of unphosphorylated STAT3 dimers and 
the nuclear accumulation of STAT3 upon phosphorylation (Vogt et al., 2011). 
Only one patient of our cohort carried a heterozygous mutation in the N-
terminal domain of STAT3. The mutation affects base pair 172 (C>T) and 
leads to the amino acid exchange histidine (H) to tyrosine (Y) at position 58 
(H58Y) (Figure 3.4).  
 
 
 
 
 
 
Figure 3.4: Chromatogram of the mutation affecting the N-terminal 
domain of STAT3 
The chromatogram represents a wild-type sequence and the heterozygous change of 
the cytosine to thymine at position 172 of the patient indicated with a blue arrow. The 
mutation leads to the amino acid exchange H58Y. 
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3.3.3 Mutations in the DNA-binding domain 
Most mutations were found in the DNA binding domain of STAT3. Forty-nine 
patients carried 20 different mutations. The majority of mutations affected the 
arginine (R) residue at position 382 in exon 13. In 16 cases, the arginine was 
replaced by tryptophan (W), in 11 patients by glutamine (Q) and in one patient 
with leucine (L). Beside the arginine 382 two further amino acid residues were 
shown to be mutated in exon 13. The phenylalanine (F) at position 384 was 
changed to leucine (L) in three patients and threonine (T) at position 389 was 
replaced by isoleucine (I) in one case.  
We also detected mutations in exons 10, 14, and 16.  
One patient harboured an in-frame duplication of three amino acids 
(C328_P330dup) in exon 10 as shown in Figure 3.5, another patient was found 
to carry the replacement from glycine to aspartic acid at position 342 (G342D).  
Two patients had mutations affecting exon 14. One carried the change from 
threonine (T) to alanine (A) at position 412, another the replacement from 
arginine (R) 423 to glutamine (Q).   
Four of the six mutations detected in exon 16 resulted in a replacement of 
asparagine (N) residue at position 466; four patients carried four different 
changes, one to aspartic acid (D), one to serine (S), one to threonine (T) and 
one to lysine (K). The deletion of the valine (V) residue at position 463 
(V463del) and the change glutamine from (Q) to histidine (H) at position 469, 
were both found in one patient respectively (Figure 3.6 and 3.7). Five 
mutations of the DNA binding domain observed in eight patients are splice-site 
mutations and are discussed in chapter 3.3.6.  
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Figure 3.5: Chromatogram of duplication mutation in exon 10 
Chromatogram of exon 10 of STAT3 showing the nucleotides, the respective peaks 
and the resulting protein sequence. (A) Wild-type sequence (B) Sequence of AD-HIES 
patient with heterozygous duplication and insertion of 9 nucleotides 
(c.982_990dupTGCATGCCC) resulting in an overlap of chromatograms. The 
duplicated nucleotide and the resulting duplicated amino acid sequences are shaded. 
   
 
  
A 
B 
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Figure 3.6: Chromatograms of the STAT3 DNA-binding domain mutations 
-part I 
The chromatograms represent wild-type sequences and the heterozygous changes (A) 
1025G>A leading to amino acid substitution G342D (B) 1144C>T, 1145G>T and 
1145G>A leading to amino acid changes R382W, R382L and R382Q (C) 1150T>A 
and 1150T>G both leading to the changes F384L (D) 1166C>T leading to the 
substitution T389I and (E) 1234A>G leading to the change T412A. All changes are 
highlighted by a blue arrow.  
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Figure 3.7: Chromatograms of the STAT3 DNA-binding domain mutations 
-part II 
The chromatograms represent wild-type sequences and the heterozygous changes (F) 
1396A>G, 1397A>G,  1397A>C and 1398C>G  leading to the amino acid changes 
N466D, N466S, N466T and N466K (G) 1268G>A leading to the substitution R423Q  
(H) 1407G>T leading to the change Q469H and (I) c.1387_1389del resulting in the 
deletion of the Valine (V) at position 463 (V463del) (the heterozygous deletion of the 
three nucleotides results in an overlap of the chromatograms). The chromatogram 
shows a reverse sequence. All changes are indicated by a blue arrow. 
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3.3.4 Mutations affecting the Src homology 2 (SH2) domain  
Twenty-five patients had twelve different mutations in the SH2 domain: the 
most frequent one, with valine (V) replaced by methionine (M) at position 637, 
was identified in twelve patients. In two other patients, the valine was replaced 
by leucine (L) and alanine (A) respectively. Several other amino acids in exon 
21 were also shown to be mutated. The serine (S) at position 636 and 668 
were replaced by tyrosine (Y) and phenylalanine (F); and tyrosines (T) 640 and 
657 were replaced by asparagine (N) and cystein (C) respectively.  The proline 
(P) at position 639 showed two different changes one to serine (S) and one to 
arginine (R). 
Three other mutations affecting the SH2 domain were found in exon 20. At 
positions 591 and 615  the lysines (K) were found to be substituted by glutamic 
acid (E) and at position 622, threonine (T) was replaced by Isoleucine (I) 
(Figure 3.8 and 3.9).  
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Figure 3.8: Chromatograms of the STAT3 SH2-domain mutations -part I 
The chromatograms represent wild-type sequences and the heterozygous changes (A) 
1771A>G leading to amino acid substitution K591E (B) 1843A>G leading to the 
change K615E (C) 1865C>T ending in the substitution T6221I (D) 1907C>A  leading to 
amino acid substitution S636Y (E) 1909G>A, 1909G>T  and 1910T>C  leading to 
amino acid changes V637M, V637L and V637A and  (F) 1915C>T and 1916C>G  
leading to the substitutions P639S and P639R respectively. All changes are 
highlighted by a blue arrow. 
 
 
Chapter 3: Sequencing of STAT3 
102 
 
 
 
 
 
Figure 3.9: Chromatograms of the STAT3 SH2-domain mutations -part II 
The chromatograms represent wild-type sequences and the heterozygous changes 
(G) 1918T>A leading to amino acid substitution Y640N (H) 1970 A>G leading to the 
change Y657C and (I) 2003C>T ending in the substitution S668F. All changes are 
highlighted by a blue arrow. 
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3.3.5 Mutations affecting the transcriptional activation 
domain  
Seven patients had six different mutations in the transcriptional activation 
domain, which is downstream of the SH2 domain. Five of these were missense 
mutations whereas one affected the splice site of exon 22. 
All mutations in this domain were located in exon 22. The amino acids found to 
be changed were the tyrosine (Y) at position 705 substituted by histidine (H), 
the leucine (L) at position 706 changes to proline (P), the threonines (T) 708 
and 714  replaced by serine (S) and alanine (A) respectively and the 
phenylalanine (F) at position 710 substituted by cysteine (C) (Figure 3.10).  
One mutation affecting the transcriptional activation domain is a splice-site 
mutation and discussed in chapter 3.3.6.  
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3: Sequencing of STAT3 
104 
 
 
 
 
Figure 3.10: Chromatograms of the STAT3 mutations affecting the 
transcriptional activation domain   
The chromatograms represent wild-type sequences and the heterozygous changes (A) 
2113T>C leading to amino acid substitution Y705H (B) 2117T>C leading to the change 
L706P (C) 2124C>G ending in the substitution T708S (D) 2129T>G  leading to amino 
acid substitution F710C and  (E) 2141G>A leading to amino acid change T714A. All 
changes are highlighted by a blue arrow.  
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3.3.6 Splice site mutations 
Although more than 90% of the mutations were located in the exons of STAT3, 
we found 6 mutations at the intron-exon boundaries. 
Four patients had 2 different heterozygous mutations at the 3′ splice site 
before exon 12, and 3 patients had distinct mutations in at the 5′ splice site 
after exon 12. All 5 mutations caused the skipping of exon 12 leading to a 
heterozygous in-frame deletion of amino acids 371 to 380 (Figure 3.11). The 
deletion of the exon has been confirmed by sequencing the cDNA as shown in 
Figure 3.12. 
One patient harboured a mutation one nucleotide after exon 22 that caused 
the exon to be skipped. The effect of this splice site mutation is complex. In 
healthy individuals, alternative splicing of exon 23 results in 2 major isoforms 
of STAT3: STAT3α and STAT3β. Whereas STAT3α contains the entire exon 
23, STAT3β lacks the first 50 bp of the same exon (Maritano et al., 2004). The 
splice site introduced by the mutation causes the 43-bp exon 20 to be skipped. 
In the wild-type STAT3α transcript, this deletion would result in a frame shift 
and possibly nonsense mediated decay. However, in conjunction with the 
shortened exon 23 of STAT3β, this deletion is predicted to produce a transcript 
coding for STAT3α with an in-frame deletion of amino acids 701 to 732, which 
would encompass both the tyrosine and serine phosphorylation sites of 
STAT3α (Figure 3.13). 
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Figure 3.11: Splice site mutations on gDNA 
The chromatograms represent wild-type sequences and the heterozygous splicesite 
mutations (A) c.1110-2A>G and c.1110-1G>A in intron 11 (B) c.1139+2insT 
sequenced in forward and reverse direction in intron 12 (C) 1139+1G>T and 
1139+1G>A in intron 12 and (D) 2144+1G>A in intron 23. The contiguous exons are 
highlited. All changes are highlighted by a blue arrow. 
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Figure 3.12: Skipping of exon 12  
cDNA sequence and schematic representation of the consequence of the mutations 
detected in the splice site regions of exon 12.  The cDNA sequences show wild-type 
sequences of healthy controls and the overlap of chromatograms in patients lacking 
exon 12 on one allele. The cDNA has been sequenced in both directions (forward and 
reverse). The identified splicing mutations cause an in-frame deletion of 10 amino 
acids (red). 
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Figure 3.13: Splice site mutation exon 22  
Two alternative splicing sites, one between exons 21 and 22 and one between exons 
22 and 23, result in three alternative wild-type transcripts: two STAT3α transcripts 
(NM_139276, NM_003150) and one STAT3β (NM_213662) transcript. The splice site 
introduced by the mutation 1 nucleotide after exon 22 causes the 43-bp exon 22 to be 
skipped. In mutant variants of NM_139276 and NM_003150, this deletion would result 
in a frame shift and a premature stop-codon. In conjunction with the 50-bp shorter 
exon 23 of STAT3β, the deletion of exon 22 is predicted to produce a transcript that 
codes for a variant of STAT3α with an in-frame deletion of 31 amino acids. (A) 
Chromatogram of healthy control and patient. (B) Schematic representation of the 
consequences of the splicing mutation. The amino acid sequences of the STAT3α 
transcripts shared with the mutated STAT3β transcript are highlighted in pink. 
 
B 
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3.3.7 Familial cases 
Nine of the 153 AD-HIES patients referred to us had affected family members. 
Sequencing of these family members showed that they carried the same 
mutation as the probands. The pedigrees of the nine families are shown in 
Figure 3.14.  In three cases (UPN60, UPN110 and UPN160) the mutations 
have been passed on to more than one offspring. In all three families, there is 
perfect segregation of the mutations with the affection status of the family 
members. The mutations inherited are the two point mutations F384L and 
G342D, and the splice site mutation c.1139+1G>A (Figure 3.15). In other five 
cases (UPN2, UPN19, UPN94, UPN106 and UPN153) there has been 
inheritance from the patient to just one offspring. These mutations include the 
point mutation H58Y affecting the N-terminal domain, R382W and N466S in 
the DNA-binding domain and V637M and Y640N in the SH2 domain. In one 
family (UPN65) two siblings carry the same mutation. It is likely that both 
inherited the mutation from the mother who presented similar symptoms but 
died before definitive diagnosis.  
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Figure 3.14: Pedigrees of familial AD-HIES cases   
Nine AD-HIES patients had affected family members. All affected family members 
showed the same mutation as the probands. Squares indicate males; circles, females. 
Filled symbols, patients; slashes, deceased individuals. The shaded square indicate 
possibly affected persons. UPN, unique personal number. Probands are highlighted by 
asterisks. 
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Figure 3.15: Pedigrees and chromatograms of two familial AD-HIES 
cases   
Pedigrees and the relative chromatograms of two AD-HIES families in which the 
mutations segregate perfectly with the affection status. The family depicted in (A) 
carries the splice site mutation c.1139+1G>T leading to the heterozygous in-frame 
deletion of exon 12. The family shown in (B) carries the point mutation c.1025G>A 
leading to the amino acid change G324D in the DNA-binding domain of STAT3. 
Squares indicate males; circles, females. Filled symbols, patients.  
A 
B 
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3.3.8 Impact of amino acid substitutions 
To assess the severity of the effect of the amino acid changes found on the 
structure and function of the STAT3 protein the online prediction tool 
PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2) was used. All 31 different 
missense mutations found were analyzed using the Ensembl transcript 
STAT3-001 ENST00000264657 as template.  
Twenty of the 31 amino acid substitutions identified in our cohort showed the 
highest probability of altering local protein structure and were therefore 
classified as 'probably damaging'.  Of these 20 mutations, eight got the 
maximum score of one. Seven mutations were classified as 'possibly 
damaging' and four as 'benign'. The severity of the effect of the amino acid 
changes is independent from the affected domain although three of the four 
alternations classified as 'benign' are three of the four alterations affecting the 
asparagine (N) residue at position 466 (N466D, N466S, N466T). The fourth 
mutation affecting the same residue (N466K) is classified as 'probably 
damaging'. 
All amino acid substitutions, their PolyPhen score and the predicted effect on 
the protein are summarised in Table 3.2; furthermore, examples of three 
Polyphen reports are shown in figure 1 of the Appendix.  
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DNA sequence  
change 
amino acid 
change 
Polyphen  
score 
Polyphen 
prediction 
c.172C>T H58Y 0,925 possibly damaging 
c.1025G>A G342D 1 probably damaging 
c.1144C>T R382W 1 probably damaging 
c.1145G>T R382L 1 probably damaging 
c.1145G>A R382Q 1 probably damaging 
c.1150T>A F384L 0,993 probably damaging 
c.1166C>T T389I 0,997 probably damaging 
c.1234A>G T412A 0,789 possibly damaging 
c.1268G>A R423Q 0,997 probably damaging 
c.1396 A>G N466D 0,092 benign 
c.1397A>G N466S 0,000 benign 
c.1397A>C N466T 0,073 benign 
c.1398C>G N466K 0,606 possibly damaging 
c.1407G>T Q469H 0,998 probably damaging 
c.1771A>G K591E 0,020 benign 
c.1843A>G K615E 0,580 possibly damaging 
c.1865C>T T622I 1 probably damaging 
c.1907C>A S636Y 0,996 probably damaging 
c.1909G>A V637M 1 probably damaging 
c.1909G>T V637L 0,865 possibly damaging 
c.1910T>C V637A 0,974 probably damaging 
c.1915C>T P639S 0,988 probably damaging 
c.1916C>G P639R 0,999 probably damaging 
c.1918T>A Y640N 1 probably damaging 
c.1970A>G Y657C 1 probably damaging 
c.2003C>T S668F 0,996 probably damaging 
c.2113T>C Y705H 0,995 probably damaging 
c.2117T>C L706P 0,995 probably damaging 
c.2124C>G T708S 0,865 possibly damaging 
c.2129T>C F710C 0,997 probably damaging 
c.2141C>G T714A 0,956 possibly damaging 
 
 
Table 3.2:  Predicted impact of amino acid substitutions 
Bioinformatic assessment of STAT3 protein missense changes and the prediction on 
the STAT3 function using the online prediction tool PolyPhen. Mutations classified as 
'probably damaging are shaded in red, those classified as 'possibly damaging' in 
yellow, whereas mutation classified as 'benign' are shaded in green.  
 
Chapter 3: Sequencing of STAT3 
114 
3.4 Discussion 
In our cohort of 153 patients with suspected AD-HIES, we found 25 novel 
mutations in STAT3 that had not been described at the time of discovery. Ten 
of the novel mutations affected the DNA-binding domain, eight the SH2 
domain, six the transcription activation domain, and one the N-terminal domain 
(Table 3.1). Therefore, it appears necessary to sequence the entire STAT3 
gene to exclude possible mutations.  
In all HIES patients with detected STAT3 mutations, only one allele was 
affected, consistent with the observation that complete loss of Stat3 leads to 
early embryonic death in Stat3 knock-out mice (Takeda et al., 1997). 
Mutations in the promoter region are possible, but are unlikely to cause AD-
HIES when present in heterozygosity because they will not exert a dominant-
negative effect which seems necessary for the AD-HIES phenotype. 
Although over 90% of mutations were located in the exons of STAT3, six 
mutations at the intron-exon boundaries were found.  Five of these mutations 
caused an in-frame deletion of the 10 amino acids encoded by exon 12.  The 
effect of the splice site mutation on exon 22 has been shown to be more 
complex: the splice site introduced by the mutation causes the 43 bp exon 22 
to be skipped. In mutant variants of the two transcripts NM_139276 and 
NM_003150, this deletion would result in a frame shift and a premature stop-
codon. In conjunction with the 50-bp shorter exon 23 of STAT3β, the deletion 
of exon 22 is predicted to produce a transcript that codes for a variant of 
STAT3α with an in-frame deletion of 31 amino acids.  
PolyPhen-2 (Polymorphism Phenotypingv2 genetics.bwh.harvard.edu/pph2) is 
a free online tool which predicts possible impact of an amino acid substitution 
on the structure and function of a human protein. The PolyPhen analysis of the 
31 missense mutations found suggested that 20 amino acid substitutions 
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identified in our cohort have the highest probability of altering local protein 
structure and were classified as probably damaging. Seven of the remaining 
11 mutations were classified as possibly damaging, four as benign. 
Interestingly, three of the four alternations classified as benign are three of the 
four alterations affecting the asparagine (N) residue at position 466 (N466D, 
N466S, N466T). For one of these mutations (N466S) familial inheritance has 
been observed (Figure 3.14). This makes it likely that the mutation is disease 
causing although not classified as damaging. Moreover, this mutation has 
been shown to have severe impact on the functionality of STAT3 (see chapter 
4). We therefore conclude that the PolyPhen classification is not always 
correct and that in this case the mutation has an impact on the function of the 
STAT3 protein.  
The fourth mutation classified as benign is the substitution K591E. 
Familial inheritance has been observed in nine cases. Five out of these nine 
are novel mutations that had not been described at the time of discovery. In all 
cases the inheritance of the mutation correlates perfectly with the affection 
status. The familial inheritance therefore might indicate that these mutations 
are disease causing although no functional data are available for all of them. In 
particular this is interesting for the mutation affecting the N-terminal domain 
since no other mutations in this domain have been reported.  
In collaboration with the National Center for Biotechnology Information at the 
National Institutes of Health (NIH) in Bethesda (USA) we evaluated the validity 
of the NIH clinical scoring sheet in predicting STAT3 mutations and sought for 
a correlation between the phenotype of the patients and the genotype.  
On the basis of the clinical features of the patients no significant 
genotype/phenotype correlation was evident between patients with mutations 
in the DNA-binding, the SH2, the transcriptional activation- or the N-terminal 
domain, indicating that the location of the mutation has no infuence on the 
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resulting phenotype. Similarly, there was no clear difference in the clinical 
presentation between the cohort of patients with STAT3 mutations and 71 
patients without a demonstrable mutation (Woellner et al., 2010).  
The same results were confirmed by other groups (Heimall et al., 2011; 
Renner et al., 2008).  
The wide repertoire of mutations identified within the STAT3 gene represents a 
broad tool to perform structure/function studies on STAT3 and gives the 
opportunity to investigate fundamental aspects of STAT3 biology that are still 
unanswered. 
The evidence that the STAT3 mutations are located in different areas of the 
protein known to exert distinct functions suggests that more than one 
molecular mechanism leads to the same clinical presentation. It has been 
shown that mutations in the DNA-binding domain cause a defective binding of 
STAT3 to the DNA (Minegishi et al., 2007) whereas mutations affecting the 
SH2 domain impair the activation-induced tyrosine phosphorylation of STAT3. 
The molecular mechanism by which heterozygous mutations in the N-terminal 
domain or the transcription activation domain of STAT3 cause the AD-HIES 
phenotype remains unclear.  
The N-terminal domain of STAT3 (amino acids 1-125) has been shown to be 
essential for the formation of unphosphorylated STAT3 dimers but not for 
assembly of tyrosine-phosphorylated STAT3 dimers. 
STAT3 harbouring a monomeric N-terminal deletion becomes phosphorylated 
and dimerizes in response to interleukin-6 stimulation but, surprisingly, does 
not accumulate in the nucleus. This highlights the importance of the N-terminal 
domain in the formation of unphosphorylated STAT3 dimers and nuclear 
accumulation of STAT3 upon phosphorylation (Vogt et al., 2011). Whether the 
lack of nuclear accumulation of STAT3 in the nucleus represents the molecular 
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mechanism leading to the AD-HIES phenotype in the two patients, carrying the 
mutation in the N-terminus of STAT3 should be investigated. 
 
Seventy-one patients did not show any mutation in the coding regions of 
STAT3 or their flanking intronic sequences. During the course of this study it 
became clear that homozygous mutations of the dedicator of cytokinesis 8 
(DOCK8) gene are responsible for the autosomal recessive form of HIES 
(Engelhardt et al., 2009; Zhang et al., 2009). Four patients out of our cohort of 
71 STAT3 wild-type (STAT3wt) HIES patients were afterwards found to carry 
DOCK8 mutations. Three of the four patients were shown to have big deletions 
of more than 20 exons (UPN81 ex3_26del, UPN82 ex2_24del, UPN21 
ex18_44del). The fourth patient (UPN83) carries a smaller deletion of exons 1 
and 2. The clinical details of the four patients are summarized in Table 1 in the 
appendix. 
 
In the following patients with anAD-HIES phenotype without proven STAT3 
mutation will be referred to as type 1 HIES patients as no inheritance pattern 
has yet been identified in these patients. 
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4.1 Introduction 
In the previous chapter we showed that more than 50% of patients referred to 
us with the clinical diagnosis of AD-HIES, carried a STAT3 mutation. Although 
the mutations found mainly cluster in the DNA-binding or the SH2 domain, 
mutations were very heterogeneous and were located all over the gene. Many 
of the mutations we found were yet undescribed and their effect on the 
function of STAT3 unknown. We therefore sought for a test able to show the 
effect of the newly discovered mutations on the functionality of STAT3. 
Furthermore, because the mutations were spread over the whole gene, it 
appears necessary to sequence the entire STAT3 gene to exclude any 
possible mutation, an expensive process because of the size of the gene. It 
therefore was desirable to find a test able to predict the existence of a mutation 
without the need of sequencing.  
Interleukin 10 (IL-10) is an anti-inflammatory cytokine exclusively signalling via 
STAT3. IL-10 is produced by several cell types including macrophages and 
regulatory T-cells and inhibits the synthesis of pro-inflammatory cytokines such 
as IFN-γ, IL-2, IL-3, TNF-α and GM-CSF (Fiorentino et al., 1991; Moore et al., 
2001).  
The receptor for IL-10 consists of two alpha molecules (IL10R1) specific to the 
interleukin-10 receptor and two beta molecules (IL10R2). The assembly of this 
heterotetrameric receptor leads to the activation of the receptor-associated 
Janus tyrosine kinases, JAK1 and TYK2, resulting in the phosphorylation of 
STAT3 and the induction of STAT3-dependent genes (Glocker et al., 2009).  It 
has been shown that the IL-10-mediated inhibition of LPS-induced TNF-α 
production is defective in patients carrying mutations in STAT3 (Minegishi et 
al., 2007). 
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Another common feature of patients with AD-HIES are significantly reduced 
numbers of Th17 cells, a T cell subset characterised by expression of the 
lineage defining transcription factor RORγt and the cytokines IL-17 and IL-22 
(Stockinger and Veldhoen, 2007). An important factor to drive human Th17 cell 
differentiation is the STAT3 activating cytokine IL-6 (Laurence and O’Shea, 
2007). IL-6 signals through STAT3, as does IL-23, a cytokine important for 
sustaining Th17 cells; STAT3 signalling therefore plays a crucial role in the 
generation of Th17 cells. IL-21, another activator of STAT3, is both a product 
and inducer of Th17 cells, providing a critical autocrine feedback loop 
(Laurence and O’Shea, 2007).  
Several groups have reported reduced numbers of circulating Th17 cells in 
AD-HIES patients with STAT3 mutations (de Beaucoudrey et al., 2008; Jiao et 
al., 2008; Ma et al., 2008; Milner et al., 2008; Renner et al., 2008).   
Reduced Th17 cell numbers are thought to add most to the clinical phenotype 
of AD-HIES especially to the increased susceptibility to bacterial and fungal 
infections. Reports that haematopoietic stem cell transplantation (HSCT) may 
correct this deficit underline the relevance of Th17 cells in the pathogenesis of 
AD-HIES (Goussetis et al., 2010).   
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4.2 Questions 
1) Do all STAT3 mutations have the same functional consequences –
independently of which domain they affect? 
2) Do all mutations lead to reduced numbers of Th17 cells? Do patients 
with a clinical phenotype of AD-HIES but without mutations within 
STAT3 (type 1 HIES patients) have reduced numbers of Th17 cells as 
well?  
3) Can the application of an IL-10 suppression assay or the enumeration 
of IL-17 producing peripheral blood CD4+ T-cells be used as potential 
functional tests for AD-HIES able to predict the presence of a STAT3 
mutation?  
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4.3 Results 
4.3.1  Functional consequences of STAT3 mutations 
To analyse the consequences of STAT3 mutations on the functionality of the 
signalling pathway in vitro, we used a TNF-α release assay as previously 
described by Minegishi et al (Minegishi et al., 2007).  We preincubated 106 
monocytes/macrophages/mL of 12 patients and 11 healthy controls with 
25ng/mL IL-10 for 1 hour and then stimulated with 50ng/mL LPS overnight. As 
IL-10 is a potent anti-inflammatory cytokine signalling via STAT3, the addition 
of IL-10 to the cells was expected to inhibit the production of TNF-α upon 
addition of LPS.   
In healthy controls and a patient without STAT3 mutation (STAT3wt), the 
addition of IL-10 reduced the TNF-α release by approximately 90%, whereas in 
a patient carrying a R382Q mutation in in the DNA-binding domain of STAT3, 
TNF-α release was reduced by only 40% (Figure 4.1).  
To ensure better comparability of data from different healthy donors and 
patients, the impact of IL-10 on TNF-α release is shown as percentage of 
maximum TNF-α release on LPS stimulation as shown in Figure 4.1.  
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Figure 4.1: Schematic representation of the TNF-α release assay 
(A) Cells were exposed overnight to LPS or LPS plus IL-10. The concentration of 
produced TNF-α in the culture supernatants was determined by ELISA. In healthy 
controls and a STAT3wt patient, addition of IL-10 almost completely reduced TNF-α 
release, whereas in the patient with the R382Q mutation in STAT3 inhibition of LPS-
induced TNF-α release is poor. (B) To ensure better comparability of data from 
different healthy donors and patients, the impact of IL-10 on TNF-α release is shown 
as percentage of maximum TNF-α release on LPS stimulation.  
 
A 
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In our cohort of more than 150 patients with the clinical AD-HIES phenotype, 
we found 25 mutations in STAT3 that have not been previously described. To 
assess the effects of these novel STAT3 mutations, we carried out the TNF-α 
release assay as described above.  
We tested eight novel mutations: one affecting the N-terminal domain (H58Y),  
three affecting the DNA-binding domain (c.1139+2insT, N466S and N466K), 
one affecting the SH2 domain (P639S) and two affecting the transcriptional 
activation domain (L706P and F710C). In addition we examined four already 
known mutations affecting the DNA-binding domain (c.1110-2A>G, R382Q, 
R382W and R382L) and 11 controls.   
All eight novel mutations showed a reduction in IL-10-mediated down 
regulation of TNF-α secretion. Not all mutations however had the same effect, 
suggesting that some mutations may lead to STAT3 proteins with a 
hypomorphic function and a remaining activity, and therefore possibly to a 
milder phenotype. Furthermore, we experienced great variability in the effect of 
some mutations in different experiments, resulting in distinct standard 
deviations (Figure 4.2) 
Additionally, we compared the effect of the eight novel mutations collectively 
with 11 healthy controls by a rank-sum test and reached significance (P < 
.0001).  
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Figure 4.2: Inhibition of TNF-α release in LPS-activated macrophages by 
IL-10.  
Inhibition of TNF-α release in LPS-activated macrophages by IL-10. Macrophages of 
12 patients with mutant STAT3, 8 of whom had novel mutations, and 11 healthy 
controls were pre-treated with IL-10 and then stimulated with LPS. Supernatants were 
examined for the presence of TNF-α by ELISA. To ensure better comparability of data 
from different healthy donors, the impact of IL-10 on TNF-α release is shown as 
percentage of maximum TNF-α release on LPS stimulation. The eight undescribed 
mutations are shaded in blue. Error bars represent standard deviations. Where 
possible results are representative of at least two independent experiments. Due to 
lack of additional cells the mutations R382W, R382L and L706P could be tested only 
once. 
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4.3.2 TNF-α ELISA as functional test for STAT3 mutations 
As the STAT3 gene is a big gene consisting of 24 exons and because the 
mutations affecting STAT3 are spread over the whole gene, we analysed the 
possibility to use the TNF-α ELISA as test able to predict the existence of a 
mutation without the need of sequencing.  
A patient with suspected Dubowitz syndrome, characterized by growth 
retardation, microcephaly and eczema, with autosomal recessive inheritance 
but unclear genetic basis was referred to us together with her brother and the 
parents. The patient had a long history of S. aureus infections affecting 
different organs and presented aged 31 with an NIH-HIES score of 77 points. 
When the patient presented with an episode of meningitis and cerebral 
abscesses, a clinical diagnosis of the putative AD-HIES in coexistence with a 
Dubowitz-like syndrome was made (Beitzke et al., 2011). 
The cells of the patient (UPN185) and those of her parents, her brother and 
one healthy control were stimulated with LPS and IL-10 as described above. 
In contrast to the healthy control, the parents and her brother, the patient's 
cells showed significantly impaired IL-10-mediated suppression of TNF-α 
release, indicating a failure of STAT3 signalling. Subsequent STAT3 
sequencing revealed a heterozygous missense mutation in exon 13 leading to 
the amino acid exchange R382W in the patient, whereas both parents and the 
brother showed a wild-type sequence (Figure 4.3). Therefore, in this case, we 
were able to correctly predict the existence of a STAT3 mutation in the patient 
and no mutation in the patient’s family members. 
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Figure 4.3: TNF-α ELISA as functional test for STAT3 mutations 
(A) Cells of the patient (UPN185), her parents, her brother and a healthy control were 
exposed overnight to LPS or LPS plus IL-10. The concentration of produced TNF-α in 
the culture supernatants was determined by ELISA. The parents and the brother of the 
patient, as the healthy donor, show almost complete reduction of TNF-α release upon 
IL-10 treatment indicating unimpaired STAT3 signalling. The patients’ cells show poor 
inhibition of LPS-induced TNF-α release. (B) Pedigree and the relative chromatograms 
of the patient and her family. The patient carries the sequence change 1144C>T 
leading to amino acid change R382W. Both parents and the brother show wild-type 
sequence therefore confirming the results of the TNF-α release assay.  
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4.3.3 IL-17 and IFN-γ production by CD4+ T cells in AD-HIES 
The induction of Th17 cells after stimulation with either the superantigen 
Staphylococcus  enterotoxin B (SEB) or the mitogen Phorbol 12-myristate 13-
acetate (PMA) and Ionomycin has been reported to be impaired in patients 
with AD-HIES carrying STAT3 mutations (de Beaucoudrey et al., 2008; Jiao et 
al., 2008; Ma et al., 2008; Milner et al., 2008; Renner et al., 2008). We 
analysed the level of Th17 cells among the PBMCs in 37 out of our 153 
patients with AD-HIES and 24 control subjects. Nineteen of these patients had 
mutations in STAT3, 18 had not. Cells were stimulated with SEB over night as 
described in the methods-section.  
Figure 4.4 shows the stimulation and the gating of a representative healthy 
control. Lymphocytes were first gated for CD4+ and CD45RO+ memory T cells 
and then on intracellular stained IL-17 and IFN-γ. The unstimulated control 
cells did neither produce IFN-γ nor IL-17. In contrast, stimulated PBMCs of the 
healthy controls showed 11.7% of IFN-γ-producing and 1.73% of IL-17-
producing memory T cells. 
Seventeen of the 19 patients harbouring mutations in STAT3 had less than 
0.5% of IL-17-producing CD4+ T cells. In contrast, all but two of our healthy 
donors had a frequency of more than 0.6%.  
Figure 4.5 shows representative flow cytometry plots of one healthy control, 
one patient carrying a mutation in the DNA-binding domain (R382W), one 
patient with a mutation in the SH2 domain (V637M) and one STAT3wt type 1 
HIES patient. It is clearly visible that patients carrying a STAT3 mutation had 
an impaired number of circulating Th17 cells.   
The 18 patients without mutations in STAT3 had significantly more IL-17-
producing T cells than the STAT3-deficient patients (P<0.0001), but 
significantly fewer than the healthy controls (P=0.0094); with less than 0.5% 
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only four of these 18 patients had a low percentage of IL-17-producing 
CD4+CD45RO+ T cells (Figure 4.6 and Table 4.1). 
We measured the frequency of SEB-induced IFN-γ-producing CD4+ T cells 
from PBMCs of the same set of subjects (Figure 4.5 and 4.6). Interestingly, the 
type 1 HIES patients without STAT3 mutations had significantly fewer IFN-γ-
producing CD4+ T cells than had healthy controls (P<0.0001). Of the 18 
patients lacking STAT3 mutations, only two had >5% IFN-γ-producing CD4+ T 
cells. Patients with AD-HIES harbouring STAT3 mutations also had 
significantly lower percentages of IFN-γ-producing CD4+ T cells than healthy 
controls (P=0.047) but significantly higher percentages than patients without 
STAT3 mutation (P=0.0002).  
Although the lack of Th17 cells or IL-17 has been made responsible for the 
occurrence of Candida albicans infections among our patients we did not find 
any correlation between the lack of Th17 cells and the incidence of Candida 
infections (Table 4.1 and Figure 4.7). 
 
Chapter 4: Functional impact of STAT3 mutations 
130 
 
 
 
 
 
 
 
 
Figure 4.4: IL-17 and IFN-γ production from PBMCs of a healthy control  
Flow cytometry analysis of CD4+CD45RO+ memory T cells from healthy control 
PBMCs stained intracellular for IL-17 and IFN-γ. Cells were stained either unstimulated 
or upon stimulation with SEB for 16 hours, Brefeldin A was added after one hour 
stimulation. 
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Figure 4.5: IL-17 and IFN-γ production from PBMCs HIES patients  
Flow cytometry analysis of CD4+CD45RO+ memory T cells from one healthy control 
one AD-HIES patient carrying the STAT3 mutation R382W, one patient with the 
mutation V637M and one STAT3wt type 1 HIES patient stained intracellular for IL-17 
and IFN-γ. Prior to staining cells were stimulated with SEB for 16 hours, Brefeldin A 
was added after one hour stimulation. Patients carrying STAT3 mutations have 
significantly reduced numbers of Th17 cells when compared to the healthy control and 
the STAT3wt type 1 HIES patient. 
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Figure 4.6: Percentage of IL-17 and IFN-γ expressing CD4+ T cells 
Percentages of IL-17 (A) and IFN-γ (B) expressing CD4+CD45RO+ memory T cells, 
determined by intracellular cytokine expression after overnight stimulation with SEB. 
Each symbol represents the value from an individual donor or patient. Statistical 
significance was determined with a Wilcoxon rank-sum test. P values are 2-sided. 
Median values are shown as horizontal bars. wt, wild-type. 
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Table 4.1: Percentages of IL-17 and IFN-γ expressing CD4+ T cells  
 
Patients with less than 0.5% CD4+CD45RO+IL17+IFN-γ- or 5% CD4+CD45RO+IL17-
IFN-γ+ cells are shaded in blue. Patients positive for Candida infections are shaded in 
purple. Undescribed mutations are shaded in grey.  
UPN, unique patient number ∗ scoring system described in Grimbacher et al. 1999 
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110 c.1025G>A G342D DNA-binding 79 0.27 12.3 yes 
114 c.1110−2A>G  D371_G380del DNA-binding 70 0.26 5.9 yes 
86 c.1110−1G>T D371_G380del DNA-binding 83 0.16 6.36 yes 
17 c.1139+1G>T D371_G380del DNA-binding 65 0.34 2.34 yes 
108 c.1119+2insT D371_G380del DNA-binding 54 0.19 4.47 yes 
15 c.1144C>T R382W DNA-binding 76 0.23 15.3 yes 
19 c.1144C>T R382W DNA-binding 63 0.62 7.11 yes 
126 c.1144C>T R382W DNA-binding 58 0.16 7.32 yes 
128 c.1144C>T R382W DNA-binding 29 0.27 2.91 yes 
183 c.1145 G>A R382Q DNA-binding nd 0.14 2.45 nd 
98 c.1145 G>T R382L DNA-binding 45 0.11 14.7 yes 
118 c.1268G>A R423Q DNA-binding 59 0.23 5.78 no 
71 c.1907C>A S636Y SH2 71 0.32 2.4 yes 
16 c.1909G>A V637M SH2 68 0.25 10.1 yes 
115 c.1909G>A V637M SH2 56 0.71 6.4 nd 
125 c.1909G>A V637M SH2 58 0.21 9.39 no 
49 c.1915 T>C P639S SH2 55 0 3.89 yes 
18 c.2129T>C F710C Transactivation 58 0.42 12 yes 
116 c.2141C>G T714A Transactivation 63 0.45 6.42 yes 
1 no mutation  72 0.38 2.65 yes 
4 no mutation  60 0.84 9.15 yes 
9 no mutation  49 0.44 1.59 yes 
10 no mutation  29 0.26 0.65 no 
14 no mutation  47 0.44 2.73 no 
20 no mutation  32 1.16 3.87 no 
22 no mutation  43 0.62 2.85 yes 
54 no mutation  29 0.75 2.46 yes 
55 no mutation  26 0.51 3.39 no 
69 no mutation  61 1.09 5.27 yes 
97 no mutation  39 1.18 2.33 yes 
113 no mutation  39 1.02 0.46 no 
123 no mutation  30 1.34 0.91 no 
124 no mutation  22 1.37 0.42 nd 
127 no mutation  49 1 4.58 yes 
139 no mutation  40 0.64 3.8 yes 
163 no mutation  nd 0.85 2.55 nd 
184 no mutation  nd 0.75 1.58 nd 
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Figure 4.7: Correlation between numbers of IL-17 expressing CD4+CD45RO+ 
T cells and the presence of Candida albicans infections 
Numbers of IL-17 expressing CD4+CD45RO+ memory T cells determined by 
intracellular cytokine expression after overnight stimulation with SEB of AD-HIES 
patients with and without Candida albicans infections. Each symbol represents the 
value from an individual donor or patient. Statistical significance was determined with a 
Wilcoxon rank-sum test. Median values are shown as horizontal bars.ns, non-
significant. 
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4.3.4 Th17 cells in a bone marrow transplanted patient 
One patient of our cohort (UPN56) who carried the mutation R382W 
underwent haematopoietic stem cell transplantation (HSCT) in 2005 at the age 
of 13. The patient had a long history of recurrent chest infections with 
longstanding established bronchiectasis and despite prophylactic antibiotics 
and intravenous immunoglobulin, the patient’s condition continued to 
deteriorate.  
After transplantation the patient had good immune reconstitution and far less 
infections. As expected, the already existing bronchiectasis did not improve 
following transplantation, but further lung infections and lung damage were 
prevented. 
We measured the levels of circulating IL-17-producing CD3+ and CD45RO+ 
memory T cells in the patient's PBMCs before and after the HSCT and 
compared them with the levels of Th17 cells of a healthy control and a patient 
with a STAT3 mutation (V637M). Prior to staining, the cells were stimulated 
with PMA/Ionomycin for five hours as described above.  
Before HSCT the patient had 0,3% of circulating IL-17 and 42,8% of IFN-γ-
producing CD3+CD45RO+ T cells. In contrast, after the HSCT the number of 
circulating Th17 cells raised to 1,16%, comparably to the healthy control 
whereas the number of IFN-γ-producing cells decreased. The STAT3 mutated 
patient had 0,2% of IL-17-producing and 51% of IFN-γ-producing cells.  
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Figure 4.8: Th17 cells of bone marrow transplanted patient 
Flow cytometry analysis of CD3+CD45RO+ memory T cells from one healthy control, 
one patient with the mutation V637M and the bone marrow transplanted STAT3  
mutated AD-HIES patient stained intracellular for IL-17 and IFN-γ. The cells of the 
patient were stained before and after bone marrow transplantation. Prior to staining 
cells were stimulated with PMA/Ionomycin for five hours, Brefeldin A was added after 
one hour stimulation. After HSCT the percentage of IL-17-producing cells is increased 
and comparable to the healthy control. 
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4.4 Discussion 
We showed that all eight novel mutations we identified in STAT3 impaired the 
IL-10-mediated inhibition of TNF-α in LPS challenged patients' macrophages 
indicating failures in the IL-10/Janus kinase/STAT3 pathway in the patients’ 
cells. Compared  with the most prevalent mutation affecting the DNA-binding 
domain of STAT3 (R382Q) this effect however was less prominent in some of 
the novel mutations, in particular the four mutations H58Y, N466K, P639S and 
F710C. This result could reflect the fact that these mutations have a different 
impact on the retained functionality of the STAT3 dimerization, nuclear 
translocation, or transcriptional activation. The variability of the remaining 
activity of the STAT3 protein may possibly lead to the observed diversity of 
phenotypes. 
Moreover, we found great variability in TNF-α release for some STAT3 
mutations. Although 'classic' STAT3 mutations lead to meaningful test results, 
(as shown for the family of patient UPN185) a remarkablevariability of results, 
leading to distinct standard deviations was observed. The differences in 
response to LPS stimulation at different time points could be due to various 
factors including lifestyle, the affection status and the medication of the patient 
at the time of blood-drawing. Moreover, most of the blood samples analyzed 
were sent to us from elsewhere and have therefore travelled for different 
periods of time. It is likely that all these variables influence the viability and 
responsiveness of the cells. As the variables mentioned are not eliminable, we 
decided that this assay is unsuitable as screening method to identify patients 
with STAT3 mutations.    
To assess whether the variability of the test results is due to different 
responsiveness of cells the analysis of a related pathway in which STAT3 is 
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not involved (like STAT1 signalling pathway) could have been performed in 
parallel.   
There are other options to test the functionality of STAT3: The formation of 
phosphorylated STAT3 dimers in STAT3 mutated patients is controversially 
discussed in the literature. Renner et al. showed that mutations in the SH2 
domain but not those in the DNA-binding domain affect activation-induced 
tyrosine phosphorylation of STAT3 whereas Al-Khatib et al. found impaired 
pSTAT3 formation in patients with mutations affecting the SH2 as well as 
those in the DNA binding domain (Al Khatib et al., 2009; Renner et al., 2008).  
The quantification of changes in the expression of STAT3 target genes such 
as SOCS3 or RORγt by real-time PCR methods upon stimulation of patients' 
cells may be another possibility to predict a putative mutation in STAT3. 
STAT3 mutations leading to the AD-HIES phonotype are heterogeneous and 
display a variable functional deficit. They all are dominant-negative with a 
suspected residual function of 25%. Since, it is difficult to set up a specific test 
capable of predicting all mutations. 
We confirmed that patients with AD-HIES carrying STAT3 mutations had 
significantly reduced numbers of IL-17-producing CD4+CD45RO+ T cells. 
Based on these data, we suggest that Th17 cells may be used as an additional 
marker to distinguish HIES patients with STAT3 mutations from patients 
without STAT3 mutations. Most patients without STAT3 mutations had a 
striking reduction of IFN-γ-producing CD4+CD45RO+ T cells. This cytokine 
imbalance has been previously described in AD-HIES and may be explained 
by an intrinsic T-cell defect (Netea et al., 2005). In our cohort of STAT3wt type 
1 HIES patients, only four of 18 had less than 0.5% IL-17-producing T cells. 
These three patients may have defects in other proteins involved in STAT3 
signalling or in other pathways involved in the differentiation of Th17 cells. 
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The lack of Th17 cells or IL-17 producing cells has been made responsible for 
the occurrence of Candida albicans infections both in AD-HIES and in other 
defects leading to increased susceptibility to fungal infections.  Nevertheless, 
among our patients were not able to identify any correlation between the lack 
of Th17 cells and the incidence of Candida infections. 
One of the STAT3 mutated AD-HIES patients of our cohort underwent 
haematopoietic stem cell transplantation in 2005 at the age of 13. The bone 
marrow transplant has been carried out with the expectation to cure the 
underlying immunologic defect. Indeed the patient has drastically improved, he 
suffered from less infections and the progressive lung destruction has been 
stalled. We showed that the number of circulating Th17 cells was restored 
after transplantation, indicating the importance of Th17 cells in the 
pathogenesis of AD-HIES with STAT3 mutations. Allogeneic HSCT for patients 
with AD-HIES presenting with progressive lung disease might therefore 
considered.  
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5.1 Introduction 
Seventy-one patients out of our cohort of 153 AD-HIES patients did not have 
any mutation in the coding regions of STAT3 or the exon flanking intronic 
sequences. To rule out so far unknown splice site variants, the cDNA of 25 of 
these STAT3 wild type patients was sequenced, but no mutation or skipped 
exon was detected.  
As the type 1 HIES patients did not show any obvious difference with regards 
to the clinical presentation when compared with patients with proven STAT3 
mutations we hypothesized that these patients may either carry (i) a mutation 
in the promoter of STAT3 leading to a not yet described, apparent, disease 
associated haploinsufficiency; or (ii) a mutation in otherSTAT3 dependent 
pathways. 
As described previously- STAT3 plays a central role in signal transduction 
induced by a broad range of cytokines, including IL-6, IL-10, IL-11, IL-17, IL-21 
and IL-22.  
In 2008 a Haitian boy has been identified with neutralizing anti-IL-6 
autoantibodies: He suffered from two episodes of unusually severe cellulites 
and subcutaneous abscesses caused by Staphylococcus aureus (Puel et al., 
2008). Since recurrent staphylococcal skin disease is a hallmark of HIES in 
both patients with mutations in STAT3 and without we decided to further focus 
on the IL-6 signalling pathway.  
IL-6 has both pro-inflammatory and anti-inflammatory properties and is 
probably one of the best-studied cytokines using the STAT3 pathway. IL-6 is 
secreted by a variety of cells including T cells, B cells, macrophages, 
keratinocytes and fibroblasts. The biological activities of IL-6 include the 
regulation of immune response, inflammation, and haematopoiesis. 
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Additionally IL-6 is one of the most important mediators of fever and of the 
acute phase response (Mihara et al., 2012).  
IL-6 signals through the IL-6 receptor, which consists of the ligand-binding IL-
6RA chain (IL-6 receptor) and the signal-transducing component, the 
glycoprotein 130 (gp130). Whereas IL-6RA is specific to the IL-6 receptor, 
gp130 is needed for several other cytokines including IL-11, IL-27, leukemia 
inhibitory factor (LIF), ciliary inhibitory factor (CNTF), oncostatin M (OSM), and 
cardiotropin-1 (CT-1) (Taga and Kishimoto, 1997).  
In contrast to gp130 which is ubiquitously expressed;, IL-6RA is primarily 
expressed on  haemopoietic cells and hepatocytes. The binding of IL-6 to the 
membrane-bound IL-6RA leads to homodimerization of gp130 and formation of 
a functional receptor complex consisting of IL-6, IL-6RA and gp130 (Scheller et 
al., 2011).  
Apart from the membrane bound form, a soluble form of IL-6RA (sIL-6RA) 
exists. Soluble IL-6RA arises from specific cleavage of membrane bound IL-
6RA by endogenous enzymes, can also bind IL-6 and then form a complex 
with gp130. Many cells, which do not express membrane bound IL-6RA can 
respond to IL-6 in the presence of this agonistic sIL-6RA (Rose-John and 
Neurath, 2004).  
After binding of IL-6 to its receptor the activation of the receptor associated 
tyrosine kinases of the JAK family, JAK1, JAK2 and TYK2 and subsequently of 
STAT3 is initiated. Figure 5.1 shows the components of the IL-6 receptor.  
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Figure 5.1: Components of the IL-6 receptor  
Schematic representation of IL-6 and the IL-6 receptor. The receptor consists of the 
ligand-binding IL-6RA chain and the signal-transducing component, the glycoprotein 
130 (gp130). The binding of IL-6 to the membrane-bound IL-6RA leads to 
homodimerization of gp130 and the formation of a functional receptor and to the 
activation of the receptor associated tyrosine kinases of the JAK family, JAK1, JAK2 
and TYK2  and  subsequently of STAT3. 
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5.2 Questions 
1) Do patients with the clinical presentation of AD-HIES but without 
mutations in the coding regions of STAT3 –or type 1 HIES patients 
carry mutations in the STAT3 promoter or do they have a functional 
impairment of STAT3? 
2) Do STAT3wt type 1 HIES patients carry mutations in one of the STAT3 
related signalling pathways e.g. the IL-6 signalling pathway? 
3) Or is the transition between the AD-HIES and AR-HIES phenotype 
more fluent and do STAT3wt patients have less severe mutations in 
DOCK8? 
4) Is there any difference in the cytokine profile of cells of STAT3wt type 1 
HIES patients after stimulation when compared to cells of STAT3 
mutant patients and healthy individuals?  
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5.3 Results 
5.3.1 Patients from a geographically confined area 
For further analysis of the IL-6/STAT3 signalling pathway five out of the 71 
STAT3wt patients were chosen. These five patients all originated from 
Sardinia. Research suggests that Sardinians have a peculiar and differentiated 
genetic structure. Even though many groups of different origins arrived in 
Sardinia throughout history, Sardinia was isolated for a long time and therefore 
the Sardinian population has turned out to be an example of genetic isolation 
among Italian, European and Mediterranean populations (Calò et al., 2008). 
Because of the alleged peculiar genetic structure of the Sardinians we 
hypothesized that these five STAT3wt  type 1 HIES patients may carry the 
same genetic aberration.  
All five patients (four male and one female aged between eight and 21 years) 
presented with a typical clinical AD-HIES phenotype with a high NIH score, 
ranging between 43 and 72. To our knowledge the patients were neither 
related to each other nor descendants of consanguinous marriages. All 
patients had elevated serum IgE levels of more than 2000 IU/mL (up to a 
maximum value of 92,100 IU/mL), numerous skin abscesses, highly elevated 
numbers of eosinophil granulocytes in the peripheral blood (> 800/µL), severe 
eczema, repeated upper respiratory tract infections and candidiasis. All five 
presented with non-immunological features of AD-HIES, too. They had 
characteristic faces with an increased nasal width and high palate; three of 
them had scoliosis and had repeated pathological fractures due to minor 
trauma. Interestingly four of the five patients had experienced failure to shed 
three or even more deciduous teeth.  
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Only two of the patients had pneumonia and interestingly none of them 
showed any parenchymal lung abnormalities such as bronchiectasis or 
pneumatoceles which are typical for AD-HIES. 
Two patients suffered from severe food allergies and asthma. Detailed 
information on the patient’s phenotype is summarised in Table 5.1.  
Whilst four patients were sporadic, one had a suspected family history (UPN1). 
The uncle of that patient died for unknown reasons in early childhood after an 
infection and the father of the patient was himself prone to illness (Figure 5.2). 
Beside the AD-HIES phenotype this patient had a history of severe chronic 
diarrhoea, anaemia, and Herpes simplex virus infection during the first years of 
life. 
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UPN 1 
21 y/o NIH score 72    
4 abscesses, >3 pneumonia, >800 eosinophils/µl, newborn rash, eczema, >6 sinusitis/otitis, 
candidiasis, >3 retained primary teeth, scoliosis, fractures, characteristic face, increased 
nose width and high palate   
Max IgE: 92,100 IU/mL 
 
  NO parenchymal lung abnormalities 
  Allergies and asthma 
  Severe chronic diarrhoea and anaemia in the first 4 years  
  Herpes simples infection 
 
UPN 4 
19 y/o NIH score 60    
3-4 abscesses, >800 eosinophils/µl, severe eczema, 3 sinusitis/otitis, candidiasis, 
 >3 retained primary teeth, scoliosis, fractures, hyperextensibility, characteristic  
face, increased nose width, high palate and midline anomaly  
Max IgE: 16,200 IU/mL 
 
 NO parenchymal lung abnormalities 
 Allergies and asthma 
 Tongue cleft 
 
UPN 22 
21 y/o NIH score 43    
1-2 abscesses, >800 eosinophils/µl, newborn rash, eczema, 
4-6 sinusitis/otitis, candidiasis, >3 retained primary teeth, characteristic face. 
Max IgE: 19,100 IU/mL 
 
 NO parenchymal lung abnormalities 
 
UPN 69 
18 y/o NIH score 61    
3-4 abscesses, 1 pneumonia, >800 eosinophils/µl, newborn rash, eczema, 
4-6 sinusitis/otitis, candidiasis, >3 retained primary teeth, scoliosis, fractures, 
characteristic face, increased nose width, high palate and midline anomaly  
Max IgE: 16,200 IU/mL 
 
 NO parenchymal lung abnormalities 
 
UPN 139 
8 y/o NIH score 43    
1-2 abscesses, other serious infections, >800 eosinophils/µl, severe eczema,  
4-6 sinusitis/otitis, candidiasis, hyperextensibility, characteristic face, increased nose width, 
high palate. 
Max IgE: 58,100 IU/mL 
 
 NO parenchymal lung abnormalities 
Table 5.1: Clinical features of five selected patients. 
Age, NIH score, clinical features and maximal serum IgE levels measured for the five 
STAT3wt patients form Sardinia that were further analyzed.  
UPN, unique personal number. IU, International units 
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Figure 5.2: Pedigree of the family of patient UPN1 from Sardinia. 
Squares indicate males; circles, females. Filled symbols, patients; slashes, deceased 
individuals. The shaded square indicates that the person is possibly affected. The 
proband is highlighted by an asterisk. 
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5.3.2 Sequencing of the STAT3 promoter 
Mutations in the promoter region of STAT3 are possible, but are unlikely to 
cause AD-HIES when present in heterozygosity because they will not exert a 
dominant-negative effect, which seems necessary for the AD-HIES phenotype. 
Nevertheless, to exclude any undescribed effects of haploinsufficiency we 
sequenced the STAT3 promoter regions in the five Sardinian patients. No 
sequence variation was found in any of the five patients in the sequence from -
403bp upstream to +102bp within the STAT3 gene, which possesses maximal 
promoter activity (Kato et al., 2000). 
 
5.3.3 Testing for STAT3 function via TNF-α ELISA 
To test the functionality of STAT3 in the five Sardinian patients, we measured 
the inhibition of TNF-α release in LPS-activated macrophages by IL-10. As 
described in the previous chapter, monocytes/macrophages of the five 
patients, two healthy controls and one patient with a previously reported 
R382Q STAT3 mutation were pre-incubated with 25ng/mL IL-10 for one hour 
and then stimulated with 50ng/mL LPS overnight.  
In the healthy control IL-10 reduced TNF-α release by approximately 90%, 
whereas in the R382Q patient, TNF-α release was reduced by only 40%. All 
five Sardinian patients, however, showed no reduction in IL-10-mediated down 
regulation of TNF-α secretion indicating that STAT3 is fully functional (Figure 
5.3). 
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Figure 5.3: Inhibition of TNF-α release in LPS-activated macrophages by 
IL-10. 
Macrophages of four STAT3wt patients from Sardinia (UPN1, UPN22, UPN69 and 
UPN139), one patient with a STAT3 mutation (R382Q) and two healthy controls were 
pretreated with IL-10 and then stimulated with LPS. (A) Supernatants were examined 
for the presence of TNF-α. (B) To ensure better comparability of data from different 
healthy donors, the impact of IL-10 on TNF-α release is shown as percentage of 
maximum TNF-α release on LPS stimulation. All four Sardinian patients, as the healthy 
donor, show almost complete reduction of TNF-α release upon IL-10 treatment 
indicating unimpaired STAT3 signalling. 
B 
A 
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5.3.4 Sequencing of DOCK8 
Even though homozygous mutations in the dedicator of cytokinesis 8 (DOCK8) 
gene have been identified in autosomal-recessive Hyper IgE syndrome (AR-
HIES) we sequenced this gene in the Sardinian patients to rule out any so far 
unknown mutations which may result in an AD-HIES phenotype. Since DOCK8 
is a big gene with 48 exons and three splice variants, the five patients were 
sequenced on cDNA level with the Ensembl transcript DOCK8-001 
ENST00000453981 as reference sequence. None of the patients revealed a 
mutation, but 12 different single nucleotide polymorphisms (SNPs) were found 
in exon 2, 3, 6, 11, 16, 20, 24, 32, 36 and 42 either in heterozygous or in 
homozygous state. All polymorphisms were previously described and are not 
associated with disease. Information about the variations identified is 
summarized in Table 5.2. Splice site mutations were ruled out by cDNA 
sequencing.   
 
5.3.5 Sequencing of components of the IL-6 signalling 
pathway 
To test for other mutations along the IL-6 signalling pathway in the five 
Sardinian patients, we sequenced the components of the IL-6 receptor (IL6RA 
and gp130), IL-6 itself and JAK1. 
The IL-6 gene is located on chromosome 7 and consists of 6 exons, the 
Ensembl transcript IL6-001 ENST00000404625 was used as reference 
sequence. No mutation or other sequence variations were detected in any 
exon of the five patients analyzed. Two heterozygous single nucleotide 
polymorphisms (SNPs) were found in the intronic regions of three patients. 
These SNPs have been previously described and are not associated with 
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disease. Detailed information on all variations detected can be found in the 
Table 5.2.    
The IL-6RA gene, the ligand binding part of the IL-6 receptor, consists of 10 
exons and is located on chromosome 1. The coding and the adjacent intronic 
parts of this gene were sequenced on gDNA level and the Ensembl transcript 
IL6R-001 ENST00000368485 was used as reference sequence. No mutation 
was detected throughout the whole coding sequence in any of the five patients 
analyzed. However six variations were found affecting exon 1, 2 and 9 as well 
as the introns 2 and 4. All variations have been described already and are not 
disease causing. Each of the five patients carried at least one variation either 
in a homozygous or a heterozygous state. Detailed information on all 
variations detected can be found in Table 5.2. 
The gene encoding gp130 is located on chromosome 5 and consists of 17 
exons. The Ensembl transcript IL6ST-001 ENST00000381298 was used as 
reference. The coding exons and their adjacent intronic parts were sequenced 
on gDNA level. No mutation was detected throughout the whole coding 
sequence in any of the five patients analyzed. Only one sequence variation 
was found in intron 4 in one patient (see Table 5.2). 
JAK1 is located on chromosome 1 and consists of 25 exons. The five patients 
were sequenced on cDNA level and the JAK1-001 ENST00000342505 
Ensembl transcript was used as reference. Patient UPN1 was found to carry a 
heterozygous mutation in the 5’UTR which has not previously been reported. 
To confirm the mutation, exon 1 was also sequenced on gDNA in all five 
patients. The heterozygous change c.-184C>T was detected on genomic DNA 
in patient UPN1 but in none of the other four patients and none of 100 healthy 
controls tested (Figure 5.4).  
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MutationTaster, a free, web-based application for rapid evaluation of the 
disease-causing potential of DNA sequence alterations 
(http://www.mutationtaster.org) classified the mutation as disease causing.  
The uncle of the patient died in early childhood for unknown reason and the 
father of the patient is himself prone to illness, therefore all available family 
members were tested for the presence of the mutation.  
The putatively affected father but also two healthy brothers, one sister and the 
nephew of the patient were all found to carry the same heterozygous variation 
(Figure 5.4).  
Apart from this so far unknown sequence variation found in patient UPN1 nine 
additional heterozygous SNPs were detected affecting exon 6, 11, 15, 16, 22 
and 25. All polymorphisms were previously described and not associated with 
any disease. Information about the variations found is summarized in Table 
5.2.  Undetected splice site mutations were excluded by cDNA sequencing.   
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Figure 5.4: JAK1 sequence variation   
(A) Chromatograms of the 5'UTR of JAK1 of the five Sardinian patients. Patient UPN1 
carries a heterozygous sequence change at position c.-184C>T, the other four patients 
sequenced show wild-type sequence. (B) Pedigree and the relative chromatograms of 
the family of patient UPN1. The father, both brothers, the sister and the nephew of the 
patient carry the same sequence variation at position c.-184C>T of JAK1. Squares 
indicate male individuals; circles indicate female individuals. Filled symbols represent 
patients; the shaded square indicates that the person is possibly affected.  
B 
A 
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DOCK8 
Name  Type Location  UPN 
rs506121  SNP exon 2 het C/T 22 
rs3209441  SNP exon 3 het 
het 
G/A  
G/A 
4 
22 
rs529208  SNP exon 3 het 
het 
C/A 
C/A 
1 
61 
rs2039045  SNP exon 6 het T/C 22 
TMP_ESP_9_334336  SNP exon 11 het A/G 4 
rs10970979  SNP exon 11 hom 
het 
het 
G  
A/G  
A/G 
22 
61 
139 
rs913703  SNP exon 16 het A/G 22 
rs10814431  SNP exon 20 het G/C 22 
rs2297075  SNP exon 24 het C/T 22 
rs2297079  SNP exon 32 hom 
het 
G  
C/G 
4 
22 
rs7854035  SNP exon 36 hom 
hom 
hom 
hom 
C 
C 
C 
C 
4 
22 
61 
139 
rs1887957  SNP exon 42 hom 
hom 
het 
A 
A  
G/A 
4 
22 
139 
 
IL6 
Name  Type Location  UPN 
rs2069827 SNP 47bp before exon 1 het 
het 
G/T 
G/T 
1 
22 
rs1524107 SNP intron 3 het C/T 139 
 
IL6 RA 
Name  Type Location   UPN 
rs4845617 SNP exon 1 het 
het 
het 
G/A 
G/A 
G/A 
1 
4 
61 
rs2228144 SNP exon 2 het 
het 
G/A 
G/A 
4 
139 
rs6694817 SNP intron 2 het 
het 
C/T 
C/T 
4 
61 
rs7518199 SNP intron 4 hom 
hom 
het 
hom 
C 
C 
A/C 
C 
1 
22 
61 
139 
rs4845374 SNP intron 9 het 
het 
T/A 
T/A 
4 
139 
rs2228145 SNP exon 9 hom 
hom 
het 
het 
C 
C 
A/C 
A/C 
1 
22 
61 
139 
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gp 130 
Name  Type Location  UPN 
rs3729959 SNP intron 4 het T/C 139 
 
 
JAK 1 
Name  Type Location   UPN 
undescribed SNP  exon 1 het C>T 1 
rs45598436  SNP exon 6 het T/C 22 
rs11585932  SNP exon 6 het A/G 139 
rs2230586  SNP exon 11 het C/T 139 
rs3737139  SNP exon 15 het C/G 139 
rs2230587  SNP exon 15 het C/T 61 
rs2230588 SNP exon 16 het A/G 4 
rs12129819  SNP exon 22 het G/A 22 
rs12353950  SNP exon 25 het T/G 22 
rs66983374  INSERTION exon 25 het -/TTAA 4 
22 
61 
 
Table 5.2: Sequence variations of the genes sequences. 
 
SNP: single nucleotide polymorphism; het: heterozygous: hom: homozygous; UPN: 
unique personal number; bp: base pairs 
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5.3.6 Functionality of mutated JAK1 
To examine possible functional consequences of the detected heterozygous 
mutation c.-184C>T in the 5’UTR of JAK1 phosphorylation of STAT1 was 
checked on addition of IFN-α  to PBMCs. IFN-α signals via JAK1 and is a 
strong activator of STAT1.  
First cells of healthy controls were stimulated with two different concentrations 
of IFN-α (100 and 200 ng/mL) for 15 minutes to assess the optimal amount of 
IFN-α needed for STAT1 phosphorylation. The phosphorylation was detected 
by immunoblotting with an Anti-phospho STAT1 antibody and was detected 
with both IFN-α concentrations used (Figure 5.5). About 106 PBMCs of two 
healthy controls, of a STAT3 mutated (V637M) travel control and of the patient 
UPN1 were then stimulated for 15 minutes with 100ng/mL IFN-α. STAT1 
phosphorylation was detected in all four individuals. STAT1 phosphorylation of 
the patient, however, appeared to be weaker than phosphorylation in the 
controls. Since the phosphorylation of the STAT3 mutated travel control was 
comparably weak we concluded that this result was most likely due to the 
transport of the blood samples from Sardinia to London and not caused by an 
impaired function of JAK1 (Figure 5.5). Hence, we concluded that the mutation 
in the 5’UTR of JAK1 of the patient is a rare polymorphism segregating within 
the family rather than a loss-of-function mutation with functional 
consequences. 
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Figure 5.5: STAT1 phosphorylation after IFN-α stimulation 
(A) Detection of STAT1 phosphorylation by immunoblotting with an Anti-phospho 
STAT1 antibody upon stimulation with two different IFN-α concentrations. (B) STAT1 
phosphorylation in 106 PBMCs of two healthy controls, a STAT3 mutated patient 
(travel control) and the patient (UPN1) on stimulation with 100ng/mL IFN-α for 15 
minutes.  
B 
A 
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5.3.7 Th17 cells 
In the previous chapter we showed that the induction of Th17 cells is impaired 
in AD-HIES patients with STAT3 mutations, as it has been described before 
(de Beaucoudrey et al., 2008; Jiao et al., 2008; Ma et al., 2008; Milner et al., 
2008; Renner et al., 2008). We analyzed the levels of Th17 cells among the 
PBMCs in four of five Sardinian type 1 HIES patients and compared them with 
14 control subjects and four STAT3 mutated patients. Cells were stimulated 
with PMA/Ionomycin for five hours prior to intracellular staining as described in 
the methods section. Figure 5.6 shows the stimulation and the gating of one 
healthy control and one STAT3 mutated patient. Lymphocytes were first gated 
for CD3+ and CD45RO+ memory T cells and then on intracellular stained IL-17 
and IFN-γ. Unstimulated control cells do neither produce IFN-γ nor IL-17. 
Stimulated PBMCs of the healthy control showed 33% of IFN-γ-producing and 
1.2% of IL-17-producing CD3+CD45RO+ memory T cells whereas the STAT3 
mutated patient has 21% of IFN-γ-producing but no increase of IL-17-
producing CD3+CD45RO+ T cells. Cells of the four Sardinian patients have 
inconsistent results (Figure 5.7). UPN22 and UPN69 both had almost 1% of IL-
17 positive cells, similarly to the healthy control. UPN1 had intermediate 
numbers of IL-17 positive cells (0,48%), whereas UPN139 had reduced counts 
of IL-17 positive cells (0.32%) although they were not completely absent. 
Numbers of IFN-γ-producing CD3+CD45RO+ T cells ranged between 16,7 and 
21,1% and were therefore in the range of the ones measured for healthy 
controls. Figure 5.8 summarizes the results of the intracellular staining; the 
difference of IL-17 positive CD3+CD45RO+ memory T cell numbers between 
the healthy controls and the Sardinian patients is not significant (p=0.1222). 
 
Chapter 5: Hunt for the genetic defect of STAT3wt AD-HIES patients 
160 
 
Figure 5.6: IL-17 and IFN-γ production from PBMCs of a healthy control 
and a STAT3 mutated AD-HIES patient. 
Flow cytometry analysis of CD3+CD45RO+ memory T cells from a healthy control and 
STAT3 mutated AD-HIES PBMCs stained intracellular for IL-17 and IFN-γ. Cells were 
stained either unstimulated or stimulated with PMA/Ionomycin for 5 hours; Brefeldin A 
was added after one hour stimulation. 
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Figure 5.7: IL-17 and IFN-γ production from PBMCs of four Sardinian 
STAT3wt type 1 HIES patients 
Flow cytometry analysis of CD3+CD45RO+ memory T cells from four Sardinian 
STAT3wt AD-HIES patients stained intracellular for IL-17 and IFN-γ. Cells were stained 
either unstimulated or stimulated with PMA/Ionomycin for 5 hours; Brefeldin A was 
added after one hour stimulation. Cells of the four Sardinian patients show different 
results 
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Figure 5.8: Percentage of IL-17 and IFN-γ expressing CD3+ T cells 
Percentage of (A) IL-17 and (B) IFN-γ expressing CD3+CD45RO+ memory T cells, 
determined by intracellular cytokine expression after stimulation with PMA/Ionomycin. 
Each symbol represents the value from an individual donor or patient. Statistical 
significance was determined with a Wilcoxon rank-sum test. P values are 2-sided. 
Median values are shown as horizontal bars. 
 
B 
A 
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5.3.8 Multiple cytokine assay 
As no mutations with functional consequences were detected in any of the 
genes sequenced and no clear conclusion could be drawn from the Th17 cell 
staining, a multiple cytokine assay was carried out to assess whether there is 
any difference in cytokine production of the Sardinian patients' blood cells 
when compared to a patient harbouring a known STAT3 mutation (V637M) 
and four healthy individuals. For this purpose the FlowCytomixTM Multiple 
Analyte Detection System (eBioscience, UK) was used. This assay quantifies 
up to 20 cytokines simultaneously. With the use of this kit the release of 12 
different cytokines (IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-
17A, IL-22 and TNF-α) was measured upon stimulation of PBMCs with 
PMA/Ionomycin for 5 hours. 
In general no significant difference in cytokine release was detected when 
comparing the Sardinian patients as a group with the healthy controls. In 
contrast the STAT3 mutated patient showed reduced releases of several 
cytokines (IL-5, IL-6, IL-8, IL-12p70) including, as expected, the production of 
IL-17 and IL-22 (Figure 5.9).   
The Sardinian patients turned out to be a heterogeneous group concerning 
cytokine release. There was no difference in production of IL-1β, IL-2 and IFN-
γ between the healthy controls, the Sardinian patients and the STAT3 mutated 
patient. For IL-5 and IL-8 the amount of released cytokines of the Sardinian 
patients was comparable to the controls, whereas the STAT3 mutated patient 
showed a reduced production.  
The levels of released IL12p70 and TNF-α were very low and therefore not 
significant. 
Interestingly one Sardinian patient (UPN1) showed higher production of IL-6 
when compared with the other Sardinian patients and the controls. Together 
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with a second patient (UPN69), this patient also had an increased release of 
IL-10. In contrast the other two patients (UPN22 and UPN139) and one healthy 
control showed no release of IL-10. In addition to IL-10 the two patients 
UPN22 and UPN139 show no production of IL-4 and IL-22. The amount of 
released IL-17 reflects the number of Th17 cells measured by intracellular 
staining: UPN1, UPN22 and UPN69 showed production of IL-17 comparable to 
the healthy controls, whereas UPN139, like the STAT3 mutated patient, lacked 
IL-17. In general, UPN 139 shows less cytokine release compared to the other 
Sardinian patients and the healthy controls. 
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Figure 5.9: Multiple cytokine assay 
Amount of cytokines released in the supernatant from PBMCs of four Sardinian 
STAT3wt type 1 HIES patients, four healthy controls and one STAT3 mutated AD-
HIES patient (V637M). Cells were previously stimulated with PMA/Ionomycin for five 
hours. The levels of the 12 cytokines IL-1b, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL12p70, 
IL-17, IL-22, IFN-γ and TNF-α were measured. 
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Figure 5.10: Multiple cytokine release 
Amount of cytokines released in the supernatant from PBMCs of four Sardinian 
STAT3wt type 1 HIES patients, compared to the mean release values of four healthy 
controls. Cells were previously stimulated with PMA/Ionomycin for five hours. The 
levels of the 12 cytokines IL-1b, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL12p70, IL-17, IL-22, 
IFN-γ and TNF-α were measured in the supernatant.  
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5.4 Discussion 
A considerable proportion of our patient cohort with the clinical diagnosis of 
AD-HIES did not show any genetic alteration within the coding exons and the 
adjacent intronic regions of STAT3 and DOCK8. To shed light on the genetic 
background of these STAT3wt patients with AD-HIES phenotype (type 1 HIES 
patients), we chose five HIES patients who all originated from Sardinia, one of 
whom had a putative positive family history of AD-HIES.  
Since one case of neutralizing anti-IL-6 autoantibodies has been described in 
a patient presenting with unusually severe cellulites and subcutaneous 
abscesses caused by Staphylococcus aureus (Puel et al., 2008)for further 
investigations we focused on components of the IL-6/STAT3 signalling 
pathway and sequenced IL-6 itself, the IL-6 receptor components IL-6RA and 
gp130 and JAK1. Despite the assumption that the patient's 'AD-HIES like- 
phenotype could be due to mutations affecting the IL-6/STAT3 signalling 
pathway none of the patients revealed a mutation in IL-6, IL-6RA and gp130. 
One of the patients carried a yet undescribed heterozygous sequence variation 
in the 5'UTR of JAK1. To examine possible functional consequences of the 
detected mutation phosphorylation of STAT1 was upon addition of IFN-α to 
PBMCs was investigated, as IFN-α signals via JAK1 and is a strong activator 
of STAT1. STAT1 phosphorylation of the patient appeared to be weaker than 
phosphorylation in the controls. However, since the phosphorylation of the 
STAT3 mutated travel control was comparably weak we concluded that this 
result was most likely due to the long travel of the blood samples and not 
caused by an impaired function of JAK1.  
Therefore,this sequence variation most likely is a rare polymorphism with no 
functional consequence rather than a disease causing mutation. Moreover, 
healthy family members were found to carry the same variation. 
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Nevertheless, to assess whether the weaker STAT1 phosphorylation is due to 
different responsiveness of cells additional controls could have been 
performed. The simultaneous detection of STAT3 phosphorylation upon 
addition of IL-6 or IL-10 would have given insight on the general ability of the 
patient's cells to phosphorylate STAT molecules. Moreover, it would have been 
advantageous to include a healthy travel control in the analysis.  
TYK2 and JAK2, which are as well involved in IL-6 signalling, were not 
sequenced. Even though one of the two TYK2-deficient patients described had 
elevated IgE levels (Minegishi et al., 2006) the role of TYK2 in the 
pathogenesis of HIES has been excluded (Woellner et al., 2007). Other 
authors identified loss-of-function TYK2 mutations in a patient who had an 
increased susceptibility to infections with Mycobacteria and who did not show 
any clinical features of HIES (Kilic et al., 2012). Our patients, however, were 
not prone to mycobacterial infections. Mutations in JAK2 mainly affect the 
hematopoietic compartment, were shown to cause Polycythemia vera as well 
as Hereditary Thrombocytosis and myelofibrosis and were therefore excluded 
a priory.  
Th17 and IFN-γ-producing CD3+CD45RO+ memory T cell numbers were 
investigated in four of the five Sardinian patients. Two patients had normal 
numbers of Th17 cells as well as IFN-γ-producing memory T cells. One patient 
had intermediate numbers of these T cell subsets whereas one patient had 
reduced numbers of Th17. These data correlate with the cytokine release data 
obtained by the multiple cytokine array. The patient with the reduced number 
of Th17 cells had also shown reduced IL-17 release after stimulations of his 
PBMCs. Interestingly, all four patients showed regular STAT3 function at least 
in response to the immunosuppressive cytokine IL-10 as confirmed by 
functional tests assessing the IL-10-mediated inhibition of TNF-α release in 
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LPS stimulated blood cells. Why one patient had reduced Th17 cell numbers 
remains elusive. Reduced numbers of Th17 cells have been described in other 
primary immunodeficiencies such as chronic mucocutaneous candidiasis 
(CMC), a complex disorder characterised by an increased susceptibility to 
infections with primarily Candida albicans (Glocker & Grimbacher, 2011).  
Reduced Th17 cell numbers in CMC patients can be caused by several 
mutations hampering the differentiation of Th17 cells from naïve T cells.  Loss-
of-function mutations in CARD9 result in reduced release of IL-1b, a key 
cytokine needed for the differentiation towards Th17 cells; gain-of-function 
mutations in the signal transducer and activator of transcription (STAT)1 
enhance cellular responses to cytokines such as IFN-α/β, IFN-γ, and IL-27, 
which potently inhibit the development of IL-17-producing T cells (Liu et al., 
2011).   
In general no significant difference in cytokine release was detected when 
comparing the Sardinian patients as a group with the healthy controls, 
suggesting that the four patients may not have the same genetic background 
as assumed. However, two patients together with one control showed no 
release of IL-10 upon stimulation with PMA/Ionomycin. In addition the same 
two patients had no release of IL-4 and IL-22. The reason for the diverging 
cytokine releases remain to be investigated. But, as this experiment has been 
preformed only once it would beneficial to repeat the experiment possibly 
applying different stimulation conditions.    
In summary, no mutation in select components of the IL-6 signalling pathways 
that might account for the phenotype of the five patients chosen was found. 
Even though the Sardinian patients turned out to be a heterogeneous group 
and showed different cytokine release patterns, they all suffered from 
candidiasis indicating an impairment of the antifungal defence. Only one 
patient, however, revealed reduced numbers of Th17 cells which have been 
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shown to be critical to fight fungal infections. This clearly shows that other 
immunomodulatory signalling pathways might be impaired in these patients 
and further studies are needed to examine these pathways. 
Recently, dominant gain-of-function mutations in STAT1 were shown to cause 
chronic mucocutaneous candidiasis (CMC). These mutations result in impaired 
STAT1 dephosphorylation and diminished numbers of Th17 cells (Liu et al., 
2011b). As CMC and reduced numbers of Th17 cells are two hallmark of the 
AD-HIES phenotype, it would be worth testing wild type STAT3 patients for the 
presence of such gain-of function STAT1 mutations.    
The development of new sequencing technologies such as next-generation 
sequencing techniques may benefit the search for other type 1 HIES causing 
genes. These novel methods allow for the rapid examination of multiple genes 
at considerably lower costs compared to conventional Sanger sequencing 
techniques. In the near future, candidate gene sequencing might be replaced 
by whole exome sequencing which enables the simultaneous analysis of 
exons and/or coding regions only of thousands of genes. This method is not 
only quicker but it also helps save resources, is more cost efficient and may 
accelerate the future search for disease causing mutations in HIES or other 
diseases.  
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The signal transducer and activator of transcription 3 (STAT3) is part of the 
JAK-STAT signalling pathway, mediating the expression of a variety of genes 
in response to stimuli, and thus plays a key role in many cellular processes 
such as cell growth and apoptosis. STAT3  is known to transduce signals of 
the entire IL-6-family of cytokines (IL-6, IL-11, IL-27, IL-31), the Leukemia 
inhibitory factor (LIF), Oncostatin M (OSM), the Ciliary neurotrophic factor 
(CNTF) and cardiotrophin-1, the IFN-family of cytokines (IL-10, IL-19, IL-20, IL-
22, IL-24, IL-26, IFN-α/β and IFN-γ), the IL-2-family of cytokines (IL-2, IL-7, IL-
9, IL-15 and IL-21), IL-5, IL-23, the Granulocyte colony-stimulating factor (G-
CSF), the Epidermal growth factor EGF, the Macrophage colony-stimulating 
factor (M-CSF) and Leptin (Darnell, 1997; Levy and Lee, 2002).  
In 2007 it has been shown by two different groups that mutations of STAT3 
lead to the autosomal dominant form of Hyper IgE Syndrome (AD-HIES) 
(Minegishi et al., 2007; Holland et al., 2007) 
AD-HIES is a rare primary immunodeficiency characterized by both 
immunologic and non-immunologic manifestations. High serum IgE levels, 
eosinophilia, eczema, recurrent severe skin and lung infections constitute the 
immunologic profile of AD-HIES, whereas characteristic facial appearance, 
scoliosis, retained primary teeth, joint hyperextensibility, recurrent bone 
fractures following minimal trauma, and craniosynostosis are the main non-
immunologic manifestations (Grimbacher et al., 1999a). 
The first STAT3 mutations described, affected the DNA-binding or the SH2 
domain of the protein and it soon became apparent that most mutations cluster 
together and form mutational “hot spots”. All variations found were 
heterozygous missense mutations or in-frame deletions or duplications, 
associated with the expression of the protein and exerting a dominant-negative 
effect (Minegishi et al., 2007).  
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We sequenced 153 patients with suspected AD-HIES, referred to us in a 
worldwide collaboration, and found 39 different STAT3 mutations in 82 
patients. Fifty-five patients carried mutations described previously, (de 
Beaucoudrey et al., 2008; Holland et al., 2007; Jiao et al., 2008; Ma et al., 
2008; Milner et al., 2008; Minegishi et al., 2007; Renner et al., 2008) 27 
patients harboured novel mutations. 
Most mutations affected either the DNA-binding or the SH2 domain, but we 
also detected one mutation in the N-terminal domain and seven in the 
transcription activation domain. 
All mutations were heterozygous missense mutations or small in-frame 
deletions or duplications. 
The fact that all STAT3 mutations identified in patients with AD-HIES to date 
are associated with protein expression supports the hypothesis that co-
expression of wild-type and mutant STAT3 protein is required to cause AD-
HIES. The notable lack of nonsense or frame shift mutations strengthens the 
notion that AD-HIES is the result of a dominant-negative effect as suggested 
by Minegishi et al. 2007. 
The evidence that the STAT3 mutations are located in areas of the protein 
known to exert distinct functions suggests that more than one molecular 
mechanism leads to the same clinical presentation. It has been shown that 
mutations in the DNA-binding domain cause a defective binding of STAT3 to 
the DNA (Minegishi et al., 2007) whereas mutations affecting the SH2 domain 
impair the activation-induced tyrosine phosphorylation of STAT3. The 
molecular mechanism by which heterozygous mutations in the N-terminal 
domain or the transcription activation domain of STAT3 cause the AD-HIES 
phenotype remains unclear.  
The N-terminal domain is conserved among the STATs and is known to be 
required for the formation of unphosphorylated STAT3 dimers (Vogt et al., 
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2011). The lack of nuclear accumulation of STAT3 upon phosphorylation seen 
in STAT3 variants missing the N-terminal domain could be the underlying 
mechanism of mutations in this domain leading to the AD-HIES phenotype. 
The transcriptional activation domains, on the other hand, are regions of a 
transcription factor which in conjunction with the DNA binding domain can 
activate transcription by getting in contact with the transcriptional machinery, 
either directly or through other proteins known as co-activators (Darnell, 1997). 
How mutations in this region affect the functionality of STAT3 is not 
understood and further studies will be required to elucidate the mechanism. 
 
Although the molecular mechanism of the impaired STAT3 function appears to 
be different depending on the domain bearing the mutation, like others, we did 
not observe any significant correlation between the site of mutation and the 
patients phenotype (Heimall et al., 2011; Renner et al., 2008) (this analysis 
was performed in collaboration with the National Centre for Biotechnology 
Information at the National Institutes of Health (NIH) in Bethesda (USA)) 
However, the low number of patients carrying mutations outside the DNA-
binding or the SH2 domain makes statistical analysis difficult. Thus, phenotypic 
differences may not become apparent until more patients with AD-HIES with 
these STAT3 mutations have been characterized. 
 
Since the mutations found in STAT3 can be spread over the entire gene, it is 
necessary to sequence the whole STAT3 gene to exclude possible mutations. 
It therefore would be desirable to find a test capable of predicting a mutation 
without the need of sequencing. 
For some of the mutations we found an impairment of the IL-10-mediated 
inhibition of TNF-α release in LPS challenged patients' macrophages, 
indicating a failure in the IL-10/Janus kinase/STAT3 pathway. This effect, 
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however, was less prominent in some of the mutations tested, in particular in 
the four novel mutations: H58Y in the N-terminal domain; N466K in the DNA-
binding domain; and P639S and F710C affecting the SH2 domain.  
Furthermore, we experienced great variability in TNF-α release for some 
STAT3 mutations; this makes this assay unsuitable as screening method to 
identify patients with STAT3 mutations.  Additionally, one should bear in mind 
that the STAT3 mutations leading to the AD-HIES phenotype are 
heterozygous, heterogeneous and display a variable functional deficit. 
Therefore, it is difficult to set up a specific test capable of predicting all 
mutations. 
 
As mutations in STAT3 lead to impaired Th17 cell differentiation, significantly 
reduced numbers of Th17 cells are a common feature of AD-HIES patients 
carrying STAT3 mutations (de Beaucoudrey et al., 2008; Jiao et al., 2008; Ma 
et al., 2008; Milner et al., 2008; Renner et al., 2008). Th17 cells are positioned 
at the intersection between innate and adaptive immune response and play a 
significant role in the defence against extracellular and intracellular pathogens 
(Peck and Mellins, 2010).   
Similar to previous reports we found that our AD-HIES patients carrying a 
STAT3 mutation had markedly decreased or absent numbers of circulating 
Th17 cells, suggesting a fundamental defect in Th17 cell differentiation. 
Reduced numbers of Th17 cells are thought to contribute most to the clinical 
phenotype of AD-HIES including to the increased susceptibility to bacterial and 
fungal infections. The relevance of Th17 cells in antibacterial and antifungal 
host defence has been demonstrated in other human diseases and 
significantly reduced numbers of Th17 cells are implicated in the pathogenesis 
of Chronic mucocutaneous candidiasis (CMC) (Glocker and Grimbacher, 
2011). Th17 cells also secrete IL-22, a cytokine that upregulates the secretion 
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of antimicrobial peptides like human β-defensins and CCL20 (Kolls et al., 
2008) which supports the critical role of Th17 cells for protecting skin and 
mucosal surfaces. 
In contrast to their role in protective immunity against fungi, Th17 cells have 
been shown to be involved in auto-immune disease, by exerting uncontrolled 
excessive tissue damage. 
Enumeration of IL-17 production by activated CD4 T cells emerges as a 
relatively quick and simple procedure that could be used to screen patients 
suspected of having AD-HIES due to inactivating mutations in STAT3. 
Moreover, future studies of individuals with AD-HIES may also help to explain 
the role of Th17 cells in infection and in other forms of dysregulated immunity, 
and may help in understanding the role of STAT3 in T-helper cell differentiation 
in humans. Furthermore, our findings suggest that therapeutic approaches to 
AD-HIES may focus on therapies improving and increasing the IL-17 
production. 
Reports that haematopoietic stem cell transplantation (HSCT) may correct this 
deficit underline the relevance of this T cell subset in the pathogenesis of HIES 
(Goussetis et al., 2010). 
 
One of the STAT3 mutated AD-HIES patients of our cohort underwent 
haematopoietic stem cell transplantation in 2005 at the age of 13. The patient 
carried the 'common' mutation R382W and despite prophylactic antibiotic 
treatment he suffered from recurrent chest infections with longstanding 
established bronchiectasis. The expectation of the transplant was to at least 
cure the immunological features of the syndrome by replacing the 
haematopoietic system. 
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To date three haematopoietic stem cell transplantation attempts have been 
reported in literature (Gennery et al., 2000; Goussetis et al., 2010; Nester et 
al., 1998).  
The first report concerned an adult AD-HIES patient who developed 
lymphoma. The patient died of transplantation-related complications 6 months 
after the procedure but showed decreased serum IgE levels and fewer HIES-
related symptoms (Nester et al., 1998).  
The authors of the second report described a 7 year-old girl who experienced 
a relapse of AD-HIES 4 years after transplantation, despite full donor 
chimerism in all leukocyte lineages (Gennery et al., 2000). To date the patient 
is still alive and well (personal communication of the authors A. Gennery and  
A. Cant). 
The latest report depicts the cases of two unrelated boys with AD-HIES 
complicated as well by high-grade non-Hodgkin lymphoma. Already two month 
after transplantation the authors measured normal IgE which remained normal 
14 and 10 years after transplantation for both patients respectively. 
Additionally, the authors state that neither patient had any additional 
pneumonia, skin infection, or other problem associated with AD-HIES following 
the transplant. AD-HIES related nonimmunologic manifestations, including skin 
lesions and osteoporosis also resolved and the coarse appearance of the skin 
of the face with pronounced pores gradually disappeared. Th17 cells levels 
were measured in both patients. IL-17-producing cell populations were found 
to be 0.8% of CD4 cells, and therefore comparable to healthy donors 
(Goussetis et al., 2010).  
In our patient we showed as well that the number of circulating Th17 cells was 
restored after transplantation, indicating the importance of Th17 cells in the 
pathogenesis of AD-HIES with STAT3 mutations. Indeed the patient has 
significantly improved, he suffered from less infections and the progressive 
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lung destruction has been stalled. Therefore, we conclude that allogeneic 
HSCT represents a curative treatment for patients with AD-HIES presenting 
with progressive lung disease leading to the prevention and even reversal of 
AD-HIES manifestations.  
 
A considerable proportion of our patient cohort (71 out of 153) with the clinical 
diagnosis of AD-HIES did not show any genetic alteration within the coding 
exons and the adjacent intronic regions of STAT3. Mutations in the promoter 
region were ruled out in advance: even though conceivable they were unlikely 
to cause AD-HIES when present in heterozygosity because they would not 
exert a dominant-negative effect which seems to be required for the AD-HIES 
phenotype.   
As no inheritance pattern has been identified for patients, resembling an 
autosomal dominant HIES phenotype but without proven STAT3 mutation we 
decided to refer to these STAT3wt patients as type 1 HIES instead of AD-
HIES. 
To shed additional light on the genetic background of STAT3wt  type 1 HIES 
we selected five patients who all originated from Sardinia.   
We focused on components of the IL-6/STAT3 signalling pathway and 
sequenced IL-6 itself, the IL-6 receptor components IL-6RA and gp130 and 
JAK1. None of the patients harboured a mutation in IL-6, IL-6RA and gp130, 
but one of them carried a yet undescribed heterozygous variation in the 5'UTR 
of JAK1. Functional assays, however, showed that this variation most likely is 
a rare polymorphism rather than a disease causing mutation with functional 
consequences. Moreover, healthy family members were found to carry the 
same variation. 
The numbers of Th17- and IFN-γ-producing memory T cells were examined in 
four of these five Sardinian patients. Two patients had normal numbers of 
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these T cell subsets, one patient had slightly decreased and one patient had 
clearly reduced cell numbers. These data correlated with the results of the 
multiple cytokine arrays. The patient with the reduced Th17 cell numbers also 
showed reduced IL-17 release upon stimulation of his PBMCs with PMA and 
Ionomycin. Interestingly, all four patients showed regular STAT3 function as 
confirmed by the capability of IL-10 to inhibit the TNF-α release in LPS 
stimulated leucocytes. The reason why one patient had reduced Th17 cell 
numbers remains to be elusive. These results confirm the heterogeneity of 
HIES and show that signalling pathways other than the IL-6/STAT3 pathway 
might be affected. Thus further studies are needed to examine the genetic 
background of type 1 HIES with wild-type STAT3 by using other strategies 
such as SNP chip analyses, whole exome sequencing, gene expression arrays 
and ELISAs reading out various pro- and anti-inflammatory cytokines. 
Heterozygous missense gain-of-function mutations of STAT1 were recently 
identified in patients with chronic Candida infections, autoimmune 
manifestations and mild bacterial or viral diseases (Liu et al., 2011a). In these 
patients, the development of Th17-cells is impaired, probably due to enhanced 
STAT1-dependent cellular responses to repressors of Th17 cell differentiation 
(Puel et al., 2012). As CMC and reduced numbers of Th17 cells are two 
hallmarks of the HIES phenotype, it would be worth testing wild type STAT3 
patients for the presence of such gain-of function STAT1 mutations.     
 
During the course of this study it also became clear that homozygous 
mutations of the dedicator of cytokinesis 8 (DOCK8) gene are responsible for 
the autosomal recessive form of HIES (AR-HIES) (Engelhardt et al., 2009; 
Zhang et al., 2009). Four patients out of our cohort of 71 STAT3wt HIES 
patients erroneously classified as autosomal dominant were found to carry 
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DOCK8 mutations suggesting the importance and value of the complete 
medical and family history. 
 
The work presented in this thesis has characterized patients with AD-HIES, the 
frequency of STAT3 mutations in AD-HIES and functional consequences of 
STAT3 mutations. Thus, the data presented contribute to a better 
understanding of the AD-HIES as well as the STAT3 signalling and its 
importance in immunity and T cell development. The results obtained may 
pave the way for alternative future therapeutical approaches such as HSCT or 
gene therapy -based treatment of AD-HIES, thereby improving the clinical 
management of affected patients.  
 
Many fundamental aspects of STAT3 biology are still unanswered but the wide 
repertoire of mutations identified within the STAT3 gene represents a suitable 
tool to perform structure/function studies on STAT3 and gives the opportunity 
to investigate fundamental aspects of STAT3 biology.   
Although the AD-HIES phenotype can partially be explained, the exact 
molecular mechanism by which heterozygous mutations in STAT3 cause AD-
HIES remains unclear. 
The paradoxical pro- and anti-inflammatory functions of STAT3 are still 
challenging questions that are linked to the understanding of the 
immunological and non-immunological features of AD-HIES. It will be 
interesting to explore the exact underlying molecular mechanisms of specific 
mutations and how these affect the function of STAT3. Moreover, the role of 
unphosphorylated STAT3 molecules in the pathogenesis of AD-HIES as well 
as the impact of STAT3 mutations on other JAK-STAT signalling pathways and 
their role in the formation of STAT1-STAT3 heterodimers requires further 
investigation.  
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Theoretically, mutations altering the function of any receptors, signalling 
pathways, and cytokines related to STAT3 may cause diseases that are more 
or less similar to classical AD-HIES. These pathways should therefore be 
further analyzed  in type 1 HIES patients without STAT3 mutations.  
 
In general, the proposed work generated basic knowledge of the molecular 
biology of STAT3 signalling in AD-HIES patients and thus may have paved the 
way to develop alternative therapies for patients suffering from either AD-HIES 
or other diseases presenting with imbalanced Th17 cells. 
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94** F 11 EU H58Y N-terminal   42 yes no no no <700 yes severe 3 no >3 <10° no yes no no no no 
7 F 12 EU a→g ex 12 (-2) DNA-B 53 yes yes yes no >800 no moderate 1-2 nail 2 <10° no yes yes nd nd no 
30 F 14 SA a→g ex 12 (-2) DNA-B 48 yes yes yes yes >800 yes moderate 4-6 oral nd <10° no no no yes no no 
114 M 22 EU a→g ex 12 (-2) DNA-B 70 yes yes yes yes >800 yes severe 4-6 oral nd 10-14° nd nd yes yes yes yes 
86 M 13 EU g→a ex 12 (-1) DNA-B 83 yes yes yes yes <700 yes severe 4-6 oral >3 10-14° yes yes yes nd yes yes 
17 F 25 EU g→t ex 12 (+1) DNA-B 65 yes yes yes yes 700-800 nd severe 1-2 nail >3 nd no no yes yes yes no 
160** F 10 EU g→a ex 12(+1) DNA-B 40 yes no yes yes >800 yes moderate 4-6 no 0 <10° no no no no no no 
108 M 14 EU ins t ex 12 (+2)  DNA-B 54 no yes yes yes >800 no moderate 1-2 systemic >3 <10° no no mild no yes no 
70 F 34 EU 982 CMP ins DNA-B 41 yes yes no no <700 no moderate 3 oral 2 10-14° no yes yes no yes no 
110** F 28 EU G342D DNA-B 79 yes yes yes yes 700-800 yes severe 4-6 nail >3 nd yes yes yes yes yes no 
79 F 8 EU R382L DNA-B 56 yes yes no no >800 yes severe 3 nail 3 <10° yes nd yes nd nd no 
98 M 25 EU R382L DNA-B 45 yes yes yes yes >800 no moderate 3 oral nd <10° no no yes nd no no 
25 F 11 EU R382Q DNA-B 72 yes yes yes yes <700 yes severe >6 systemic >3 <10° yes yes mild no no no 
37 F 6 EU R382Q DNA-B 46 no yes no no <700 nd severe >6 no >3 <10° no yes yes yes yes no 
44 M 9 ME R382Q DNA-B 62 yes yes yes no 700-800 yes moderate >6 nd >3 <10° no yes mild yes no no 
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47 F 24 ME R382Q DNA-B 62 yes yes yes yes >800 yes severe 1-2 no nd nd yes no yes yes no nd 
61 M 14 ME R382Q DNA-B 57 yes yes yes nd nd no severe >6 nail >3 nd no no yes nd yes no 
72 M 19 ME R382Q DNA-B 60 yes yes yes nd 700-800 yes severe 4-6 systemic >3 nd nd nd no yes nd nd 
77 M 19 ME R382Q DNA-B 61 yes yes yes yes 700-800 nd moderate >6 nail 0 nd yes nd yes yes nd no 
92 M 12 ME R382Q DNA-B 50 yes yes yes nd <700 yes severe nd nd nd nd nd yes yes yes no nd 
95 F 15 EU R382Q DNA-B 48 yes yes yes yes 700-800 nd moderate 1-2 nd nd nd yes yes mild yes nd nd 
164 M   EU R382Q DNA-B     no detailed clinical information available 
183 M   EU R382Q DNA-B     no detailed clinical information available 
15 M 29 EU R382W DNA-B 76 yes yes yes yes >800 yes severe 1-2 nail >3 nd yes nd yes yes yes no 
19** M 15 EU R382W DNA-B 63 yes yes yes yes <700 yes severe 1-2 nail >3 <10° yes yes mild yes yes no 
29 F 29 SA R382W DNA-B 64 yes yes yes yes >800 yes moderate 4-6 nail >3 <10° no no yes yes no no 
31 M 12 SA R382W DNA-B 57 yes yes yes yes >800 yes moderate 4-6 nail 3 nd yes no no yes no no 
43 M 20 ME R382W DNA-B 62 yes yes yes no nd yes severe 4-6 oral >3 <10° no yes mild yes yes no 
56 M 15 EU R382W DNA-B 59 yes yes yes no >800 yes severe nd no >3 <10° yes no yes nd nd no 
63 M 28 ME R382W DNA-B 61 yes yes yes no >800 yes mild 1-2 nail >3 <10° no yes mild no no no 
73 M 17 ME R382W DNA-B 73 yes yes yes yes 700-800 yes severe nd nd >3 15-20° nd yes yes yes nd nd 
126 F 11 EU R382W DNA-B 58 yes yes yes yes >800 yes mild 3 oral 0 10-14° no no mild yes yes nd 
128 F 3 EU R382W DNA-B 29 yes yes no no <700 no moderate 1-2 nail 0 <10° yes no mild yes no no 
129 M 11 EU R382W DNA-B 64 yes yes yes yes <700 no severe 1-2 systemic >3 <10° yes no yes yes yes no 
135 M 7 EU R382W DNA-B 60 yes yes yes yes 700-800 yes severe 3 oral nd nd no yes yes nd yes no 
136 F 15 ME R382W DNA-B 62 yes yes yes nd >800 yes severe >6 nail 0 <10° no nd yes yes no no 
162 M   EU R382W DNA-B     no detailed clinical information available 
185 F   EU R382W DNA-B     no detailed clinical information available 
6 F 50 EU F384L DNA-B 54 yes yes yes no <700 yes severe nd no 0 10-14° yes no yes yes no no 
60** M 29 ME F384L DNA-B 71 yes yes yes yes >800 nd mild >6 nail >3 <10° yes yes yes yes yes nd 
154 F 3 EU F384L DNA-B 20 no no no no nd yes moderate 1-2 no 3 <10° no no no no no no 
65** M 23 ME T389I DNA-B 52 yes yes no no >800 yes severe 1-2 nail 2 <10° no no yes yes no no 
143 F 16 EU T412A DNA-B 69 yes yes yes yes >800 no moderate 1-2 no nd >20° yes yes yes no yes no 
118 F 32 EU R423Q DNA-B 59 yes yes yes no <700 no severe 4-6 no 0 10-14° yes yes yes yes no yes 
130 F 14 EU V463 del DNA-B 56 no yes yes yes >800 no moderate 1-2 no >3 <10° no no yes yes yes no 
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26 F 11 EU N466D DNA-B 55 yes yes no yes <700 yes severe 1-2 oral >3 <10° no yes yes yes yes no 
2** F 30 EU N466S DNA-B 41 no yes yes no >800 no mild 4-6 no >3 nd yes nd mild nd nd nd 
46 F 15 ME N466T DNA-B 66 yes yes yes no nd no moderate >6 nd >3 >20° no yes yes yes no no 
102 M 12 EU N466K DNA-B 45 yes yes no no <700 no moderate >6 oral >3 <10° yes yes yes yes no no 
36 M 16 EU Q469H DNA-B 57 yes no no yes nd yes severe 1-2 oral >3 <10° yes no yes yes yes no 
57 F 18 EU K591E SH2 75 yes yes yes yes >800 yes severe 1-2 nail >3 <10° yes yes yes nd nd nd 
147 M 2 EU K615E SH2 32 yes yes no yes >800 no moderate 3 nail nd nd no no mild yes no no 
187 M   EU K615E SH2     no detailed clinical information available 
5 M 11 EU T622I SH2 47 yes yes yes no >800 no moderate 1-2 no 2 10-14° no no yes nd yes no 
71 M 24 EU S636Y SH2 71 yes yes yes yes >800 yes mild 1-2 oral 2 >20° no yes mild yes yes nd 
104 M 6 EU V637A SH2 72 yes yes yes no >800 no severe >6 nail >3 <10° yes yes yes yes no no 
16 F 39 EU V637M SH2 68 yes yes yes no >800 no severe 4-6 nail >3 nd yes yes yes yes yes no 
32 M 15 SA V637M SH2 37 yes yes no yes <700 yes moderate 3 no 2 <10° no no mild yes no yes 
33 M 25 SA V637M SH2 45 yes yes yes no <700 no moderate 4-6 oral 0 <10° no no yes yes no no 
42 F 11 ME V637M SH2 58 yes yes yes yes >800 no moderate 1-2 no >3 nd no no yes yes yes no 
45 M 9 ME V637M SH2 44 yes yes yes no nd yes moderate 4-6 oral >3 <10° no yes no yes no no 
66 F 21 EU V637M SH2 56 yes yes no yes <700 no severe 1-2 nail >3 <10° yes yes yes yes yes no 
67 M 12 EU V637M SH2 59 yes yes yes yes >800 yes severe 1-2 no 1 <10° yes nd mild no yes no 
106** M 4 EU V637M SH2 30 yes yes no yes >800 no moderate 3 no 0 <10° no no mild yes no no 
115 M 19 EU V637M SH2 56 yes yes nd nd nd nd severe nd nd >3 <10° yes no yes yes yes no 
125 M 16 EU V637M SH2 58 yes yes yes yes >800 yes severe 4-6 no nd 10-14° no no yes yes no nd 
151 M 5 EU V637M SH2 47 yes yes no no >800 yes severe 1-2 oral >3 <10° no no no no yes no 
186 M   EU V637M SH2     no detailed clinical information available 
157 M 9 EU V637L SH2 42 yes yes no no <700 yes mild 1-2 no 0 <10° yes yes yes nd no no 
49 M 7 NA P639S SH2 55 yes yes yes no <700 yes severe 4-6 nail >3 <10° no no mild no yes yes 
158 F 7 EU P639R SH2 46 yes yes yes nd >800 no moderate 1-2 oral >3 <10° no yes mild nd yes no 
153** M 43 EU Y640N SH2 44 yes yes no yes <700 no no >6 no >3 <10° no no yes yes yes no 
109 F 21 EU Y657C SH2 33 yes no no yes >800 no moderate 3 nail 0 <10° no no no nd no no 
175 F   EU Y657C SH2     no detailed clinical information available 
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27 M 15 SA S668F SH2 56 yes yes yes yes >800 yes moderate 4-6 oral 2 <10° yes no no yes no no 
152 M 31 EU Y705H TAD 79 yes yes yes yes <700 no moderate 4-6 nail >3 15-20° yes yes yes yes yes yes 
169 M   EU L706P TAD     no detailed clinical information available 
103 F 23 EU T708S TAD 53 no yes yes no >800 yes severe 1-2 oral >3 <10° nd nd yes yes nd no 
159 F 18 EU T708S TAD 54 yes yes yes nd nd nd moderate 3 nail 0 15-20° no yes yes yes nd yes 
18 M 23 EU F710C TAD 58 yes yes yes no >800 yes severe 1-2 oral 2 <10° no no mild yes yes no 
116 M 8 EU T714A TAD 63 yes yes no yes >800 yes severe >6 oral nd 10-14° no yes yes yes yes nd 
96 M 9 EU g→a ex 22(+1) TAD   32 no yes yes no >800 nd moderate 1-2 no nd <10° no nd mild nd nd no 
1 M 19 EU no mutation     72 yes yes no yes >800 yes severe >6 nail >3 10-14° yes no yes yes yes no 
4 M 17 EU no mutation     60 yes no no no >800 no severe 3 nail >3 10-14° yes yes yes yes yes yes 
9 M 30 EU no mutation 49 yes no no no 700-800 yes severe 4-6 nail >3 <10° no no yes yes no no 
10 M 59 EU no mutation 29 yes no no no <700 yes moderate 3 no 2 <10° no no yes yes no no 
11 F 55 EU no mutation 55 yes yes yes no 700-800 no moderate >6 nail 0 <10° yes no mild no no no 
12 F 15 EU no mutation 38 yes no no nd 700-800 yes severe 4-6 no 3 <10° no no mild yes no no 
14 F 34 EU no mutation 47 yes yes no yes <700 no severe >6 no 0 10-14° no no yes yes no yes 
20 F 9 EU no mutation 32 no yes no no >800 no mild 1-2 no 3 <10° no no mild yes yes no 
21 M 8 EU no mutation   Dock8 49 yes yes yes no >800 no severe 3 oral 2 <10° no no mild yes nd no 
22 F 18 EU no mutation     43 yes no no no >800 yes severe 4-6 nail >3 <10° no no yes no no no 
28 M 15 SA no mutation 44 yes yes yes no <700 yes moderate 3 oral 2 <10° no yes no yes no no 
35 M 7 EU no mutation 39 yes yes yes no 700-800 nd severe nd nd 0 <10° no yes no no yes no 
38 M 21 EU no mutation 57 yes yes yes nd >800 yes severe 1-2 no 2 <10° no yes yes no nd no 
52 M 14 EU no mutation 35 yes yes no no >800 no mild 1-2 no 0 <10° no no mild no no no 
54 M 21 EU no mutation 29 no yes no no >800 no no 1-2 oral 0 <10° no no no no no no 
55 M 19 EU no mutation 26 yes no no no >800 no severe 1-2 no 0 15-20° no no no no no no 
58 F 9 EU no mutation 38 no yes yes no <700 yes moderate 1-2 no >3 <10° no no mild nd no no 
59 M 21 EU no mutation 45 yes yes yes yes <700 yes moderate nd no 0 10-14° no no nd no yes yes 
69 M 25 EU no mutation     61 yes yes no no >800 yes severe 4-6 nail >3 10-14° yes no yes yes yes yes 
75 F ME no mutation 35 yes yes yes yes >800 nd moderate >6 nd nd nd nd nd nd nd nd nd 
76 F 29 ME no mutation 42 yes yes yes yes <700 nd moderate 4-6 nail 0 <10° no no no no no no 
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78 M 6 EU no mutation 46 no yes nd no >800 yes severe 4-6 systemic nd <10° no no yes yes yes no 
80 M 39 ME no mutation   Dock8 48 yes yes yes no >800 nd severe 4-6 systemic nd <10° no no no no no no 
81 F 9 ME no mutation   Dock8 44 yes yes no yes >800 nd moderate 3 nail 0 <10° no no mild yes no no 
82 M 10 ME no mutation   Dock8 63 yes yes yes yes >800 yes moderate >6 systemic 3 <10° no yes no yes no no 
83 M 9 ME no mutation   Dock8 40 no yes yes yes >800 nd moderate 4-6 nail 0 <10° no nd mild nd no no 
88 M 15 ME no mutation 53 yes yes yes yes >800 nd severe 4-6 no nd nd nd yes mild yes nd nd 
90 M 16 EU no mutation 29 yes no no no 700-800 no severe 3 no 2 10-14° no no mild yes yes no 
97 M 5 EU no mutation 39 yes yes no yes >800 yes severe 1-2 oral 0 nd no nd mild nd nd no 
105 F 8 EU no mutation 19 no no no no <700 no mild 1-2 no 0 <10° yes yes no no no no 
107 F EU no mutation 26 no yes yes no <700 no no 1-2 no >3 <10° yes no no no no no 
112 M 4 EU no mutation 21 yes no nd no 700-800 nd severe nd nd nd nd no nd mild nd nd no 
113 F 5 EU no mutation 39 no no no yes >800 yes severe 1-2 no 0 <10° no yes mild yes yes nd 
122 M 11 EU no mutation 29 yes yes no yes <700 no moderate 3 no 0 <10° no no no no yes no 
123 F 24 EU no mutation 30 yes no no yes <700 no severe 1-2 no 2 <10° no no mild no no no 
124 M 1 EU no mutation 22 no no no no >800 no severe 1-2 nd 0 <10° no nd no nd yes no 
127 F 7 EU no mutation 49 yes yes yes no >800 no severe 1-2 oral 2 <10° no no mild yes yes yes 
137 M 11 EU no mutation 29 no yes no nd 700-800 nd nd 4-6 nd 3 nd nd yes nd nd yes nd 
138 M 40 EU no mutation 43 yes no no no >800 nd severe 4-6 no 0 <10° no no yes yes no yes 
139 M 6 EU no mutation     40 yes no no yes >800 no severe 4-6 oral nd <10° no yes mild yes yes no 
140 F 10 EU no mutation 38 no yes no no >800 yes severe 1-2 no 3 <10° no nd mild no yes no 
141 F 1 EU no mutation 30 no yes no yes >800 no severe 1-2 no nd nd nd no no no yes no 
142 F 13 EU no mutation 32 no no no no >800 yes moderate 1-2 no 2 10-14° yes no no no yes no 
144 M 14 EU no mutation 53 no yes yes no >800 nd severe 1-2 no >3 <10° no yes yes nd yes no 
145 F 2 EU no mutation 23 yes no no no 700-800 no mild 1-2 no nd <10° yes no no no no no 
146 F 20 EU no mutation 38 no yes yes no >800 no moderate 1-2 no 0 <10° no yes no no no no 
148 F 7 EU no mutation 35 no no no no >800 no severe >6 no no 10-14° no yes mild yes yes no 
149 F 23 EU no mutation 47 yes no no no >800 yes severe 3 nail 3 <10° no yes mild no yes no 
150 F 16 EU no mutation 41 no yes yes no 700-800 nd severe nd no >3 <10° no nd no no no no 
155 F 4 EU no mutation 30 no yes yes no <700 no mild 1-2 oral 0 <10° no yes no no no no 
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156 M 14 EU no mutation     50 yes yes yes no >800 no severe 3 nail 0 <10° no no mild yes no no 
91 F   ME no mutation       no detailed clinical information available 
161 F 
  EU no mutation       no detailed clinical information available 
163 F   EU no mutation       no detailed clinical information available 
165 M   EU no mutation       no detailed clinical information available 
166 F   EU no mutation       no detailed clinical information available 
167 F   EU no mutation       no detailed clinical information available 
168 F   EU no mutation       no detailed clinical information available 
170 F   EU no mutation       no detailed clinical information available 
171 F   EU no mutation       no detailed clinical information available 
172 F   EU no mutation       no detailed clinical information available 
173 F   EU no mutation       no detailed clinical information available 
174 M   EU no mutation       no detailed clinical information available 
176 F   EU no mutation       no detailed clinical information available 
177 F   EU no mutation       no detailed clinical information available 
178 F   EU no mutation       no detailed clinical information available 
179 M   EU no mutation       no detailed clinical information available 
180 F   EU no mutation       no detailed clinical information available 
181 F   EU no mutation       no detailed clinical information available 
182 F   EU no mutation       no detailed clinical information available 
184 M   EU no mutation       no detailed clinical information available 
Table Appendix 1: Clinical findings and STAT3 mutations of the 153 analyzed patients´ 
EU, Europe; F, female; M, male; ME, Middle East; NA, North America; ND, not determined; SA, South America; p.?, unknown effect on protein level. 
*Scoring system described in Grimbacher et al. 1999 
**Patients having affected family members  
Patients with mutations in DOCK8 are shaded in green 
The five Sardininan patients who were further studied are shaded in light blue 
Patients refered to us without detailed clinical information are shaded in purperl.  
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Figure Appendix 1: Polyphen reports 
Examples of three Polyphen reports are shown for the three STAT3 mutations R382W, 
N466K and K591E. The effect of the mutatiob R382W is predicted to be probally 
damaging, the mutation N466K is classiefied as possibly damaging, K591 E as benign. 
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Exon Primer Name  Sequence  Product length (bp) 
2 stat3 ex2 
fw 5’-ctg tgt tgg gca atg gct act tct-3’  
426 
rv 5’-ttg ccc aca tgc cct tct aag ata-3’ 
3 stat3 ex3 
fw 5’-tga atg ggt tat agc atc agg ttt-3’ 
364 
rv 5’-tag cca aat gag aaa aga gat gct-3’ 
4 stat3 ex4 
fw 5’-ctg aag cct ttg ttc cgt tgt ttc-3’ 
282 
rv 5’-gat ttt cca ttc ctc cca gac cag-3’ 
5&6 stat3 ex5&6 
fw 5’-caa gcc aaa caa gaa ggg tag tta-3’ 
883 
rv 5’-ccg cct taa gat cca aac aga g-3’ 
7 stat3 ex7B 
fw 5’-ctc aaa gga gcc tgg tca tta agg-3’ 
957 
rv 5’-agt caa ctc cag agc agg aac ttc-3’ 
8 stat3 ex7&8 
fw 5’-gtt ttt tct tcc ttc gca gac atg-3’ 
550 
rv 5’-gga aaa gtc ccc acg ttg gag aat-3’ 
9&10 stat3 ex9&10B 
fw 5’-ttg tag tgg tct cca tgt att cag-3’ 
595 
rv 5’-aca gtg tac tgc ctg tga cac c-3’ 
11 stat3 ex11 
fw 5’-cag ctt ggc cta ttt acc tgt tg-3’ 
310 
rv 5’-agg ctt ttg aaa act ttt gtc cac-3’ 
12-14 stat3 ex12-14 
fw 5’-tgc gct gat caa ctg taa ctg aat-3’ 
652 
rv 5’-ggc ctg aag tga ctt ttt gga ata-3’ 
15 stat3 ex15B 
fw 5’-agc tgg ggc tat agg tgt gc -3’ 
354 
rv 5’-aaa tcc cag tgg aag ttt ttg gtc -3’ 
16 stat3 ex16&17A 
fw 5’-ccg tga gat gcg ggt gaa gag att-3’ 
511 
rv 5’-atg gcc caa atg aac agc cct atg-3’ 
18-20 stat3 ex18-20 
fw 5’-ctg att att ttg tgg ccc att gtg-3’ 
867 
rv 5’-ttt tgc gag tct gag tga aac agg-3’ 
21 stat3 ex21 
fw 5’-agc cag cct gaa tat ttc cac agt-3’ 
448 
rv 5’-caa gga tcc caa aat ttc caa ctt-3’ 
22 stat3 ex22B 
fw 5’-aac cct gag ggg cag ctg ga-3’ 
441 
rv 5’-ggg ggt tga caa gac aca atg g-3’ 
23 stat3 ex23B 
fw 5’-ccc gtt ttg cct tca ttt cta ata-3’ 
530 
rv 5’-cac atg tgg cat tca tac cat ctc-3’ 
24 
coding 
stat3 ex24 I 
fw 5’-aca gta gat caa ggg cag aag-3’ 
819 rv 5’-tct tct att tgg atg tca gca-3’ 
Table Appendix 2: Primer table I 
Primers used for the amplification of the coding, genomic sequence of STAT3 
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 Primer Name  Sequence  Product length (bp) 
31-647 stat3 mRNA I fw 5’-gag ggg gag ccg ggg gtt cc-3’ 618 
rv 5’-cac ggc tgc tgt ggg gtg gtt g-3’ 
368-911 stat3 mRNA 1-2 fw 5’-ggg cat atg cgg cca gca aag aat-3’ 544 
rv 5’-agc ccc gcc agc tca ctc acg at-3’ 
34-1275 stat3 mRNA II fw 5’-aat gga gat tgc ccg gat tgt gg-3’ 742 
rv 5’-gaa ctg gac gcc ggt ctt gat gac-3’ 
896-1510 stat3 mRNA 2-3 fw 5’-gtg agc tgg cgg ggc ttt tgt cag-3’ 615 
rv 5’-ctc ggc ccc cat tcc cac atc tct-3’ 
1160-1836 stat3 mRNA III fw 5’-aga gaa tcg tgg agc tgt tta ga-3’ 677 
rv 5’-gag ttt ctc tgc cag tgt agt cag-3’ 
1603-2289 stat3 mRNA 3-4 fw 5’-gag acc cac tcc ttg cca gtt gtg-3’ 687 
rv 5’-gaa tgc ctc ctc ctt ggg aat gtc-3’ 
1767-2604 stat3 mRNA IV fw 5’-ctg gca gtt ctc ctc cac cac caa-3’ 838 
rv 5’-tgc agg tag gcg cct cag tcg tat-3’ 
2343-2933 stat3 mRNA 4-5 fw 5’-cgc tgc ccc ata cct gaa gac caa-3’ 591 
rv 5’-gca ggc acc agg agg cac ttg tc-3’ 
2402-3122 stat3 mRNA V fw 5’-cca ttg acc tgc cga tgtc-3’ 721 
rv 5’-gaa agg cta tgc tga tac agt gtt-3’ 
2813-3482 stat3 mRNA 5-6 fw 5’-ggg ggt ggc tag agg gag aaa a-3’ 670 
rv 5’-gct taa agc acc aag gag gct gtt-3’ 
3012-3768 stat3 mRNA VI fw 5’-cct tgc tga cat cca aat aga aga-3’ 757 
rv 5’-taa ggc acc cac aga aac aac cta-3’ 
3565-4075 stat3 mRNA 6-7 fw 5’-cct ggc ctt tgg tgt tga aat agg-3’ 511 
rv 5’-ttg ccc tgc atg aac tga atg aag-3’ 
3649-4488 stat3 mRNA VII fw 5’-tgt aat gta ttg gcc ttt tag tga-3’ -3’840 
rv 5’-aga gtg ttg ctg gag aag taa gag-3’ 
4034-4724 stat3 mRNA 7-8 fw 5’-tgg cac ttg taa tgg cgt ctt cat-3’ 691 
rv 5’-ggg cct gag gac cct gtt ctt ta-3’ 
4356-4950 stat3 mRNA VIII fw 5’-tta aat caa att agc tgg tct ctg-3’ 595 
rv 5’-tct gga agt taa agt aga tac agc-3’ 
Table Appendix 3: Primer table II 
Primers used for the amplification of the cDNA of the Signal Transducer and Activator 
of Transcription STAT3 (transcript NM_139276.2) 
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Exon Primer Name  Sequence  Product length (bp) 
1 IL6 exon 1  fw 5’-agg cgg gtc ctg aaa tgt tat gc-3’ 624 
rv 5’-ctc tcc cca ttg cca ctg agt ctc-3’ 
2&3 IL6 exon 2&3 fw 5’-aat cag ccc cac ccg ctc tgg-3’ 702 
rv 5’-gcc ccg ttg gcc tca aat cta cag-3’ 
4 IL6 exon 4 fw 5’-tgc ccc cac tcc act gg-3’ 428 
rv 5’-gct tga agt tgg cct cct cat-3’ 
5 IL6 exon 5 fw 5’-tgc ccc cac tcc act gg-3’ 428 
rv 5’-gct tga agt tgg cct cct cat-3’ 
6 IL6 exon 6 fw 5’-gca ccc cag tta atc tca ttc a-3’ 781 
rv 5’-gtg gtg gca gtg aca aga aac t-3’ 
Table Appendix 4: Primer table III 
Primers used for the amplification of the coding, genomic sequence of IL-6 
 
 Primer Name  Sequence  Product length (bp) 
4-738 IL-6RAmRNA 1 fw 5’-ggt ccc ctg ttc tcc ccg ctc ag-3’ 735 
rv 5’-ggc cgg ccc ggt agc atg aat agt-3’ 
569-1334 IL-6RAmRNA 2 fw 5’-tct gac ctg ccc ggg ggt aga gc-3’ 766 
rv 5’-ccc gaa ctc ctc ctg ggc acg aa-3’ 
1150-1954 IL-6RAmRNA 3 fw 5’-ggc aag acc ccc act cct gga act-3’ 805 
rv 5’-agg ccg cac acc cct gag ata agc-3’ 
1794-2579 IL-6RAmRNA 4 fw 5’-cca cgg agc cct tat gac atc agc-3’ 786 
rv 5’-caa agc caa tgc agt tgc ctc tgt-3’ 
2352-3127 IL-6RAmRNA 5 fw 5’-gcc tgg gga cgg ctt tta ctt-3’ 776 
rv 5’-att gcc cag gct gat ctc aaa ctt-3’ 
2965-3642 IL-6RAmRNA 6 fw 5’-gtg tgg ggg aag cac cat aac t-3’ 678 
rv 5’-aaa aga gga agg cac cga ggt aag-3’ 
3437-4176 IL-6RAmRNA 7 fw 5’-gaa aaa cca gcg tgt gac tac tcc-3’  
rv 5’-ccc agg ttg gtc tca aac tcc-3’ 
Table Appendix 5: Primer table IV 
Primers used for the amplification of the cDNA of the IL-6 receptor A (IL-6RA) 
(transcript NM_139276.2) 
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 Primer Name  Sequence  Product length (bp) 
75-812 gp130mRNA 1 fw 5’-ctg cca ggc cga cgg gtc-3’ 738 
rv 5’-gtg cat gag gtg ggg gtg tca cg-3’ 
675-1500 gp130mRNA 2 fw 5’-cga ggg gaa gaa aat gag gtg tga-3’ 826 
rv 5’-agc tgc atc tga ttt gcc aac aa-3’ 
1324-2067 gp130mRNA 3 fw 5’-ttg cct cct ttt gaa gcc aat g-3’ 744 
rv 5’-ctt ccc acc ttc atc tgt gta tgc-3’ 
1952-2785 gp130mRNA 4 fw 5’-gaa atg aaa ctg ctg tga atg tgg-3’ 834 
rv 5’-tga ctg atg aaa ctt gct ttg acc-3’ 
2592-3397 gp130mRNA 5 fw 5’-ctt ctc aag atc cga gtc tac c-3’ 806 
rv 5’-caa aat cag tat agc tgt gct cac-3’ 
3248-4147 gp130mRNA 6 fw 5’-gat ttt gtg ctg ttt cag gat gtt-3’ 900 
rv 5’-caa gtt gtc tta gtg tgc ctc aaa-3’ 
4001-4797 gp130mRNA 7 fw 5’-tca gag tac tgg gta gat gaa c-3’ 797 
rv 5’-ttt gcc taa agt ggg aaa ct-3’ 
4637-5461 gp130mRNA 8 fw 5’-tct cag aat att gtt cac att aga-3’ 825 
rv 5’-cta gtt ttt aca taa ata acc aga-3’ 
5292-6052 gp130mRNA 9 fw 5’-att tga gca cta ata tgt aat gt-3’ 761 
rv 5’-cta ttt ctc aaa cta gat gct c-3’ 
5905-6684 gp130mRNA 10 fw 5’-aag gga ttt tac cac atg aag tc-3’a 780 
rv 5’-tag gtt aat gca aaa gat aat acg-3’ 
6515-7330 gp130mRNA 11 fw 5’-cat tgt cat tga ttt caa aga agg-3’ 816 
rv 5’-gca att cac tgc aaa ggt aaa-3’ 
7169-8072 gp130mRNA 12 fw 5’-tga cta gca tta ggt atg ttt ctt-3’ 904 
rv 5’-tat atg tga agg agt tac tgt tgg-3’ 
7888-8438 gp130mRNA 13 fw 5’-cat ggc atc ctc ctg cta ctt ctt-3’ 551 
rv 5’-taa ctt gcc caa gca ctg gac tta-3’ 
8269-8964 gp130mRNA 14 fw 5’-ttt ctc tag ccc aaa ggc agt g-3’ 696 
rv 5’-acc ata tag ctc acc atg tta tcc-3’ 
Table Appendix 6: Primer table V 
Primers used for the amplification of the cDNA of the IL-6 receptor signalling unit 
gp130 (transcript NM_139276.2) 
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 Primer Name  Sequence  Product length (bp) 
20-635 Jak1 mRNA 1 fw 5’-cgc cca gtc ccg gct gtc ctc-3’ 616 
rv 5’-tga cgc cac act gac tgc tca ttg 
565-1283 Jak1 mRNA 2 fw 5’-cac tac cgg atg agg ttc tat ttc-3’ 719 
rv 5’-ttt ttc cgc ttc agt tta ttt tt-3’ 
1166-1789 Jak1 mRNA 3 fw 5’-acg gtg gaa acg ttc tct act acg-3’ 624 
rv 5’-ggt ccg aac cgt gca gac tgt-3’ 
1534-2161 Jak1 mRNA 4 fw 5’-ccc ccg ttg atc gtc cac a-3’ 628 
rv 5’-cct cga aga agg cca ggg aaa ta-3’ 
2044-2757 Jak1 mRNA 5 fw 5’-tct ggg acc ctg atg gat tac aag-3’ 714 
rv 5’-agg cct ctg att ggg gtc ata gtt-3’ 
2590-3244 Jak1 mRNA 6 fw 5’-acc acg ctc tgg gaa atc tgc tac-3’ 655 
rv 5’-att gcc gag aac cca aat agt cca-3’ 
3083-3836 Jak1 mRNA 7 fw 5’-cag aag acg gag gaa atg gta tta-3’ 754 
rv 5’-ttc agt gac ttt ttg gac aga aca-3’ 
3636-4430 Jak1 mRNA 8 fw 5’-gaa atg ctg gga att cca acc at-3’ 795 
rv 5’-ctg gca cag gct tag ttc ttg aga-3’ 
4162-5000 Jak1 mRNA 9 fw 5’-gac tta gcc ctc aaa ttt cag tat-3’ 839 
rv 5’-ata gag tgg cca cag gtt tga cac 
Table Appendix 7: Primer table VI 
Primers used for the amplification of the cDNA of the receptor associated tyrosine 
kinase JAK1 (transcript NM_139276.2) 
 
 
